

SUMF EXHIBIT 7

EXHIBIT 15 OF DR. LUIGI WARREN'S
NOVEMBER 16, 2018 DEPOSITION

**THE CHILDREN'S MEDICAL CENTER CORPORATION
AFFILIATION WITH
IMMUNE DISEASE INSTITUTE, INC.**

February 20, 2009

I. AGREEMENTS

TAB

- 1.1. Affiliation Agreement by and between The Children's Medical Center Corporation ("CMCC") and Immune Disease Institute, Inc. ("IDI"), dated December 24, 2008.
 - 1.1.1. Exhibits.
 - 1.1.1.1. Exhibit 1.3(a) – Amended and Restated Articles of Organization.
 - 1.1.1.2. Exhibit 1.3(b) – Amended and Restated Bylaws.
 - 1.1.1.3. Exhibit 4.1 – Attorney General Notice.
 - 1.1.1.4. Exhibit 4.5 – Employees and Independent Contractors.
 - 1.1.1.5. Exhibit 5.1.5 – Opinion from Edwards Angell Palmer & Dodge, LLP.
 - 1.1.1.6. Exhibit 5.1.8 – Consents.
 - 1.1.1.7. Exhibit 5.2.5 – Opinion from Ropes & Gray, LLP.
 - 1.1.1.8. Exhibit 6.3.4 – Faculty Members.
 - 1.1.1.9. Exhibit 6.3.7 – Administrative Personnel.
 - 1.1.1.10. Exhibit 6.4.1 – Endowment Investment Agreement.
 - 1.1.2. IDI Disclosure Schedule.
 - 1.1.2.1. Schedule 2.1 – Subsidiaries, Affiliates and Other Interests in Entities.
 - 1.1.2.2. Schedule 2.3(a) – IDI Board of Trustees and IDI Board of Overseers.
 - 1.1.2.3. Schedule 2.3(b) – IDI Officers.
 - 1.1.2.4. Schedules 2.3(c) and (d) – IDI Bank and Investment Accounts.
 - 1.1.2.5. Schedule 2.4(a) – Governmental Approvals and Notices.
 - 1.1.2.6. Schedule 2.4(b) – Agreement and Instrument Waivers, Consents and Notifications.
 - 1.1.2.7. Schedule 2.6 – Employee Loans as of October 31, 2008.
 - 1.1.2.8. Schedule 2.8 – Pending Litigation.
 - 1.1.2.9. Schedule 2.9.1 – IDI Intellectual Property Rights.

1

A

B



TAB

1.1.2.10.	Schedule 2.9.11 – Outbound Licenses.	
1.1.2.11.	Schedule 2.9.12 – Domain Names.	
1.1.2.12.	Schedule 2.11.1 – Employee Benefit Plans.	
1.1.2.13.	Schedule 2.11.3 – Change in Control Agreements.	
1.1.2.14.	Schedule 2.11.5 – Audit of Plans.	
1.1.2.15.	Schedule 2.12 – Material Agreements.	
1.1.2.16.	Schedule 2.17 – Insurance Policies.	
1.1.2.17.	Schedule 2.19.1 – Owned Real Property and Real Property Leases.	
1.1.2.18.	Schedule 2.19.2 – Encumbrances on Real Property.	
1.1.3.	CMCC Disclosure Schedule.	C
1.1.3.1.	Schedule 3.4 – Required Consents.	
1.2.	Amended and Restated Articles of Organization of IDI, as filed with the Secretary of State of The Commonwealth of Massachusetts on February 20, 2009.	2
1.3.	Amended and Restated Bylaws of IDI.	3

II. PRE-CLOSING DELIVERABLES

2.1.	Certificate of IDI Chief Executive Officer.	4
2.2.	Certificate of CMCC Chief Executive Officer.	5
2.3.	Opinion of Edwards Angell Palmer & Dodge, LLP, counsel to IDI.	6
2.4.	Opinion of Ropes & Gray, LLP, counsel to CMCC.	7

III. THIRD PARTY NOTICES AND CONSENTS

3.1.	Consent of GlaxoSmithKline Research & Development Limited.	8
3.2.	Consent of President and Fellows of Harvard College.	9
3.3.	Consent of Blood Research Institute, Inc.	10
3.4.	Written confirmation of oral discussion with National Institutes of Health.	11
3.5.	Notice to the Attorney General of The Commonwealth of Massachusetts.	12

IV. ANCILLARY DOCUMENTS

4.1.	Endowment Investment Agreement by and between CMCC and IDI.	13
4.2.	Instrument of Appointment for CMCC-appointed trustees.	14
4.3.	IDI Certificate of Good Standing.	15
4.4.	CMCC Certificate of Good Standing.	16

1

EXECUTION COPY

AFFILIATION AGREEMENT
by and between
THE CHILDREN'S MEDICAL CENTER CORPORATION
and
IMMUNE DISEASE INSTITUTE, INC.

This Affiliation Agreement (the "Agreement") is entered into as of this 24th day of December, 2008 by and between The Children's Medical Center Corporation ("CMCC") and the Immune Disease Institute, Inc. ("IDI"), each a Massachusetts nonprofit corporation. CMCC and IDI are each sometimes referred to herein as a "Party" and, collectively, as the "Parties."

RECITALS

WHEREAS, the Parties have discussed the possibility of effectuating a corporate affiliation between them (the "Affiliation") to further their respective charitable missions by furthering scientific knowledge and public health through research in immunology, inflammation and other areas of biomedical science, and to advance medical education in these areas;

WHEREAS, pursuant to these discussions, CMCC and IDI have entered into a non-binding Letter of Intent, dated August 14, 2008 (the "Letter of Intent"), whereby each Party agreed, subject to certain contingencies, to effect a commonality of control between them which would permit an affiliation of their respective organizations;

WHEREAS, the Parties believe that the Affiliation will facilitate the growth and attraction of research funding through synergies and interdisciplinary grant proposals; provide greater coordination of research programs, thereby increasing efficiencies in those programs; enhance IDI's access to funding and revenue sources; increase private philanthropy to IDI; and preserve and create opportunities for research and medical education in Massachusetts;

WHEREAS, the members of the Board of Trustees of IDI (the "IDI Board of Trustees") and the members of the Board of Trustees of CMCC (the "CMCC Board of Trustees") have each approved the Affiliation, and each of IDI and CMCC considers it to be in its respective best interests and in the interests of the public it serves to enter into the Affiliation on the terms, conditions and contingencies set forth herein.

NOW, THEREFORE, in consideration of the foregoing and of the mutual agreements and covenants hereinafter set forth and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. THE AFFILIATION.

1.1. The Affiliation shall be effectuated subject to satisfaction of the conditions contained in Sections 5 and 6 hereof, including, without limitation, (a) naming CMCC as the sole corporate member of IDI, (b) the adoption by IDI of the Amended and Restated Articles of Organization (as defined herein) and the Amended and Restated Bylaws (as defined herein), as more fully described in Section 5.1.6 hereof, and (c) the modification of the composition of the IDI Board of Trustees, as more fully described in Section 5.1.6 hereof.

1.2. The closing of the Affiliation (the "Closing") will take place at the offices of Ropes & Gray, LLP, One International Place, Boston, Massachusetts, 02110, no later than three (3) business days immediately following the satisfaction of all closing conditions and the receipt of all necessary Consents or Permits (as hereinafter defined) of any Governmental Authority (as hereinafter defined) whose consent is required or sought for the consummation of the Affiliation, or on such other date and place as CMCC and IDI shall mutually agree. The date on which the Closing occurs is referred to herein as the "Closing Date." The Affiliation shall become effective at 11:59 pm on the date the Amended and Restated Articles of Organization are approved and filed by the Secretary of State of the Commonwealth of Massachusetts or such later date and time as is agreed upon by the Parties and specified in the Amended and Restated Articles of Organization. The time at which the Affiliation shall become effective is referred to as the "Effective Time."

1.3. At the Effective Time (a) the articles of organization of IDI ("Articles of Organization") shall, by virtue of the Affiliation and without further action by the trustees of IDI, be amended and restated in the form attached hereto as Exhibit 1.3(a) (the "Amended and Restated Articles of Organization") until thereafter changed or amended as provided therein or by applicable law; and (b) the bylaws of IDI ("Bylaws") shall, by virtue of the Affiliation and without further action by the trustees of IDI, be amended and restated in the form attached hereto Exhibit 1.3(b) (the "Amended and Restated Bylaws") until thereafter changed or amended as provided therein or by applicable law.

2. REPRESENTATIONS AND WARRANTIES OF IDI.

Except as set forth in the corresponding section and subsection of IDI's disclosure schedule attached hereto as Schedule 2 (with such disclosures to qualify any other section and subsection for which the appropriateness of the disclosure is reasonably apparent on its face), IDI represents and warrants to CMCC as follows:

2.1. Organization. IDI is a not-for-profit corporation duly organized, validly existing and in good standing under the laws of the Commonwealth of Massachusetts. Other than receipt of all necessary Consents or Permits, IDI has all requisite power and authority and has taken all necessary action required for the due authorization, execution, delivery and performance by IDI of this Agreement, and the entry into and consummation of the Affiliation. IDI has no subsidiaries, affiliates, membership interest or equity interest (other than equity interests in publicly traded companies) in any entity, except as set forth on Schedule 2.1 attached hereto. Without giving effect to the Affiliation, no individual, partnership, joint venture, corporation

(including not-for-profit corporation), limited liability company, limited liability partnership, trust, unincorporated organization, or Governmental Authority or any department or agency thereof (collectively, a "Person") has any interest or expectation of interest as a member or otherwise of IDI.

2.2. Authorization; Validity; Company Action. The execution and delivery of this Agreement, the entry into and consummation of the Affiliation and the consummation of the transactions contemplated hereby have been duly and validly authorized by all requisite corporate action, including without limitation the approval of the IDI Board of Trustees, and no other corporate proceedings on the part of IDI are necessary to authorize this Agreement or the Affiliation or to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by IDI, and assuming due authorization, execution and delivery by CMCC, constitutes a valid and binding agreement of IDI, enforceable against IDI in accordance with its terms, except as may be limited by (i) bankruptcy, insolvency, moratorium or other similar laws affecting or relating to enforcement of creditors' rights generally or (ii) general principles of equity (regardless of whether enforceability is considered in a proceeding at law or in equity). The rights, designation, powers, qualifications, limitations and restrictions of CMCC as the sole member of IDI are as stated in the Amended and Restated Articles of Organization and Amended and Restated Bylaws, which shall become effective at the Effective Time.

2.3. Governing Boards, Officers, Investments and Signatories. The IDI Board of Trustees and the IDI Board of Overseers are as set forth on Schedule 2.3(a) attached hereto, and the officers of IDI are as set forth on Schedule 2.3(b) attached hereto. A statement listing all investment and bank accounts, including but not limited to checking accounts, savings accounts, certificate of deposits, money market accounts, and brokerage accounts of IDI (collectively, the "Investments") and the approximate amount of money or value of such Investments is attached hereto as Schedule 2.3(c). The names of all authorized signatories of IDI are attached hereto as Schedule 2.3(d).

2.4. Consent and Approval; No Conflicts. The execution of this Agreement, the entry into and consummation of the Affiliation, the contemplated merger under Section 6.1.2, and the compliance of IDI with the provisions of this Agreement do not (i) conflict with or result in any breach of any provision of the Articles of Organization or Bylaws; (ii) other than as set forth on Schedule 2.4(a) attached hereto, require any consent, approval, waiver, filing with or notification to, any foreign, federal, state, local or municipal court or other judicial authority, legislative or executive body, administrative agency (including, without limitation, the National Institutes of Health), commission or other governmental or regulatory body or authority (each, a "Governmental Authority"); (iii) result in a violation or breach of or default (or gives rise to any right of termination, cancellation or acceleration) under, or require any consent, approval, waiver, filing with or notification under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, license, grant, agreement, Lease (as defined herein) or other instrument or obligation to which IDI is a party, except as set forth on Schedule 2.4(b); or (iv) violate any order, writ, injunction, decree, statute, rule or regulation applicable to IDI.

2.5. Financial Statements. Prior to the date hereof, IDI has furnished to CMCC or its representatives (i) the audited consolidated statement of financial position of IDI as of June 30,

2008, (ii) the related audited consolidated statements of activities and cash flows for the year then ended (collectively the "Audited Financial Statements") and (iii) comparable unaudited statements as of September 30, 2008 and for the three months then ended (collectively, the "Unaudited Financial Statements"). The Audited Financial Statements and the Unaudited Financial Statements have been prepared in accordance with generally accepted accounting principles applied on a consistent basis during the relevant periods (except as may otherwise be noted therein), and present fairly, in all material respects, the financial position, results of operations and the cash flows (as appropriate) of IDI as of the dates, and for the periods, indicated thereon, except for the absence of footnotes and as otherwise noted therein, and subject, in the case of the Unaudited Financial Statements, to normal recurring year-end adjustments which are not material individually or in the aggregate. There are no material liabilities or obligations (absolute, accrued, contingent or otherwise) of a type that generally accepted accounting principles would require to be on the Audited Financial Statements or the Unaudited Financial Statements which are not fully reflected or reserved against in such statements, except for liabilities and obligations that may have arisen in the ordinary course of business and consistent with past practice since September 30, 2008. IDI has maintained its books and records in accordance with generally accepted accounting principles and practices applied on a consistent basis, and such books and records are, and during the periods covered by the Audited Financial Statements and Unaudited Financial Statements were, true, correct and complete in all material respects.

2.6. Conduct of Business. Since June 30, 2008, (a) IDI has conducted business in the ordinary course consistent with past practice, and (b) IDI has not (1) borrowed any money or mortgaged, pledged or subjected to any lien any of its assets, tangible or intangible (absolute, accrued or contingent); (2) sold, leased, assigned or transferred any of its tangible assets except in the ordinary course of business consistent with past practice; (3) suffered any change, event or development or series of changes, events or developments which is material except for investment losses and as disclosed in the Unaudited Financial Statements; (4) suffered any damage, destruction or casualty loss to its physical properties (whether or not covered by insurance) which has been or would reasonably be expected to be material; (5) been the subject of any investigation by a Governmental Authority or had litigation threatened; (6) except for fair consideration canceled or compromised any debts that are material, individually or in the aggregate, or waived or permitted to lapse any claims or rights relating to debt that is material, individually or in the aggregate, or sold, transferred or otherwise disposed of any of its properties or assets that are material individually or in the aggregate; (7) made any change in any method of accounting or accounting practice; (8) increased any salaries, wages or any employee benefits, adopted or amended any employee benefit plans, paid any bonuses or otherwise increased the compensation of any of its officers, employees or consultants, other than in the ordinary course of business and consistent with past practice; (9) granted any change of control, severance, or termination pay, or instituted any new, or modified any existing, change of control, severance, or termination pay plan or practice; (10) made any loan to or engaged in any other transaction with any officer, employee, consultant, or affiliate of IDI, other than payment of salaries and benefits to such persons in the ordinary course of business or in connection with travel or other business-related expenses and other than tuition loans pursuant to IDI's tuition loan program and housing loans pursuant to commitments in effect on September 30, 2008 and previously disclosed to CMCC and set forth on Schedule 2.6 attached hereto; (11) made or committed to make any

capital expenditures individually in excess of \$100,000; or (12) agreed to take any action referred to in this paragraph; except, with respect to subsections (1), (3), (10) and (11) of this section, in accordance with its fiscal year 2009 budget previously furnished to CMCC or pursuant to an existing HEFA lease facility.

2.7. Absence of Undisclosed Liabilities. IDI has no liabilities or obligations (whether accrued, absolute, contingent, unliquidated or otherwise, whether due or to become due) other than (a) liabilities or obligations reserved against or otherwise disclosed in the Audited or the Unaudited Financial Statements, (b) liabilities for Actions set forth on Schedule 2.8 hereto and (c) liabilities or obligations arising since September 30, 2008 which were incurred in the ordinary course of business consistent (in amount and kind) with past practice (none of which is a liability resulting from a breach of contract, breach of warranty, tort, infringement claim, or lawsuit).

2.8. Litigation. Except as set forth on Schedule 2.8 attached hereto, there are no actions, suits or proceedings pending or, to the knowledge of IDI, threatened against IDI at law or in equity or before or by any federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign ("Actions"). Additionally, IDI is not in default with respect to any judgment, writ, injunction, decree, rule or regulation of any court or federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign.

2.9. Intellectual Property.

2.9.1. Schedule 2.9.1 sets forth, as of the date hereof, a complete and accurate list of all of the following IDI Intellectual Property Rights: all Patents; all registrations of Copyrights and applications therefor; and all registrations of Trademarks and service marks and applications therefore. Except as set forth in Schedule 2.9.1.IV., IDI Intellectual Property Rights are free and clear of all mortgages, liens, security interests, leases, pledges, encumbrances, equities, claims, charges, options, written restrictions, rights of first refusal, title retention agreements or other exceptions to title which affect IDI Intellectual Property Rights or restrict the use by IDI of IDI Intellectual Property Rights in any way with the exception of Patents jointly owned with other Persons (such jointly owned Patents indicated as such in Schedule 2.9.1) and Outbound Licenses listed in Schedule 2.9.11 ("IP Liens"). "IDI Intellectual Property Rights" means all Intellectual Property Rights (as hereinafter defined) owned by, co-owned by, subject to an obligation of assignment to, or licensed to IDI, or in which IDI has any right, title or interest as of the date of this agreement. "Intellectual Property Rights" shall mean any or all of the following and all worldwide common law and statutory rights in, arising out of, or associated therewith: (i) patents and applications therefor and all reissues, divisions, renewals, extensions, provisionals, continuations and continuations-in-part thereof ("Patents"); (ii) software, copyrights, copyrights registrations and applications therefor, and all other rights corresponding thereto throughout the world including moral and economic rights of authors and inventors, however denominated ("Copyrights"); (iii) industrial designs and any registrations and applications therefor; (iv) trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications therefor and all goodwill associated therewith ("Trade marks"); (v) trade secrets (including those trade secrets defined in the Uniform

Trade Secrets Act and under corresponding foreign statutory and common law), inventions and discoveries, whether or not patentable, invention disclosures, business, technical and know-how information, non-public information and confidential information and rights to limit the use or disclosure thereof by any Person, including databases and data collections and all rights therein ("Trade Secrets"); and (vi) any other proprietary rights or rights similar or equivalent to any of the foregoing (as applicable).

2.9.2. All current employees, consultants and contractors of IDI have executed a Participation Agreement substantially in IDI's standard form that, among other things, binds such employees, consultants and contractors to the terms of IDI's Research and Technology Development Policy, including an obligation to assign to IDI all Inventions, as that term is used in the Participation Agreement. All former employees, consultants and contractors of IDI who contributed to IDI Intellectual Property Rights either have (i) executed a Participation Agreement substantially in IDI's standard form that, among other things, binds such employees, consultants and contractors to the terms of IDI's Research and Technology Development Policy, including an obligation to assign to IDI all Inventions, as that term is used in the Participation Agreement or (ii) otherwise agreed to assign all such rights to IDI. Except as permitted under a Participation Agreement substantially in IDI's standard form, to the knowledge of IDI, there has been no disclosure by IDI or its former or current employees, consultants or contractors of any confidential or proprietary information of IDI. A true and accurate copy of the Research and Technology Development Policy, including a true and accurate copy of IDI's form of Participation Agreement, has been furnished to CMCC. Each inventor named on the Patents listed in Schedule 2.9.1 has executed an agreement assigning his, her or its entire right, title and interest in and to such Patents, and the inventions embodied and claimed therein, to IDI, except that in the case of Patents jointly owned with other Persons, to the knowledge of IDI, to the appropriate owners. To the knowledge of IDI, no such inventor has any contractual or other obligation that would preclude any such assignment or otherwise conflict with the obligations of the inventor to IDI, or in the case of Patents, to the appropriate owners.

2.9.3. There have not been in the past five years and there are no actions pending or, to IDI's knowledge, threatened with regard to the ownership of any IDI Intellectual Property Rights, and, to the knowledge of IDI, there is no valid basis for any such action.

2.9.4. To IDI's knowledge, IDI Intellectual Property Rights collectively constitute all of the Intellectual Property Rights necessary to enable IDI to research, develop, use, offer to sell, import, commercialize or otherwise exploit products or services as currently under development by IDI.

2.9.5. There have not been in the past five years and there are no pending claims or to IDI's knowledge claims threatened that (i) IDI, (ii) the IDI Intellectual Property Rights or (iii) the manufacture, development, use, sale, offering for sale, importing, commercialization or other exploitation of the IDI Intellectual Property Rights has infringed or is infringing any Intellectual Property Rights of any third party. To IDI's knowledge, (i) the IDI Intellectual Property Rights and (ii) the manufacture, development, use, sale, offering for sale, importing, commercialization or other exploitation of the IDI Intellectual Property Rights, do not and will

not infringe, constitute contributory infringement, inducement to infringe, misappropriation or unlawful use of Intellectual Property Rights of any third party.

2.9.6. The IDI Intellectual Property Rights listed in Schedule 2.9.1 have been duly registered and / or filed with or issued by the appropriate Governmental Entity (as hereinafter defined) in the jurisdictions indicated in Schedule 2.9.1. All such IDI Intellectual Property Rights are pending and have not been abandoned or expired and have been timely prosecuted, the representations in this sentence being to IDI's knowledge in the case of Patents jointly owned with other Persons for which such Persons have responsibility. All issued Patents, registered Trademarks and registered Copyrights within the IDI Intellectual Property Rights are in full force and effect and, to IDI's knowledge, valid and subsisting, the representations in this sentence being to IDI's knowledge in the case of issued Patents jointly owned with other Persons for which such Persons have responsibility. Patent applications included in Patents are pending with the applicable Governmental Entity, the representations in this sentence being to IDI's knowledge in the case of Patents jointly owned with other Persons for which such Persons have responsibility. All steps necessary to maintain such IDI Intellectual Property Rights including the payment when due of all maintenance fees and annuities and the filing of all necessary renewals, statements and certifications have been taken, and all necessary affidavits of continuing use have been timely filed, such representations being to IDI's knowledge in the case of Patents jointly owned with other Persons for which such Persons have responsibility. A "Governmental Entity" means any court, arbitral tribunal, administrative agency or commission or other governmental or other regulatory authority or agency, or foreign, federal, state, local or supranational entity.

2.9.7. To IDI's knowledge, there are no published patents, patent applications, articles or other prior art references that would reasonably be expected to adversely affect the validity or enforceability of any issued Patents. None of the IDI Intellectual Property Rights have been declared invalid or unenforceable, in whole or in part, by any Governmental Entity, and there are no ongoing interferences, oppositions, reissues, reexaminations or other proceedings involving any of the Patents including ex parte and post-grant proceedings, before any Governmental Entity, the representations in this section being to IDI's knowledge in the case of Patents jointly owned with other Persons for which such Persons have responsibility.

2.9.8. IDI has met its duty of candor as required under 37 C.F.R. 1.56 and complied with analogous laws outside the United States requiring disclosure of references. With respect to IDI Intellectual Property Rights, there have been no material misrepresentations or concealment of any material information to the United States Patent and Trademark Office or other applicable Governmental Entity by IDI, or in connection with the prosecution of any Patents listed in Schedule 2.9.1, in violation of 37 C.F.R. Section 1.56 or similar disclosure requirements.

2.9.9. To IDI's knowledge, IDI Intellectual Property Rights have not been infringed or misappropriated, and are not being infringed or misappropriated, by any third party. There is no claim asserted, threatened or planned to be asserted by IDI that any third party has infringed, misappropriated or otherwise violated any Intellectual Property Rights of IDI.

2.9.10. There are no options, rights, licenses or interests of any kind relating to IDI Intellectual Property Rights licensed or granted to IDI (other than software licenses for generally available software, employee assignment agreements, nondisclosure agreements and material transfer agreements ("MTAs")) ("Inbound Licenses"). With respect to each Inbound License, to IDI's knowledge: (i) no claim is pending or threatened with respect to any Inbound License or that challenges the legality or validity of any underlying item of Intellectual Property Rights subject to the Inbound License; and (ii) no sublicense or similar right has been granted by IDI with respect to any Inbound License.

2.9.11. Schedule 2.9.11 sets forth a true, complete and accurate list of all material agreements or instruments with respect to any options, rights, licenses or interests of any kind relating to Intellectual Property Rights licensed or granted by IDI to any third party (other than software licenses for generally available software, employee assignment agreements, and nondisclosure agreements) ("Outbound Licenses").

2.9.12. Schedule 2.9.12 lists all domain names owned by IDI. IDI owns all the domain names necessary for the conduct of business by IDI as currently conducted.

2.9.13. IDI does not own copies of any third-party software that is used in or is necessary for its business as currently conducted, other than software generally available to the public.

2.9.14. All personally identifiable information and data, including but not limited to health records and personal health information, used by or in the possession of IDI has been collected, stored, maintained, used and disclosed in accordance with all applicable legal requirements. IDI maintains policies and procedures regarding data security, privacy and the protection of personally identifiable information, including but not limited to health records and personal health information, that are commercially reasonable and, in any event, in compliance with all applicable legal requirements. There have been no security breaches relating to, violations of any security policy regarding or any unauthorized access of any data or information used in the business of IDI. To the knowledge of IDI, IDI has given all notices, made all disclosures, and obtained all necessary consents related to collection, storage, maintenance, use and disclosure of all such data or information. The transactions contemplated to be consummated hereunder will not violate any IDI policies or laws relating to collection, storage, maintenance, use or disclosure of any such data or information.

2.9.15. IDI has taken all reasonable precautions to protect the secrecy, confidentiality and value of all Trade Secrets.

2.10. Labor Relations and Employment. There are no union or collective bargaining agreements relating to employees of IDI and with respect to such employees: (a) IDI is in compliance with all applicable laws respecting employment and employment practices, including without limitation, terms and conditions of employment, classification of employees as exempt for overtime purposes, classification of service providers as independent contractors or consultants, and wages and hours; (b) there are no labor troubles (including any arbitrations, grievances, strikes, lockouts, slowdowns, or stoppages) pending or threatened against or

affecting IDI, and there have been no such troubles in the past five years; and (c) during the last five years, IDI has not received any written notice that any representation petition respecting the employees of IDI has been filed and no petition or proceedings have been threatened by or on behalf of any employee or group of employees with the National Labor Relations Board or any other labor relations board seeking recognition of a bargaining representative. Additionally, there are no actions pending or threatened by any employee of IDI, no employee of IDI has provided a written claim to IDI, in each case relating to IDI's employment of such employee. During the past five years, there have not been any layoffs, plant closings, reductions in workforce, or other actions that have resulted or triggered or could result or trigger notice requirements or liability under the Worker Adjustment and Retraining Notification ("WARN") Act or under any similar or local plant closing notice law. There is not presently pending, and for the past five years there has not been, any compliance review conducted by the U.S. Department of Labor, Office of Federal Contract Compliance Programs ("OFCCP") that resulted in, or that has the potential to result in (A) any adverse finding with respect to IDI, (B) any corrective or adverse action taken with respect to IDI, (C) any conciliation agreement between the OFCCP and IDI, or (D) the loss of federal contractor status of IDI.

2.11. Employee Benefits.

2.11.1. Attached hereto as Schedule 2.11.1 is a true and complete list of each deferred compensation, bonus or other incentive compensation plan, program, agreement or arrangement; each severance or termination pay, medical, surgical, hospitalization, life insurance and other "welfare" plan, fund or program (within the meaning of Section 3(1) of ERISA); each profit-sharing, stock bonus or other "pension" plan, fund or program (within the meaning of Section 3(2) of ERISA); each employment, termination, independent contractor, severance, change of control, or similar agreement; and each other material employee benefit plan, fund, program, agreement or arrangement, in each case, that is sponsored, maintained or contributed to or required to be contributed to by IDI or to which IDI is a party, whether written or oral, for the benefit of any employee, officer or consultant of IDI (the "Plans"). Additionally, IDI has provided to CMCC or its representatives a written statement of IDI's cost related to each employee welfare benefit plan (as that term is defined in Section 3(1) of ERISA) which is a Plan, including information about the portion of such cost which is borne by the employees of IDI through payroll deductions or otherwise. As of the Closing Date the portion of the Plans relating to severance, vacation, and other assorted benefits which have accrued shall not exceed \$500,000. All Plans are in material compliance with all applicable provisions of ERISA, as well as with all other applicable federal, state and local statutes, ordinances and regulations. All reports or other documents required by law or contract to be filed with any governmental agency, or distributed to Plan participants or beneficiaries, with respect to the Plans have been timely filed or distributed. Each of the Plans intended to be "qualified" within the meaning of Section 401(a) of the Code has received a favorable determination letter from the Internal Revenue Service and IDI knows of no event that would cause the Plan to lose its qualified status.

2.11.2. No Plan provides welfare or insurance benefits (whether or not insured) to any participating employee of IDI or their dependents or beneficiaries beyond such participant's termination of employment or termination of service of non-employees, other than coverage mandated by applicable state law or Part 6 of Title I of ERISA, Section 4980B of the Code and

the regulations and guidance promulgated and issued thereunder, respectively ("COBRA") and benefits, the full cost of which are borne by such participant (or his or her dependent or beneficiary). IDI has not maintained, or been obligated to contribute to, or incurred any liability with respect to, a Plan that is subject to the provisions of Title IV of ERISA, and IDI has not incurred any liability under Section 4201 of ERISA with respect to any "multi-employer plan" (as such term is defined in Section 4001(a)(3) of ERISA) or any other plan subject to Title IV of ERISA, and the Affiliation and the contemplated merger under Section 6.1.2 will not constitute a complete or partial withdrawal from or with respect to any such "multi-employer plan" or other plan subject to Title IV of ERISA or any collective bargaining agreement to which IDI is a party or by which IDI is bound or otherwise give rise to any liability of IDI in connection therewith. IDI does not have nor has ever had any funding arrangement intended to qualify as a VEBA under Section 501(c)(9) of the Code.

2.1.1.3. Except as set forth in Schedule 2.11.3 attached hereto, the consummation of the Affiliation and the contemplated merger under Section 6.1.2 will not, either alone or in combination with another event, (i) entitle any current or former employee or officer of IDI to severance pay, unemployment compensation or any other payment or (ii) accelerate the time of payment or vesting, or increase the amount of compensation due to any such employee or officer.

2.1.1.4. IDI has complied with all of its obligations under COBRA, and does not expect to incur any liability in connection with the benefit continuation rights under COBRA with respect to employees of IDI. No Plan is a multiple employer welfare arrangement.

2.1.1.5. There are no pending, or to the knowledge of IDI, threatened or anticipated claims by or on behalf of any Plan, by any employee of IDI or beneficiary thereof covered under any such Plan, or otherwise involving any such Plan (other than routine claims for benefits). Except as set forth on Schedule 2.11.5 attached hereto, no Plan is or, within the last six years, has been the subject of an examination or audit by any domestic or foreign governmental or regulatory authority, agency, commission, body, court or other legislative, executive, judicial or governmental entity. No Plan is the subject of an application or filing under, or is a participant in, a government-sponsored amnesty, voluntary compliance, self-correction or similar program.

2.12. Material Agreements. IDI has provided to CMCC or its representatives (a) true and correct copies of each written contract, agreement, license agreement, document, instrument, understanding, and any and all amendments thereto of IDI and (b) all oral agreements and understandings of IDI have been adequately disclosed to the satisfaction of CMCC and its representatives that are material to the operation of IDI or any of its subsidiaries, except for contracts, agreements, documents, instruments, understandings or arrangements with total payments less than \$100,000 in the aggregate (each a "Material Agreement"). A list of the Material Agreements is set forth in Schedule 2.12 attached hereto.

2.13. No Defaults. IDI is not and, to the knowledge of IDI, no other party is in breach or violation of, or default under, in any material respect, any Material Agreement, except such events of default and other events as to which requisite waivers or consents have been obtained.

IDI has not received notice of any claim of default under any Material Agreement, and, to the knowledge of IDI, no event has occurred that would result in a breach or violation of, or a default under, in any material respect, any Material Agreement.

2.14. No Material Claims or Judgments. As of the date hereof, (a) there are no claims, actions, investigations, or proceedings pending or, to the knowledge of IDI after having made reasonable efforts to investigate or inquire, threatened against IDI by any Governmental Authority; (b) IDI is not subject to any outstanding judgment, rule, order, writ, injunction or decree of any Governmental Authority; and (c) IDI is not subject to any agreement, stipulation or settlement with any person that compromises or settles any action, investigation or proceeding.

2.15. Consents and Permits. As of the date hereof, IDI is not and has not conducted business in violation in any material respect of any applicable law or any order, writ, injunction or decree of any court or Governmental Authority. IDI has all permits, certifications, licenses, approvals, orders, consents and other authorizations of any Governmental Authority necessary to conduct its business as currently conducted (collectively, the "Consents and Permits"). IDI is not in material violation of the terms of any Consent or Permit, nor is the cancellation or suspension of any Consent or Permit threatened in writing.

2.16. Taxes. IDI is tax-exempt under Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the "Code"), and is exempt from paying Massachusetts state sales tax and Massachusetts local property tax, and there are no federal, state or local investigations or audits pending with respect to the status thereof. IDI has timely filed or caused to be filed all federal, state and local tax and information returns which are required to be filed, and has paid or has caused to be paid all taxes as shown on said returns or on any assessment received by it, to the extent that such taxes have become due. IDI is not obligated to make any "gross-up" or similar payment to any individual on account of any tax under Section 409A of the Code. IDI does not have nor could reasonably expected to incur prior to or in connection with the Closing, any liability or obligation with respect to tax reporting of or withholding on amounts includable in gross income as a result of Section 409A of the Code.

2.17. Insurance. Attached hereto as Schedule 2.17 is a list of current insurance policies maintained by IDI. There is currently no claim pending by IDI under any insurance policies currently in effect and covering the property, business or employees of IDI and all premiums due and payable with respect to the policies maintained by IDI have been paid to date. The insurance coverage maintained by IDI provides coverage for all assets of IDI that are of insurable character against risk of liability, casualty and fire and other losses and liabilities customarily obtained to cover comparable entities and assets in amounts, scope and coverage which are consistent with prudent industry practices. IDI has not made any claims with its insurers other than worker's compensation claims during the 12 months prior to the date hereof.

2.18. Accounts Receivable. Except to the extent of the amount of the reserve for doubtful accounts reflected in the Audited Financial Statements or the Unaudited Financial Statements all Accounts Receivable reflected therein and all Accounts Receivable that have arisen since the Audited Financial Statements (except Accounts Receivable that have been collected since such date) are valid and enforceable claims, and constitute bona fide Accounts

Receivable resulting from the sale of goods and services in the ordinary course of the business. The Accounts Receivable are subject to no valid defense, offsets, returns, allowances or credits of any kind, and IDI has no reason to believe that the Accounts Receivable are not reasonably collectible except as to the extent of the amount of the reserve for doubtful accounts reflected in the Unaudited Financial Statements. Except for the Accounts Receivable (i) IDI has not made any loan or advance to any person and (ii) IDI has not loaned or advanced any of the Accounts Receivable to any person. For purposes of this Agreement, "Accounts Receivable" is defined as (i) all trade accounts receivable and other rights to payment from researchers of IDI and the full benefit of all security for such accounts or rights to payment, including all trade accounts receivable representing amounts receivable in respect of services provided or rendered to researchers of IDI; (ii) all other accounts or notes receivable of IDI and the full benefit of all security for such accounts or notes; and (iii) any claim, remedy or other right related to any of the foregoing.

2.19. Real Property.

2.19.1. Schedule 2.19.1 attached hereto sets forth all real property owned by IDI ("Owned Property") and each of the leases, subleases, and licenses (the "Leases") of real property, including all amendments and modifications thereto, to which IDI is a party, and each of the Leases is in full force and effect and is legal, valid, binding and enforceable in accordance with its terms. Prior to the date hereof, IDI has delivered to CMCC correct and complete copies of the Leases and any notices of lease and subordination, non-disturbance, and attornment agreements related thereto. There are no defaults by IDI or, to the knowledge of IDI, by any other party thereto, which might with due notice or lapse of time or both curtail the present use by IDI of any of its real property. Subject to obtaining the consent of President and Fellows of Harvard College and Blood Research Institute, Inc. with respect to lease of 200 Longwood Avenue, Boston, the Affiliation and the contemplated merger under Section 6.1.2 will not result in a breach of or default under, the termination of, or any increase of any amounts payable under, any Lease.

2.19.2. Except as set forth on Schedule 2.19.2 attached hereto, IDI has good and marketable title to, and, with respect to the Leases, a valid leasehold interest in, all of its real property free and clear of any mortgages, judgments, claims, liens, security interests, pledges, escrows, charges or encumbrances of any kind or character including encumbrances on the underlying fee to the real property leased pursuant to the Leases (collectively the "Encumbrances"). None of the Encumbrances set forth on Schedule 2.19.2 has, individually or in the aggregate, a material adverse effect on the use or value of the Owned Property or IDI's leased real property as currently operated or as contemplated under the Affiliation and the contemplated merger under Section 6.1.2. Prior to the date hereof, IDI has provided to CMCC a list setting forth the addresses and uses of all real property that IDI owns, leases or subleases, and any liens or Encumbrances on any such owned real property or leasehold interest, specifying in the case of each such lease or sublease, the name of the lessor or sublessor, as the case may be. There are commercially reasonable non-disturbance or recognition agreements for the benefit of IDI from IDI's landlords' lenders or ground lessors with respect to IDI's Leases. There are no pending or, to IDI's knowledge, threatened condemnation proceedings or administrative actions that may adversely affect the business or operations of IDI, the premises leased under the Leases

or the buildings in which such premises are located.

2.19.3. To IDI's knowledge, the improvements at the Owned Property and the premises leased pursuant to the Leases are structurally sound, in good condition, free of any material damage or waste and served by all utilities necessary and desirable for the conduct of IDI's business as currently conducted. The equipment and personal property located at the Owned Property and the premises leased pursuant to the Leases and used in connection with the conduct of IDI's business are in good condition and repair (subject to normal wear and tear), and are suitable, adequate and sufficient for the current operation of IDI's business.

2.19.4. The Owned Property has a valid and enforceable right to vehicular access to a public road. No building located at the Owned Property or any appurtenance thereto or equipment thereon, or any improvements planned therefor, or the use or operation thereof, violates in any material respect any restrictive covenant of record (or other private agreement, whether or not recorded) applicable to the Owned Property, and no such building, equipment, or planned improvements encroach upon the easement or real property of another Person, which encroachment is necessary for the business of IDI or could reasonably be expected to have a material adverse effect on such business or the value of such building, equipment, or planned improvements. No Person has any possessory interest in or right to occupy (whether by written or oral agreement or otherwise) any of the Owned Property or IDI's leased real property except IDI.

2.20. Compliance with Laws Relating to Real Property. There is no material violation of any law, regulation or ordinance (including, without limitation, laws, regulations or ordinances relating to zoning, environmental, city planning or similar matters) relating to any real property owned, leased or subleased by IDI.

2.21. Environmental Laws and Regulations. (i) Hazardous Materials (as hereinafter defined) have not been generated, used, treated or stored on, transported to or from or disposed of on, at, under or from any Property (as hereinafter defined) in a manner that could give rise to liability for IDI under Environmental Laws (as hereinafter defined); (ii) there has been no release of Hazardous Materials in any amount or concentration that would require remediation or reporting under Environmental Laws on, at or from any Property for which release IDI may be liable under Environmental Laws; (iii) IDI has been in compliance with all applicable Environmental Laws and the requirements of any permits issued under such Environmental Laws, except where failure to obtain such permits would not be expected to have, individually or in the aggregate, a material adverse effect; (iv) there are no underground storage tanks currently used by IDI, or to IDI's knowledge, other underground storage tanks, polychlorinated biphenyl-containing equipment or asbestos containing materials at any of the Owned Property or IDI's leased real property which could give rise to liability under Environmental Laws; (v) there are no past, pending or, to the knowledge of IDI, threatened environmental claims against IDI; (vi) except as provided in the Leases, IDI has not, either expressly or by operation of law, assumed responsibility for or agreed to indemnify or hold harmless any Person for any liability or obligation, arising under or relating to Environmental Laws, including, but not limited to, any obligation for investigation, corrective or remedial action; (vii) there are no facts or circumstances, conditions or occurrences regarding the current or former business, assets or

operations of IDI, or their predecessors, that reasonably could be anticipated to form the basis of an environmental claim against IDI; and (viii) IDI has made available to CMCC complete and accurate copies of all environmental assessments, investigations, reports, studies, audits, tests, reviews and other analyses in the possession of IDI relating to all Property currently owned, leased or operated in connection with the business of IDI. For purposes of this Section 2.2.1, (i) "Environmental Law" means any federal, state, foreign or local statute, law, rule, regulation, ordinance, code or rule of common law and any judicial or administrative interpretation thereof binding on IDI or its operations or property as of the date of this Agreement and Closing Date, including any judicial or administrative order, consent decree or judgment, relating to the environment, Hazardous Materials, or the protection of human health; (ii) "Hazardous Materials" means any petroleum or petroleum products, radioactive materials, asbestos in any form, polychlorinated biphenyls and radon gas, and any chemicals, materials or substances regulated under any applicable Environmental Law; and (iii) "Property" means any real property, plant, equipment, building or facility and improvements (including leasehold improvements), now or heretofore, owned, leased or operated by IDI.

3. REPRESENTATIONS AND WARRANTIES OF CMCC.

Except as set forth in the corresponding section and subsection of CMCC's disclosure schedule attached hereto as Schedule 3 (with such disclosures to qualify any other section and subsection for which the appropriateness of the disclosure is reasonably apparent on its face), CMCC represents and warrants to IDI as follows:

3.1. Organization. CMCC is a not-for-profit corporation duly organized, validly existing and in good standing under the laws of the Commonwealth of Massachusetts. CMCC has all requisite power and authority and has taken all necessary action required for the due authorization, execution, delivery and performance by CMCC of this Agreement, and the entry into and consummation of the Affiliation.

3.2. Authorization; Validity; Company Action. The execution and delivery of this Agreement, the entry into and consummation of the Affiliation and the consummation of the transactions contemplated hereby have been duly and validly authorized by all requisite corporate action, including without limitation the approval of the CMCC Board of Trustees, and no other corporate proceedings on the part of CMCC are necessary to authorize this Agreement or the Affiliation or to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by CMCC, and, assuming due authorization, execution and delivery by IDI, constitutes a valid and binding agreement of CMCC enforceable against CMCC in accordance with its terms, except as may be limited by (i) bankruptcy, insolvency, moratorium or other similar laws affecting or relating to enforcement of creditors' rights generally or (ii) general principles of equity (regardless of whether enforceability is considered in a proceeding at law or in equity).

3.3. Taxes. CMCC is tax-exempt under Section 501(c)(3) of the Code, and there are no federal, state or local investigations or audits pending with respect to the status of CMCC. CMCC has timely filed or caused to be filed all federal, state and local tax and information returns which are required to be filed, and has paid or has caused to be paid all taxes as shown on

said returns or on any assessment received by it, to the extent that such taxes have become due, except any such taxes that are immaterial in amount and reserved against or any such taxes, levies, assessments, deficiencies or claims which are being contested in good faith by appropriate proceedings.

3.4. Consent and Approval; No Conflicts. Except as set forth on Schedule 3.4 attached hereto, the execution of this Agreement, the entry into and consummation of the Affiliation, the contemplated merger under Section 6.1.2 and the compliance of CMCC with the provisions of this Agreement do not (i) violate or result in any breach of any provision of the articles of organization of CMCC (the "CMCC Articles of Organization") or the bylaws of CMCC (the "CMCC Bylaws"); (ii) require any consent, approval, waiver, filing with or notification to any Governmental Authority; (iii) result in a violation or breach of or default (or give rise to any right of termination, cancellation or acceleration) under, or require any consent, approval, waiver, filing with or notification under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, license, grant, agreement, lease or other instrument or obligation to which CMCC is a party; or (iv) violate any order, writ, injunction, decree, statute, rule or regulation applicable to CMCC.

3.5 Financial Statements. Prior to the date hereof, CMCC has furnished to IDI or its representatives (i) the audited consolidated balance sheet of CMCC as of September 30, 2007 and (ii) the related audited consolidated statements of operations and changes in net assets and cash flows for the year then ended (collectively the "Audited Financial Statements") and (iii) comparable unaudited statements as of August 31, 2008 and for the eleven months then ended (collectively the "Unaudited Financial Statements"). The Audited Financial Statements and the Unaudited Financial Statements have been prepared in accordance with generally accepted accounting principles applied on a consistent basis during the relevant periods (except as may otherwise be noted therein), and present fairly, in all material respects, the financial position, results of operations and the cash flows (as appropriate) of CMCC as of the dates, and for the periods, indicated thereon, except for the absence of footnotes and as otherwise noted therein, and subject, in the case of the Unaudited Financial Statements, to normal recurring year-end adjustments which are not material individually or in the aggregate. There are no material liabilities or obligations (absolute, accrued, contingent or otherwise) of a type that generally accepted accounting principles would require to be on the Audited Financial Statements or the Unaudited Financial Statements which are not fully reflected or reserved against in such statements, except for liabilities and obligations that may have arisen in the ordinary course of business and consistent with past practice since August 31, 2008. CMCC has maintained its books and records in accordance with generally accepted accounting principles and practices applied on a consistent basis, and such books and records are, and during the periods covered by the Audited Financial Statements and Unaudited Financial Statements were, true, correct and complete in all material respects.

3.6. Litigation. There are no Actions pending or, to the knowledge of CMCC, threatened against CMCC which involve any of the transactions contemplated herein or which, if adversely determined against CMCC, would result in any materially adverse change in the business, operations, prospects, properties or assets or in the condition (financial or otherwise) of CMCC or its subsidiaries. Additionally, CMCC is not in default with respect to any judgment,

writ, injunction, decree, rule or regulation of any court or federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, which would have a materially adverse effect on the condition (financial or otherwise) of CMCC.

4. PRE-CLOSING COVENANTS.

4.1. Between the date hereof and the Closing, IDI shall:

- (a) conduct its business in the ordinary course consistent with past practice, maintain its corporate existence, preserve intact its organizational structure and use commercially reasonable efforts to (i) keep available the services of its officers and employees, and (ii) maintain its existing relationships and goodwill with researchers, donors, governmental and quasi-governmental agencies with which it is affiliated or does business, or any lenders;
- (b) amend the Bylaws and Articles of Organization in a manner consistent with this Agreement as of the Effective Time;
- (c) notify CMCC of any material change in its financial position reflected on its Unaudited Financial Statements;
- (d) notify CMCC of receipt of any notice from any regulatory authority, including without limitation any state or federal medical oversight body, of any pending or threatened disciplinary action, change of status or any other such notice that would have a material adverse effect on the operations or finances of IDI;
- (e) notify CMCC immediately of any notice, whether written or oral, from the IRS regarding a change or potential change in its tax status;
- (f) use its commercially reasonable efforts to (i) obtain all Consents and Permits from any Governmental Authority; (ii) obtain all consents from and/or provide notifications to all third parties required hereunder, including those set forth on Exhibit 5.1.8 hereto, necessary to consummate the Affiliation; and (iii) provide written notice of the Affiliation to the Massachusetts Attorney General in the form attached hereto as Exhibit 4.1 (the "Attorney General Notice");
- (g) not enter or agree to enter into any membership arrangement with any Person; (ii) terminate any employee or officer of IDI or any of its subsidiaries except in the ordinary course of business consistent with past practice; (iii) sell, transfer or otherwise dispose of any assets with a value in excess of \$100,000, individually or in the aggregate; (iv) purchase or otherwise acquire real estate or businesses; or (v) make or commit to make any capital expenditures individually or in the aggregate in excess of \$100,000, other than in accordance with its fiscal year 2009 budget or pursuant to an existing HEFA lease facility;
- (h) except as required by applicable law, not take any action that would prevent the

Affiliation or that would prevent a Governmental Authority from granting all necessary Consents and Permits;

- (i) except as required by applicable law or pursuant to contractual obligation in effect as of the date hereof, not (i) execute, establish, adopt or amend, or accelerate rights or benefits under any agreement relating to severance or change in control, any employment or consulting agreement with current or former employees, independent contractors, other service providers, officers or members of either the IDI Board of Trustees or the IDI Board of Overseers; (ii) increase the compensation payable or to become payable to any of its officers, employees, independent contractors or other service providers; (iii) grant or increase any severance or termination pay to any officer, employee, independent contractor or other service provider of IDI; or (iv) amend any existing Plan or adopt any new Plan.
- (j) not change its accountants, fiscal year or accounting policies, practices or methods except as required by generally accepted accounting principles;
- (k) not enter into any agreement with any other Person outside of the ordinary course of business consistent with past practices;
- (l) not waive any of its rights under, or release any other Person from such other Person's obligation under, or amend or terminate any Material Agreement; and
- (m) not enter into any commitments or agreements to do any of the actions contemplated by sections (f)-(l) of this paragraph.

4.2. Between the date hereof and the Closing, CMCC shall:

- (a) notify IDI of any material change in its financial position reflected on its Unaudited Financial Statements;
- (b) notify IDI of receipt of any notice from any regulatory authority, including without limitation any state or federal medical oversight body, of any pending or threatened disciplinary action, change of status or any other such notice that would have a material adverse effect on the operations or finances of CMCC;
- (c) notify IDI immediately of any notice, whether written or oral, from the IRS regarding a change or potential change in its tax status; and
- (d) direct its representatives and advisors to take all actions necessary to consummate the Affiliation.

4.3. Prior to and from and after the Closing, IDI shall afford to CMCC and its employees, counsel, accountants and other authorized representatives full access, during normal business hours, upon reasonable advance notice, with due regard to IDI's ongoing operations, to all of the books, records, personnel files, accounts and properties of or relating to (including,

without limitation, all work papers of IDI's accountants) IDI and to all officers, employees, independent contractors, and other service providers of IDI, for any reasonable purpose whatsoever.

4.4. Prior to the Closing, CMCC shall afford to IDI and its employees, counsel, accountants and other authorized representatives full access, during normal business hours, upon reasonable advance notice, with due regard to CMCC's ongoing operations, to all of the books, records, accounts and properties of or relating to (including, without limitation, all work papers of CMCC's accountants) CMCC, for any reasonable purpose related to its due diligence review of CMCC in connection with the Affiliation.

4.5. Exhibit 4.5 attached hereto sets forth a list of all employees, consultants and independent contractors of IDI who work on a full-time or part-time basis, as well as all other service providers of IDI who work for IDI on a full-time basis, and their respective job titles, benefits and severance arrangements in effect as of the Closing. IDI shall provide to CMCC a list setting forth the compensation amounts of all individuals listed on Exhibit 4.5.

4.6. Between the date hereof and the Closing Date, IDI shall maintain in full force and effect its corporate existence, rights, governmental approvals, Consents and Permits, insurance policies, and all licenses and other rights and shall not enter into any employment, consulting, severance or other benefits arrangement or agreement (except such arrangements or agreements as IDI would enter into in the ordinary course of business), and shall operate the business in a manner consistent with past practice.

4.7. Subject to terms and conditions set forth in this Agreement, IDI and CMCC shall cooperate with each other and use their respective commercially reasonable efforts to take or cause to be taken all actions reasonably necessary or advisable to consummate the Affiliation as soon as practicable, including obtaining all necessary consents, approvals and nonobjections from third parties and Governmental Authorities.

4.8. From the date of this Agreement until the Effective Time or, if earlier, the termination of this Agreement in accordance with its terms, IDI shall not, and IDI shall cause each officer, trustee, employee, independent contractor, other service provider, agent or representative (collectively, "Representatives") of IDI not to, directly or indirectly, (i) solicit, initiate or knowingly encourage or facilitate (including by way of furnishing non-public information) any inquiries relating to, or the making or submission of, or any inquiry, offer, proposal or indication of interest that constitutes, or would reasonably be expected to lead to, an affiliation, merger or other similar strategic relationship with IDI (an "Affiliation Proposal"), (ii) participate or engage in any discussions or negotiations with, or disclose or provide any non-public information or data relating to IDI or afford access to the properties, assets, books or records or employees of IDI to any Person other than CMCC (any such Person and its Representatives a third party) relating to an Affiliation Proposal, (iii) accept, approve, endorse or recommend an Affiliation Proposal, or (iv) enter into any agreement, arrangement, contract or commitment (including any agreement in principle or letter of intent or understanding) with respect to or contemplating an Affiliation Proposal or enter into any agreement, arrangement, contract or commitment requiring IDI to abandon, terminate or fail to consummate the proposed

Affiliation. From the date of this Agreement until the Effective Time or, if earlier, the termination of this Agreement in accordance with its terms, IDI shall promptly (and in any event within 48 hours) notify CMCC of (i) any Affiliation Proposal that IDI receives or of any request for information or inquiry that IDI receives which relates to or reasonably could lead to an Affiliation Proposal, which notification shall include, (ii) the material terms and conditions of such Affiliation Proposal, request or inquiry and (iii) the identity of the Person making such Affiliation Proposal, request or inquiry.

5. OBLIGATIONS TO CONSUMMATE THE AFFILIATION.

5.1. The obligation of CMCC to consummate the Affiliation shall be subject to the fulfillment on or prior to the Closing Date of the following conditions, any or all of which may be waived by CMCC, in whole or in part, to the extent permitted by Applicable Law:

5.1.1. IDI shall have performed in all material respects each of the covenants, obligations and agreements contained in this Agreement required to be performed by it prior to or at the Closing;

5.1.2. The representations and warranties made by IDI in this Agreement shall be true, complete and accurate in all material respects on and as of the Closing Date as though made on and as of the Closing Date;

5.1.3. Between the date hereof and the Closing Date, neither IDI nor the business, properties, assets, or condition (financial or otherwise) of IDI has been materially adversely affected whether by fire, casualty, act of God or otherwise, and there shall have been no other changes in the business, properties, assets, condition (financial or otherwise), management or prospects of IDI that would have individually or in the aggregate a material adverse effect on the business, condition or results of operations of IDI, provided that neither of the following shall be taken into account in determining the occurrence of such material adverse effect: (i) a reduction in IDI's National Institutes of Health grant funding consistent with general trends in such funding and (ii) a decline in the market value of IDI's investment portfolio. Notwithstanding the foregoing, IDI agrees that it shall not materially change its portfolio investments between the date hereof and the Closing Date without the prior written consent of CMCC;

5.1.4. CMCC shall have received a certificate of IDI, dated the Closing Date, signed by the Chief Executive Officer of IDI that the conditions specified in the aforementioned paragraphs shall have been fulfilled;

5.1.5. CMCC shall have received from Edwards Angell Palmer & Dodge, LLP, counsel to IDI, an opinion, as set forth in Exhibit 5.1.5.

5.1.6. IDI shall amend its Articles of Organization and Bylaws to read as set forth in Exhibits 1.3(a) and 1.3(b) attached hereto, to among other things (a) name CMCC as its sole member; (b) provide that the Historical Trustees (defined below) shall have the authority to elect three (3) trustees to the IDI Board of Trustees in accordance with Section 5.1.7 herein,

provided that CMCC shall have the authority to object to any such trustee in CMCC's reasonable discretion; (c) provide that CMCC will have the sole authority to appoint all of the trustees on the IDI Board of Trustees (other than the Historical Trustees and the GSK Trustee), and the sole authority to remove any trustees (other than the Historical Trustees and the GSK Trustee) with or without assignment of cause; (d) provide that any Historical Trustee or the GSK Trustee may be removed (i) for cause by agreement of two-thirds of the total number of trustees and (ii) without assignment of cause by agreement of two-thirds of the total number of trustees (provided that in the case of (ii), with respect to the removal of a Historical Trustee, such number shall include a majority of the Historical Trustees eligible to vote); and (e) provide that CMCC shall have the sole authority to amend the Amended and Restated Bylaws or Amended and Restated Articles of Organization, subject to the consent rights of the Historical Trustees as set forth Section 9 of Exhibit 1.3(b). For purposes of this Agreement, the GSK Trustee means the trustee that the parties anticipate will be appointed by GlaxoSmithKline Research & Development Limited ("GSK") to the IDI Board of Trustees pursuant to Section 11 of the Research Collaboration Agreement by and between IDI and GSK, dated May 14, 2008 (the "GSK Agreement").

5.1.7. CMCC and IDI shall have agreed in writing upon the number of trustees to be appointed to the IDI Board of Trustees effective as of the Effective Time, including the number of trustees to be selected by IDI (the "Historical Trustees"), in accordance with Section 5.1.6 herein. Notwithstanding anything in this Agreement to the contrary, no individual shall serve as a Historical Trustee unless and until CMCC shall have determined, in its sole discretion, that each such individual is independent of CMCC for control purposes.

5.1.8. Each of the consents set forth on Exhibit 5.1.8 of this Agreement, in form and substance reasonably satisfactory to CMCC, shall have been obtained;

5.1.9. Neither IDI nor CMCC shall have received any notification from the Attorney General objecting to the Affiliation on any grounds in response to the Attorney General Notice;

5.1.10. No Legal Proceeding or order of any Governmental Authority shall be pending or threatened (i) challenging this Agreement or the transactions contemplated hereby or (ii) seeking to delay, restrain or prohibit the Affiliation or any other action contemplated by this Agreement; and

5.1.11. IDI shall have provided written confirmation of oral notice of the Affiliation to the National Institutes of Health ("NIH") and no notice of objection to said Affiliation shall have been received by IDI or CMCC, provided that an indication that IDI's indirect cost recovery rate may be adjusted as a result of the Affiliation shall not constitute such objection, provided that IDI's indirect cost recovery rate remains at or above eighty-nine percent (89%).

5.2. The obligation of IDI to consummate the Affiliation shall be subject to the fulfillment on or prior to the Closing Date of the following conditions, any or all of which may be waived by IDI, in whole or in part to the extent permitted by applicable law:

5.2.1. CMCC shall have performed in all material respects each of the covenants, obligations and agreements contained in this Agreement required to be performed by it prior to or at the Closing;

5.2.2. The representations and warranties made by CMCC in this Agreement shall be true, complete and accurate in all material respects on and as of the Closing Date as though made on and as of the Closing Date;

5.2.3. Between the date hereof and the Closing Date, neither CMCC nor any of its the business, properties, assets, or condition (financial or otherwise) of either have been materially adversely affected whether by fire, casualty, act of God or otherwise, and there shall have been no other changes in the business, properties, assets condition (financial or otherwise) or management of CMCC or that would have individually or in the aggregate a material adverse effect on the business, condition or results of operations of CMCC;

5.2.4. IDI shall have received a certificate of CMCC, dated the Closing Date, signed by the Chief Executive Officer or Chief Financial Officer of CMCC that the conditions specified in the aforementioned paragraphs shall have been fulfilled;

5.2.5. IDI shall have received from Ropes & Gray, LLP, counsel to CMCC, an opinion, as set forth in Exhibit 5.2.5.

5.2.6. Each of the consents set forth on Exhibit 5.1.8 of this Agreement, in form and substance reasonably satisfactory to IDI, shall have been obtained;

5.2.7. Neither IDI nor CMCC shall have received any notification from the Attorney General objecting to the Affiliation on any grounds in response to the Attorney General Notice;

5.2.8. No Legal Proceeding or order of any Governmental Authority shall be pending or threatened (i) challenging this Agreement or the transactions contemplated hereby or (ii) seeking to delay, restrain or prohibit the Affiliation or any other action contemplated by this Agreement; and

5.2.9. IDI shall have provided written confirmation of oral notice of the Affiliation to the National Institutes of Health ("NIH") and no notice of objection to said Affiliation shall have been received by IDI or CMCC, provided that an indication that IDI's indirect cost recovery rate may be adjusted as a result of the Affiliation shall not constitute such objection, provided that IDI's indirect cost recovery rate remains at or above eighty-nine percent (89%).

6. POST-CLOSING COVENANTS.

6.1. Corporate Governance Matters.

6.1.1. Until the merger of IDI into CMCC or a controlled affiliate of CMCC pursuant to Section 6.1.2 below, the Historical Trustees and the GSK Trustee will continue to

serve on the IDI Board of Trustees for terms set forth in the Amended and Restated Bylaws. Any vacancy on the IDI Board of Trustees resulting from the resignation or removal of (i) a Historical Trustee shall be filled by a majority of the Historical Trustees then in office and (ii) the GSK Trustee shall be filled by the GSK Trustee then in office; provided, however, that CMCC shall have the authority to object to any trustee appointed by the Historical Trustees in CMCC's reasonable discretion.

6.1.2. Anytime on or after October 1, 2012 (or earlier with the mutual agreement of a majority of the Historical Trustees), CMCC shall have the right to merge IDI into CMCC or a controlled affiliate of CMCC and the faculty members of IDI will become employees of the successor to IDI or such CMCC affiliate as customarily employs faculty of the same specialty. Upon any such merger, such faculty members will be entitled to participate in such salary, benefit and compensation programs as are customarily available to CMCC-employed faculty, subject to the requirements of applicable law.

6.1.3. In the event of a merger pursuant to Section 6.1.2 herein, until the fifth (5th) anniversary of the Effective Time, the Historical Trustees, acting unanimously, shall continue to have the authority to enforce the terms of the Affiliation for the benefit of the IDI Program (defined below). Without limiting the foregoing, the Historical Trustees, acting unanimously, shall have the authority to retain separate legal counsel, at IDI's sole cost and expense, if such trustees reasonably determine that the hiring of such counsel is necessary to enforce the provisions of this Section 6 to the extent such terms are for the express benefit of the IDI Program (defined below).

6.2. Program Matters.

6.2.1. As soon as reasonably practical after the Effective Time, CMCC will cause IDI to be recognized as a CMCC multidisciplinary research program (the "IDI Program") with status equivalent to CMCC's existing multidisciplinary research programs in Vascular Biology, Genomics, Bio-Informatics, Stem Cell Biology, and Neuroscience (the "CMCC Existing Programs"). The IDI Program will be named the "Program in Cellular and Molecular Medicine" or such other name as the IDI Board of Trustees may determine from time to time with the approval of a majority of the Historical Trustees, such approval not to be unreasonably withheld or delayed.

6.2.2. Until the fifth (5th) anniversary of the Effective Time, the IDI Program shall be entitled to all of the rights, and be subject to all of the obligations, that CMCC provides and / or requires of the CMCC Existing Programs, including, without limitation, CMCC's guarantee of CMCC program status for the IDI Program. For the avoidance of doubt, CMCC commitments with respect to CMCC's support of the IDI Program for the five (5) year period beginning at the Effective Time shall continue for such 5-year period in the event IDI is merged into a CMCC affiliate as set forth in Section 6.1.2.

6.3. Personnel / Recruitment Matters.

6.3.1. Dr. Fred Alt will be the Executive Director of the IDI Program (the "IDI Director") until the fifth (5th) anniversary of the Effective Time. If for any reason Dr. Alt should cease to be the IDI Director during the five (5) year period following the Effective Time, a majority of trustees on IDI's Board of Trustees shall appoint a successor to Dr. Alt; provided, that such successor has been approved by a majority of the Historical Trustees, such approval not to be unreasonably withheld or delayed.

6.3.2 Until the fifth (5th) anniversary of the Effective Time, the IDI Director shall report directly to the Chief Executive Officer and the Chief Operating Officer of CMCC. The salary of the IDI Director shall be set and approved jointly by the Chief of the applicable CMCC Department and the Chief Executive Officer of CMCC.

6.3.3. Until the fifth (5th) anniversary of the Effective Time, the IDI Director shall serve as a member of CMCC's Research Strategy Group ("RSG") and Research, Recruitment, and Resource Committee ("RRRC"), or any such successor committees.

6.3.4. As soon as reasonably practical after the Effective Time, each faculty member of IDI, a list of whom is set forth on Exhibit 6.3.4, shall become a faculty member of an appropriate department at Children's Hospital Boston. Salaries for such faculty members shall comply with Harvard Medical School Compensation Guidelines and shall be subject to the approval of the Chief of the applicable department at Children's Hospital Boston, in consultation with the IDI Director.

6.3.5. Until the fifth (5th) anniversary of the Effective Time, the IDI Program shall be entitled to recruit faculty, post doctorates and other personnel in the same fashion as the CMCC Existing Programs. To the extent that any recruitment by the IDI Program requires resources of CMCC, or to the extent that the IDI Program desires to receive resources from CMCC to achieve a recruitment, such recruitment shall be subject to the processes and approvals required of any Program seeking CMCC support (currently, the approval of RRRC and the CMCC Chief Executive Officer ("CEO")). It is the intent of the Parties initially to recruit three (3) additional faculty after the Effective Time and subject to approval by RRRC and the CEO. CMCC will reimburse IDI for fifty percent (50%) of the salary, benefits and customary start up expenses associated with said additional personnel for up to three (3) years for each such individual.

6.3.6. Until the first (1st) anniversary of the Effective Time, Theodore M. Cronin will be retained as IDI's Chief Executive Officer and Chief Financial Officer, unless he resigns from employment or is otherwise terminated earlier for cause. Until the earlier of (i) the fifth (5th) anniversary of the Effective Time and (ii) merger of IDI into CMCC or a controlled affiliate of CMCC pursuant to Section 6.1.2 above, any successor to Mr. Cronin must be approved by a majority of the Historical Trustees, such approval not to be unreasonably withheld or delayed.

6.3.7. Until the second (2nd) anniversary of the Closing Date, CMCC will use reasonable efforts to offer comparable employment with a CMCC affiliate to any full-time administrative employee of IDI as of the Closing Date, a list of whom as of December 1, 2008 is set forth on Exhibit 6.3.7, whose employment is terminated after the Closing Date without assignment of cause. Notwithstanding anything in this Agreement to the contrary, under no circumstances shall any party, including IDI and / or a current or former employee of IDI, have any right or other cause of action to enforce the foregoing obligation against CMCC.

6.4. Financial Matters.

6.4.1. In order to provide IDI with the benefit of CMCC's investment management expertise and to effectuate any additional provisions related to the obligations contemplated by Section 6.4.2 herein, the Parties shall as soon as practicable after the Effective Time execute an agreement to transfer management of IDI's endowment (the "IDI Endowment") to CMCC (the "Endowment Investment Agreement") substantially in the form of Exhibit 6.4.1 hereto. As provided in the Endowment Investment Agreement, CMCC shall allocate \$20 million of its existing endowment, which shall remain under the designation and control of CMCC, to be invested along side the IDI Endowment (together the "Combined Funds").

6.4.2. In the event that, prior to the merger of the IDI Program into a CMCC affiliate as contemplated by Section 6.1.2 herein, CMCC suffers any individual or series of losses, liabilities, obligations, damages, diminution in value, notices, actions, suits, proceedings, claims, demands, assessments, judgments, costs, penalties or expenses (including reasonable attorneys' and other professionals' fees and disbursements) having an adverse financial impact equal to or greater than One Million Dollars (\$1,000,000) in the aggregate (individually a "Loss" and, collectively, "Losses") based upon or arising from any breach of any representation, warranty or other obligation made by IDI in this Agreement, CMCC shall provide written notice of such Loss(es) to the Historical Trustees (provided that failure to so notify shall not deprive CMCC of its rights under this Section; and provided further that the \$1,000,000 aggregate loss amount shall not apply in the case of Loss(es) arising on the account of IDI's fraud). Notwithstanding anything in this Agreement to the contrary, in the event of any such Loss(es), CMCC shall have the right to access and utilize funds from the IDI Endowment to reimburse CMCC in the amount of such Loss(es), and to the extent the funds available in the IDI Endowment are not available to cover such Loss(s), CMCC may also decrease the amount of financial support that CMCC is obligated to provide to the IDI Program under this Agreement, including, without limitation, the Support Payments (as hereinafter defined) in accordance with Section 6.4.3 herein. In addition, without limiting the foregoing, and without in any way limiting CMCC's rights under this Agreement generally, CMCC expressly reserves the right to make operational and/or programmatic changes to the IDI Program to the extent the event giving rise to the Loss(es) is recurring or causes ongoing losses to the IDI Program.

6.4.3. Each of IDI and CMCC agrees that the IDI Program will be subject to the spending rules and oversight of funds established by CMCC, as the same may be amended from time to time. IDI covenants and agrees that IDI shall use commercially reasonable efforts to manage its financial resources such that IDI's Operating Loss shall not exceed more than

\$1,000,000 in any fiscal year. For purposes of this Section 6.4.3, "Operating Loss" is defined as (i) IDI's operating revenue, (ii) less IDI's operating expenses, (iii) plus five percent (5%) of the Combined Funds. Until the fifth (5th) anniversary of the Effective Time, CMCC agrees to support any such operating loss up to \$1,000,000 in any fiscal year (the "Support Payments"). CMCC agrees that it will not fund any Support Payments from the Combined Funds.

6.4.4. Until the fifth (5th) anniversary of the Effective Time, CMCC will actively engage in fundraising on behalf of and in cooperation with the IDI Program in substantially the same fashion as CMCC does for the CMCC Existing Programs, and CMCC will commit substantially similar resources to the IDI Program in support of this effort. Such fundraising will be conducted so as not to infringe upon existing relationships established by CMCC departments, divisions or programs or use their names without consent of their chair, chief or program director.

6.4.5. Until the fifth (5th) anniversary of the Effective Time, the IDI Program will occupy the space at the Alpert Building and in the Center for Life Science Boston Building. CMCC also agrees that during this period, CMCC will use reasonable efforts to ensure that any adjustments to the IDI Program space will not result in the IDI Program having space in more than two locations.

6.4.6. As soon as reasonably practical after the Effective Time, CMCC and the IDI Program will jointly explore opportunities that will allow the IDI Program to achieve administrative efficiencies and / or benefits; provided that no such efficiencies will be undertaken until the first (1st) anniversary of the Effective Time unless otherwise agreed to by the Chief Executive Officer of IDI or a majority of the Historical Trustees.

6.5. Intellectual Property Matters. All IDI Intellectual Property Rights not previously licensed as of the Effective Time shall at the Effective Time be subject to the policies and procedures established by CMCC with respect to intellectual property of CMCC and/or its affiliates, as the same may be amended from time to time; provided, however, that this section shall not apply to any IDI Intellectual Property Rights subject to the GSK Agreement.

6.6. Trustee and Officer Indemnification and Insurance.

6.6.1. IDI shall indemnify and advance expenses to individuals who were trustees and officers of IDI prior to the Effective Time at least to the extent provided in the Articles of Organization and the Bylaws on the date hereof, regardless of any amendment, repeal or other modification of the Articles of Organization and the Bylaws.

6.6.2. Prior to the Effective Time or as soon as practicable thereafter, IDI shall obtain and fully pay for "tail" insurance policies with a claims period of at least six years from and after the Effective Time from IDI's current director and officer liability insurance ("D&O Insurance") carrier or another carrier with the same or better credit rating, for the persons who, as of the date hereof, are covered by IDI's existing D&O Insurance with terms at least as favorable as IDI's existing D&O Insurance with respect to matters existing or occurring at or prior to the

Effective Time (including in connection with this Agreement and the Affiliation), and IDI shall maintain such D&O Insurance in full force and effect for the full term.

6.6.3. From the Effective Time and until such time as IDI may merge into CMCC or a controlled affiliate of CMCC pursuant to Section 6.1.2, IDI will provide to the trustees and officers of IDI the same indemnification and advance of expenditures rights and CMCC will arrange for IDI to have D&O Insurance coverage consistent with the coverage CMCC provides for its own trustees and officers. CMCC will arrange for IDI to have D&O Insurance coverage consistent with the coverage extended to CMCC and its affiliates provided that IDI recognizes and agrees that such coverage will not be in effect as of the Closing Date if the Closing occurs prior to April 1, 2009; provided further that CMCC reasonably anticipates that the coverage will be made retroactive to the Effective Date.

7. PUBLIC DISCLOSURE. Each of CMCC and IDI agrees that it shall not make any public announcement or issue any press release in connection with the transactions contemplated hereby, except (i) as provided in this paragraph, (ii) in accordance with the terms of the Confidentiality Agreement (as defined below), and (iii) pursuant to a mutual agreement of the parties hereto; provided, however, that nothing contained herein shall prevent any Party, at any time, from furnishing any information required by any Governmental Authority or from issuing any announcement, press release, public statement or other information to the press or any third party with respect to this Agreement if required by applicable law; provided, further, that to the extent reasonably practical, the Parties agree to consult with each other as to the content of any such disclosure so required and consider in good faith the comments of the other thereon. The Parties will jointly agree upon and approve any press release to be issued by CMCC on or after the date hereof in connection with this Agreement.

8. TERMINATION.

8.1. This Agreement may be terminated on or prior to the Closing (a) by the mutual written consent of IDI and CMCC or (b) by either IDI or CMCC if the Closing shall not have occurred on or before six (6) months from the date hereof, unless the terminating party has failed to perform or observe any agreement or condition set forth herein that is required to be observed by such party on or before the Closing.

8.2. In the event that IDI willfully breaches this Agreement, IDI shall reimburse CMCC for all expenses incurred in connection with the Affiliation, including without limitation attorneys fees, accountants fees, filing fees and any other reasonable fees that CMCC determines directly relate to the Agreement or the Affiliation

8.3. In the event that CMCC willfully breach this Agreement, CMCC shall reimburse IDI for all expenses incurred in connection with the Affiliation, including without limitation attorneys fees, accountants fees, filing fees and any other reasonable fees that IDI determines directly relate to the Agreement or the Affiliation.

9. MISCELLANEOUS.

9.1. All notices, requests, consents, reports and demands shall be in writing and shall be hand delivered, sent by facsimile or other electronic medium, or mailed, postage prepaid, to IDI or to CMCC at the address set forth below or to such other address as may be furnished in writing to the other parties hereto:

To IDI:

Theodore M. Cronin
Acting President and Chief Financial Officer
Immune Disease Institute, Inc.
800 Huntington Avenue
Boston, MA 02115

With a copy to:

David R. Pokross, Jr.
Edwards Angell Palmer & Dodge, LLP
111 Huntington Ave.
Boston, MA 02199

To CMCC:

James Mandell, M.D.
Chief Executive Officer
The Children's Medical Center Corporation
300 Longwood Ave.
Boston, MA 02115

With copies to:

Stuart J. Novick
Senior Vice President & General Counsel
Children's Hospital Boston
300 Longwood Avenue
Boston, MA 02115

Michele Garvin
Ropes & Gray, LLP
One International Place
Boston, MA 02110

9.2. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by either

Party, including by operation of law without the prior written consent of the other Party. Except for the rights of (i) IDI trustees and officers to indemnification and insurance protection under Section 6.6 and (ii) the Historical Trustees to enforce this Agreement under Section 6.1.3, this Agreement is not intended to confer upon any Person other than the Parties any rights or remedies hereunder.

9.3. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (regardless of the laws that might otherwise govern under applicable Massachusetts principles of conflicts of law) as to all matters, including but not limited to matters of validity, construction, effect, performance and remedies, and IDI and CMCC hereby agree to irrevocably and unconditionally submit to the exclusive jurisdiction of any state or federal court sitting in Suffolk County, Massachusetts over any suit, action or proceeding arising out of or relating to this Agreement.

9.4. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

9.5. This Agreement may be executed in counterparts, including by facsimile, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. The Parties agree that they have been represented by counsel during the negotiation and execution of this Agreement and, therefore, waive the application of any applicable law, regulation, holding or rule of construction providing that ambiguities in an agreement, document or provision will be construed against the party drafting such agreement, document or provision.

9.6. Definitions in this Agreement shall apply equally to both the singular and plural forms of the terms defined. All Exhibits attached hereto shall be deemed incorporated herein as if set forth in full herein and, unless otherwise defined therein, all terms used in any Exhibit shall have the meanings ascribed to such terms in this Agreement. The words "hereof," "hereinafter," "herein" and "hereunder" and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The word "including" or any variation thereof means "including, without limitation" and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it. Unless otherwise expressly provided herein, any statute referred to herein means such statute as may from time to time be amended, modified or supplemented.

9.7. If for any reason any term or provision of this Agreement is held to be invalid or unenforceable, all other valid terms and provisions hereof shall remain in full force and effect, and all of the terms and provisions of this Agreement shall be deemed to be severable in nature.

9.8. This Agreement including the Exhibits referred to herein and the Confidentiality Agreement between IDI and CMCC dated February 6, 2008 (the "Confidentiality Agreement") embody the entire agreement and understanding of the parties hereto in respect of the transactions contemplated by this Agreement. There are no restrictions, promises, representations, warranties, covenants or undertakings, other than those expressly set forth or


referred to herein or therein. This Agreement supersedes all prior agreements and understandings between the Parties with respect to such transactions other than the Confidentiality Agreement.

[Signature page follows]

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective, duly authorized officers as of the date first above written.

THE CHILDREN'S MEDICAL CENTER
CORPORATION

By: _____


James Mandell, M.D.
Chief Executive Officer

IMMUNE DISEASE INSTITUTE, INC.

By: _____

Theodore M. Cronin
Acting President and Chief Financial Officer

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective, duly authorized officers as of the date first above written.


THE CHILDREN'S MEDICAL CENTER
CORPORATION

By: _____

James Mandell, M.D.
Chief Executive Officer

IMMUNE DISEASE INSTITUTE, INC.

By: _____


Theodore M. Cronin
Acting President and Chief Financial Officer

A

EXHIBIT 1.3(a)

AMENDED AND RESTATED ARTICLES OF ORGANIZATION

See Attached.

EXHIBIT 1.3(b)

AMENDED AND RESTATED BYLAWS

See Attached.

EXHIBIT 4.1

ATTORNEY GENERAL NOTICE

See Attached.

EXHIBIT 4.5

EMPLOYEES AND INDEPENDENT CONTRACTORS

Immune Disease Institute - Administrative & Facilities Personnel

Last	First	Title
Administration		
Cronin	Theodore	Acting President & CFO
Simmons	Steven	Director of Finance & Operations
Majewski	Amanda	Office Manager/Administrator
Bradley	Margaret	Chief Scientific Administrative Officer
DiPasquale	Zachary	Administrative Assistant
Norris	John	Envir. Health & Safety Mgr
Boothby	Catherine	Administrative Assistant
		Executive Officer for Institutional
Rosenbaum	Rachelle	Relations
Nicholson	Shirley	IACUC Coordinator
Viehman	Louise	Administrative Assistant
Animal Facility		
Chenaif	Miriam	Animal Caretaker
Sumpf	Sierra	Animal Caretaker
Ramirez	Francia	Animal Caretaker
Facilities		
Bono	George	Director of Construction Projects
Garcia	Oscar	Facilities Assistant
Landry	Peter	Facilities Manager
Schmidt	Howard	Sr. Security/Helpdesk SC
Accounting, Finance & Grants Administration		
Carriuolo	Stephen	Controller
Houriham	Helen	Grants Manager
Morris	Barbara	Financial Analyst
Craig	Nicole	Accountant/Financial Analyst
Frank	David	Accountant/Payroll Mgr.
Goto-Hardy	Megumi	A/P Clerk
Chen	Eva	Accts Payable Coordinator
Cheung	Elisa	Accounts Payable Supv.

Core Facility

Ketman	Kenneth	Cell Sorter Operator
Barteneva	Natalie	Director Flow Cytometry
Leung	Harry	Dir. Microscope Core Fac

Human Resources

Morgan Williams	Christine	Hum. Resources Generalist
Wilson	Nicole	H.R. Intern
Rosenbaum	Joshua	Human Resources Rep.
Santos	Gabriel	Immigration Specialist
Donovan	Doreen	HR Director

IT Services

LaSalle Jr.	Jurvis	IT Manager & Systems Architect
Lamb	Braden	Jr. Desktop Specialist
May	Timothy	Desktop Support Specialist
O'Connor	Justin	Systems Administrator
Perry	James	Jr Systems Administrator

Glass Wash Facility

Williams	Ronald	Laboratory Aide
Garcia	Hector	Laboratory Aide
Halhoul	Latifa	Laboratory Aide
Hines	Jesse	Supervisor Glasswash

Technology Development

Hsu	Amy	Admin. Asst.
Dietz	Ryan	Director of Tech Development

Procurement

Buchanan, Jr.	Jack	Procurement Manager
---------------	------	---------------------

Scientific Personnel**Alper Lab**

Borotto	Nicholas	Co-op Student
Garbarino	Kathleen	Co-op Student
Jalloh	Yanoh	Co-op Student
Kunnenkeri	Sushruta	Co-op Student
Tarnacki	Jennifer	Co-op Student
Alford	Dennis	Research Scientist
Larsen	Charles	Jr. Investigator
Trautwein	Michael	Research Technic.
Alper	Chester	Sr. Investigator

Alt Lab

Needham	Judith	Administrative
Basu	Uttiya	Assistant
Choi	Vivian	Research Fellow
Datta	Abhishek	Research Fellow
Franklin	Andrew	Research Fellow
Gostissa	Monica	Research Fellow
Phan	Ryan	Research Fellow
Schwer	Bjoern	Research Fellow
Wang	Jing	Research Fellow
Zhang	Yu	Research Fellow
Zhu	Li	Research Fellow
Acquaviva	Lisa	Research Technic.
Bianco	Julia	Research Technic.
Gallagher	Michael	Research Technic.
Hansen	Erica	Research Technic.
Patel	Harin	Research Technic.

Carroll Lab

Carroll	Elisabeth	Sr. Research Associate
Conway	Ryan	Animal Technologist
Constantin	Myrna	Research Fellow
Tsiftoglou	Stefanos	Research Fellow
Fernandez		
Gonzalez	Santiago	Research Fellow
Kim	Young-A	Research Fellow
Kuligowski	Michael	Research Fellow
Pitcher	Lisa	Research Fellow
Ma	Minghe	Research Assoc.
Carroll	Michael	Sr. Investigator

Davis Lab

Fernandes	Stacey	Research Technic.
Mejia De La		
Roca	Juan	Research Fellow
Lu	Fengxin	Research Fellow
Davis	Alvin	Sr. Investigator

Goldfeld Lab

Blodgett	Christopher	Admin. Asst.
Biglione	Sebastian	Research Fellow
Jasenosky	Luke	Research Fellow
Haridas	Viraga	Research Fellow
Falvo	James	Instructor
Ranjbar	Shahin	Jr. Investigator

Tsytsykova	Alla	Jr. Investigator
Goldfeld	Anne	Sr. Investigator
Hur		
Peisley	Alys	Research Fellow
Hur	Sun	Jr. Investigator
Kirchhausen		
Boecking	Till	Research Fellow
Rapoport	Iris	Research Assoc.
Cocucci	Emanuele	Research Fellow
Guan	Rong	Research Fellow
McDonald	Catherine	Admin. Asst.
Kural	Comert	Research Fellow
Lu	Lei	Research Fellow
Saffarian	Saviz	Research Assoc.
Yu	Anan	Research Fellow
Boll	Werner	Research Assoc.
Marino	Eric	Imaging Specialist
Kirchhausen	Tomas	Sr. Investigator
Rossi		
Zguro	Dhoksiana	Research Technic.
Beerman	Isabel	Research Fellow
Warren	Luigi	Research Fellow
Gazit	Roi	Research Fellow
Rossi	Derrick	Jr. Investigator
Winau Lab		
Winau	Florian	Jr. Investigator
Fraser Lab		
Ding	Wei-Zi	Research Technic.
Fraser	Patricia	Jr. Investigator
Silberstein Lab		
Pivarnik	Gregory	Research Technic.
Graves	Katherine	Research Technic.
Stegner	Joseph	Research Assoc.
Waters	Collin	Research Technic.
Silberstein	Leslie	Sr. Investigator
		CHCT Prog.
Thostenson	Kari	Administrator
Armant	Myriam	Assistant Director

Rajewsky Lab

Grundy	Jaclyn	Lab Technician
Jensen	Kari	Research Technic.
Xia	Junrong	Research Technic.
Pellerin	Alex	Research Technic.
Zhang	Baochun	Research Fellow
Koralov	Sergei	Research Fellow
Wang	Jing	Research Technic.
Derudder	Emmanuel	Research Fellow
Srinivason	Lakshmi	Research Fellow
Wang	Donghai	Research Fellow
Chakraborty	Tirtha	Research Fellow
Thai	To-Ha	Research Fellow
Seagal	Jane	Research Fellow
Otipoby	Kevin	Research Fellow
Ottaviano	Michelle	Admin. Asst.
Bamberg	Michael	Lab Manager
		Mgr.
Ghitza	Dvora	Con.Mut.MouseFac
Rajewsky	Klaus	Sr. Investigator

Remold Lab

Stolley	James	Research Technic.
Gong	Dapeng	Research Fellow
Cooley	Jessica	Lab Manager
Benarafa	Charaf	Instructor
Remold-		
O'Donnell	Eileen	Sr. Investigator

Shimaoka Lab

Silkworth	Whitney	Research Technic.
Morishita	Yoshiyuki	Research Fellow
Srinivasan	Charudharshini	Research Fellow
Park	Eun Jeong	Research Fellow
Peer	Dan	Research Fellow
Shimaoka	Motomu	Investigator

Springer Lab

Drabek	Andrew	Research Technic.
Eng	Edward	Research Fellow
Mondal	Subhanjan	Research Fellow
Shi	Minlong	Research Fellow
Zhang	Qing	Research Fellow
Zhou	Yanfeng	Research Fellow

Chen	Xing	Research Fellow
Zhang	ChengZhong	Research Fellow
Kim	Jongseong	Research Fellow
Sen	Mehmet	Research Fellow
Smagghe	Benoit	Research Fellow
Yu	Yamei	Research Fellow
Zhu	Jianghai	Research Fellow
Schuerpf	Thomas	Research Fellow
Grey	Michael	Research Fellow
Mi	Li Zhi	Research Fellow
Zhu	Jieqing	Research Fellow
Pierce	April	Admin. Asst.
Xie	Can	Research Fellow
Mulligan	Eadaoin	Lab Manager
Lu	Chafen	Investigator
Springer	Timothy	Sr. Investigator

Von Andrian Lab

Alton	Jennifer	Admin. Asst.
		Short term Research
Perdomo Ortiz	Lilia	Schol
Cheng	Guiying	Research Assoc.
Mazo	Irina	Jr. Investigator

Wagner Lab

Carbo Cots	Carla	Research Fellow
Schatzberg	Daphne	Research Technic.
Yang	Janie	Research Technic.
Canault	Matthias	Research Fellow
Duerschmied	Daniel	Research Fellow
Cifuni	Stephen	Research Technic.
Brill	Alexander	Research Fellow
Chauhan	Anil	Instructor
Zhao	Bingqiao	Research Fellow
Cowan	Lesley	Admin. III
Wagner	Denisa	Sr. Investigator

Rao Lab

Keil	Brittany	Research Technic.
Kenney	Grace	Research Technic.
Kwon	Hyoung	Research Technic.
Pishyareh	Mojgan	Research Technic.
Stevanovic	Irena	Research Fellow
Gelinas	Curtis	Research Technic.
Banfield-Weir	Jake	Admin. Asst.

Bandukwala	Hozefa	Research Fellow
Ghosh	Srimoyee	Research Fellow
Zhou	Yubin	Research Fellow
Meraner	Paul	Research Fellow
Sundrud	Mark	Research Fellow
Koh	Kian Peng	Research Fellow
Mueller	Martin	Research Fellow
Oberdoerffer	Shalini	Research Fellow
Li	Huiming	Research Fellow
Ohora	Masatsugu	Instructor
Sharma	Sonia	Research Fellow
Hogan	Patrick	Investigator
Lee	Jung	Lab Manager
Lamperti	Edward	Research Assoc.
Rao	Anjana	Sr. Investigator

Lieberman

McKernan	Shannon	Research Technic.
Tsai	Perry	Research Technic.
Ferrini, II	Roger	Research Fellow
Thiery	Jerome	Research Fellow
Yan	Nan	Research Fellow
Petrocca	Fabio	Research Fellow
Wu	Yichao	Research Fellow
Ahmed	Fariyal	Research Fellow
Navarro Lopez	Francisco	Research Fellow
Leonard	Julie	Admin. Asst.
Lal	Ashish	Instructor
Martinvalet	Denis	Research Fellow
Xu	Zhan	Research Assoc.
Lieberman	Judy	Sr. Investigator

NRSA

Pipkin	Matthew	Research Fellow
--------	---------	-----------------

Independent Contractors

Kathleen Dimino
 Robert Forrester
 Dr. May S. Jacobson
 Sherwin Kevy
 Ian Levesque
 Patricia McCaffrey, PhD

Piotr Sliz Agreement dated December 21, 2007

EXHIBIT 5.1.5

OPINION FROM EDWARDS ANGELL PALMER & DODGE LLP

See Attached.

EXHIBIT 5.1.8

CONSENTS

1. Lease by President and Fellows of Harvard College to Blood Research Institute, Inc., dated September 3, 1992
2. Sublease by Blood Research Institute, Inc. to Center for Blood Research, Inc., dated September 3, 1992
3. Research Collaboration Agreement by and between Immune Disease Institute, Inc. and GlaxoSmithKline Research & Development Limited, dated May 14, 2008

EXHIBIT 5.2.5

OPINION FROM ROPES & GRAY, LLP

See Attached.

EXHIBIT 6.3.4

FACULTY MEMBERS

<u>Name</u>	<u>Harvard Medical School Appointment</u>
1. Frederick W. Alt, Ph.D.	Charles A. Janeway Professor of Pediatrics & Professor of Genetics
2. Chester A. Alper, M.D.	Professor of Pediatrics
3. Michael Carroll, Ph.D.	Professor of Pediatrics (Pathology)
4. Alvin E. Davis, III, M.D.	Professor of Pediatrics
5. Anne E. Goldfeld, M.D.	Associate Professor of Medicine
6. Sun Hur, Ph.D.	Lecturer (pending Assistant Professor) of Biological Chemistry and Molecular Pharmacology
7. Tomas Kirchhausen, Ph.D.	Professor of Cell Biology
8. Judy Lieberman, M.D., Ph.D.	Professor of Pediatrics
9. Eileen Remold-O'Donnell, Ph.D.	Professor of Pediatrics
10. Anjana Rao, Ph.D.	Professor of Pathology
11. Klaus Rajewsky, M.D.	Fred S. Rosen Professor of Pediatrics & Professor of Pathology
12. Derrick J. Rossi, Ph.D.	Assistant Professor of Pathology
13. Motomu Shirnaoka, M.D., Ph.D.	Associate Professor of Anesthesiology
14. Leslie Silberstein, M.D.	Professor of Pathology (Pediatrics)
15. Timothy Springer, Ph.D.	Latham Family Professor of Pathology
16. Erdyni Tsitsiklov, Ph.D.	Assistant Professor of Pediatrics
17. Ulrich von Andrian, M.D., Ph.D.	Edward Mallinckrodt Jr. Professor of Immunopathology (Pathology)
18. Denisa D. Wagner, Ph.D.	Professor of Pathology
19. Florian Winau, M.D.	Lecturer (pending Assistant Professor) of Pathology

EXHIBIT 6.3.7

ADMINISTRATIVE PERSONNEL

Last	First	Title
Administration		
Cronin	Theodore	Acting President & CFO
Simmons	Steven	Director of Finance & Operations
Majewski	Amanda	Office Manager/Administrator
Bradley	Margaret	Chief Scientific Administrative Officer
DiPasquale	Zachary	Administrative Assistant
Norris	John	Envir. Health & Safety Mgr
Boothby	Catherine	Administrative Assistant
Rosenbaum	Rachelle	Executive Officer for Institutional Relations
Nicholson	Shirley	IACUC Coordinator
Viehman	Louise	Administrative Assistant
Animal Facility		
Chenaif	Miriam	Animal Caretaker
Sumpf	Sierra	Animal Caretaker
Ramirez	Francia	Animal Caretaker
Facilities		
Bono	George	Director of Construction Projects
Garcia	Oscar	Facilities Assistant
Landry	Peter	Facilities Manager
Schmidt	Howard	Sr. Security/Helpdesk SC
Accounting, Finance & Grants Administration		
Carriuolo	Stephen	Controller
Houriham	Helen	Grants Manager
Morris	Barbara	Financial Analyst
Craig	Nicole	Accountant/Financial Analyst
Frank	David	Accountant/Payroll Mgr.
Goto-Hardy	Megumi	A/P Clerk
Chen	Eva	Accts Payable Coordinator
Cheung	Elisa	Accounts Payable Supv.
Core Facility		
Ketman	Kenneth	Cell Sorter Operator
Barteneva	Natalie	Director Flow Cytometry
Leung	Harry	Dir. Microscope Core Fac

Human Resources

Morgan Williams	Christine	Hum. Resources Generalist
Wilson	Nicole	H.R. Intern
Rosenbaum	Joshua	Human Resources Rep.
Santos	Gabriel	Immigration Specialist
Donovan	Doreen	HR Director
IT Services		
LaSalle Jr.	Jurvis	IT Manager & Systems Architect
Lamb	Braden	Jr. Desktop Specialist
May	Timothy	Desktop Support Specialist
O'Connor	Justin	Systems Administrator
Perry	James	Jr Systems Administrator

**Glass Wash
Facility**

Williams	Ronald	Laboratory Aide
Garcia	Hector	Laboratory Aide
Halhoul	Latifa	Laboratory Aide
Hines	Jesse	Supervisor Glasswash

Technology Development

Hsu	Amy	Admin. Asst.
Dietz	Ryan	Director of Tech Development

Procurement

Buchanan, Jr.	Jack	Procurement Manager
---------------	------	---------------------

Administrative Assistants to Investigators

Needham	Judith	Administrative Assistant
Blodgett	Christopher	Administrative Assistant
McDonald	Catherine	Administrative Assistant
Thostenson	Kari	CHCT Prog. Administrator
Ottaviano	Michelle	Administrative Assistant
Pierce	April	Administrative Assistant
Alton	Jennifer	Administrative Assistant
Cowan	Lesley	Administrative Assistant
Banfield-Weir	Jake	Administrative Assistant
Leonard	Julie	Administrative Assistant

EXHIBIT 6.4.1

ENDOWMENT INVESTMENT AGREEMENT

See Attached.

B

SCHEDULE 2

IDI DISCLOSURE SCHEDULE

SCHEDULE 2.1

SUBSIDIARIES, AFFILIATES AND OTHER INTERESTS IN ENTITIES

Subsidiaries

None.

Affiliates

Blood Research Institute, Inc., a Massachusetts not-for-profit corporation. The president of IDI serves as a trustee.

Stock Ownership – Not Publicly Traded

Natural Antibodies, 20,000 shares

Cardicum Pharmaceuticals, Inc., 484 shares

LigoCyte Pharmaceuticals, Inc., 5,000 shares

Mosaic Technologies, Inc., 8,000 shares

SCHEDULE 2.3(a)

IDI BOARD OF TRUSTEES AND IDI BOARD OF OVERSEERS

IDI BOARD OF TRUSTEES

Frederick W. Alt, PhD
Steven M. Berzin
Robert Carpenter
Anish B. Dhanda
M. Douglas Dunn
Winifred Perkin Gray
Arthur R. Greene, Jr.
Zsolt Harsanyi
Yumiko Honda

Michael Lytton, M.Sc., J.D.
Vicki Modell
Martin Peretz, PhD
Joan Pinck
Walter M. Pressey
Sarah J. Schiermeyer
Enid M. Starr
William H. Tehan
Gary D. Tureski

IDI HONORARY TRUSTEES

Casimir de Rham, Jr.
David A. Mittell

Maurice M. Pechet, M.D., PhD
Douglas M. Surgenor

IDI BOARD OF OVERSEERS

A. Edward Allinson
Laurence Aucella
Robert Forrester
Howard J. Goldman
John T. Hemenway
Eric R. Hubbard
E. Barlow Keener
Jessica Brilliant Keener
John Landis
Frederick H. Lovejoy, Jr., M.D.

William J. McCune, Jr.
Matthew McPherron
Frederick H. Modell
Joseph Perini
David R. Pokross, Jr.
Nancy Potter
Harriet L. Robinson, PhD
Timothy A. Springer, PhD
Timothy R. Surgenor
Christopher M. Walter

SCHEDULE 2.3(b)

IDI OFFICERS

Walter M. Pressey	Chairman of the Board
Michael Lytton	Vice Chairman of the Board
Theodore M. Cronin	Acting President, CEO and CFO
Steven M. Berzin	Treasurer
Frederick W. Alt, PhD	Scientific Director
Chester A. Alper, PhD	Vice President
David R. Pokross, Jr.	Clerk
Rachelle A. Rosenbaum	Assistant Clerk

SCHEDULE 2.3(c) and (d)

IDI BANK & INVESTMENT ACCOUNTS

Approximate Balance 10/31/08Citizens Bank

Signatories:

Theodore Cronin
Steven Simmons

Accounts:

1. Commercial checking	\$1,356,753
2. Operating money market	1,289
3. Endowment money market	157,499
4. Payroll	0
5. Benefit account	0

State Street Global Advisors

Signatory: Theodore Cronin

Accounts

BWA1 Commingled Funds

1. Russell 3000 Index CTF	\$4,987,481
2. MSCI All Country World Equity Index Fund	2,452,378
3. Real Asset CTF	1,173,306
4. Passive Intermediate Government Credit Bond Fund	1,804,597
5. Treasury Money Market Fund	1,946,937
6. National City Corp (individual stock)	14,999

BWA3 Cash Account: Treasury Money Market Fund 3,303,109

SCHEDULE 2.4(a)

GOVERNMENTAL APPROVALS AND NOTICES

1. Notice to the National Institutes of Health would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement.
2. Filing of a certificate of merger with the Secretary of State of Massachusetts

SCHEDULE 2.4(b)

AGREEMENT AND INSTRUMENT WAIVERS, CONSENTS, NOTIFICATIONS

CONSENTS

1. Lease by President and Fellows of Harvard College to Blood Research Institute, Inc., dated September 3, 1992
2. Sublease by Blood Research Institute, Inc. to Center for Blood Research, Inc., dated September 3, 1992
3. Research Collaboration Agreement by and between Immune Disease Institute, Inc. and GlaxoSmithKline Research & Development Limited, dated May 14, 2008
4. Consent of Citizens Bank under agreements Nos. 99, 100, 101 and 102 listed on Schedule 2.12 would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement.
5. Consent of President & Fellows of Harvard College (Landlord) under the lease agreement with the CBR Institute for Biomedical Research, Inc., dated June 21, 2006 would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement.
6. Consent of the Massachusetts Health and Educational Facilities Authority under the Authority's Revenue Bonds, Capital Asset Program Issue, Series M-1A, dated October 17, 2003 would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement.
7. Consent of the Massachusetts Health and Educational Facilities Authority under the Authority's Revenue Bonds, Capital Asset Program Issue, Series M-3A (2004) Pool 3, dated November 2, 2004 would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement.
8. Consent of the Massachusetts Health and Educational Facilities Authority and Banc of America Public Capital Corp under the Master Lease and Sublease Agreement dated January 11, 2007 and Schedule No. 1 dated February 6, 2007 and Schedule No. 2 dated April 29, 2008 would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement.
9. Consent of the Massachusetts Health and Educational Facilities Authority and Hewlett-Packard Financial Services under the Master Lease and Sublease Agreement dated 12/13/2005 and Schedule No. 1 dated 1/18/2006 would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement.
10. Consent of the Massachusetts Health and Educational Facilities Authority and Banc of America Public Capital Corp under the Master Lease and Sublease Agreement dated as of April 29, 2008 would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement.

NOTIFICATIONS

1. Notification to 800 Huntington LLC under the Sublease dated May 10, 2006 between 800 Huntington LLC and CBRI would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement.
2. Notification to 800 Huntington LLC under the Subordination, Non-Disturbance and Attornment Agreement dated June 29, 2006 among Citizens, 800 Huntington LLC and CBRI would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement.
3. Notification to CLSB I LLC under the Lease dated May 23, 2006 between CLSB I LLC and CBRI as amended through a 3rd Amendment would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement..¹

¹ Consent of CLSB I LLC is not required, so long as the "Transfer Net Worth Test" is satisfied. The Transfer Net Worth Test shall be satisfied if, immediately following a merger of IDI into a CMCC affiliate, the CMCC affiliate has a net worth at least equal to IDI's net worth on the date three months prior to the merger. (Art. 13, §13.01)

SCHEDULE 2.6

EMPLOYEE LOANS AS OF OCTOBER 31, 2008

Dr. Denisa Wagner	Education Loan	\$288,206
Dr. Denisa Wagner	Housing Loan	\$46,288
Dr. Ulrich Von Andrian	Housing Loan	\$80,000
Dr. Fredrick Alt	Housing Loan	\$120,000
Dr. Derrick Rossi	Housing Loan	\$150,000

SCHEDULE 2.8

PENDING LITIGATION

Murphy & McManus, LLC, Plaintiff
Norfolk Superior Court No. 2006-2022

SCHEDULE 2.9.1

IDI INTELLECTUAL PROPERTY RIGHTS

I. Patents & Applications

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
00-003	Japan	05/04/2001	2001-580432	Colloid Compositions for Solid Phase Biomolecular Analytical Systems	Filed	
00-003	United States	11/06/2007	11/935,817	Colloidal Compositions for Solid Phase Biomolecular Analytical, Preparative and Identification Systems	Filed	
00-003	Canada	02/14/2003	2,408,094	Colloid Compositions for Solid Phase Biomolecular Analytical Systems	Filed	
00-003	European	04/25/2001	01932980.4	Colloid Compositions for Solid Phase Biomolecular Analytical Systems	Filed	
00-003	PCT	05/04/2001	PCT/US01/14373	Novel Colloid Compositions Useful in the Preparation of Solid Phase Biomolecular Analytical, Preparative and Identification Systems	Filed	
00-003	United States	03/03/2005	11/071,674	NOVEL COLLOIDAL MICROARRAYS	Filed	
00-003	United States	05/04/2001	09/848,777	Colloid Compositions Useful in the Preparation of Solid Phase Biomolecular Analytical, Preparative and Identification Systems	Issued	
00-004	PCT	08/31/2001	PCT/US01/27227	Modified Polypeptides Stabilized in a Desired Conformation and Methods for Producing Same	Filed	
00-004	United States	03/15/2005	11/080,043	Modified Polypeptides Stabilized in a Desired Conformation and Methods for Producing Same	Filed	
00-004	Canada	08/31/2001	2,417,432	Modified Polypeptides Stabilized in a Desired Conformation and Methods for Producing Same	Filed	

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
00-004	European	08/31/2001	01966492.9	Modified Polypeptides Stabilized in a Desired Conformation and Methods for Producing Same	Filed	
00-004	Japan	08/31/2001	2002-522490	Modified Polypeptides Stabilized in a Desired Conformation and Methods for Producing Same	Filed	
00-004	United States	08/31/2001	09/945,265	Modified Polypeptides Stabilized in a Desired Conformation and Methods for Producing Same	Issued	
00-004	United States	03/15/2005	11/080,026	Modified Polypeptides Stabilized in a Desired Conformation and Methods for Producing Same	Notice of Allowance	
00-006	European	05/11/2001	01989905.3	Compositions and Methods for Prolonging Survival of Chilled Platelets	Filed	Yes
00-006	United States	11/05/2001	10/007,856	Compositions and Methods for Prolonging Survival of Chilled Platelets	Filed	Yes
00-006	United States	11/05/2001	10/007,856	Compositions and Methods for Prolonging Survival of Chilled Platelets	Filed	Yes
00-006	PCT	11/05/2001	PCT/US01/46408	Compositions and Methods for Prolonging Survival of Chilled Platelets	Filed	Yes
00-006	Canada	11/05/2001	2,431,332	Compositions and Methods for Prolonging Survival of Chilled Platelets	Filed	Yes
00-007	United States	06/08/2001	10/297,371	Methods and Compositions for Inhibiting Immunoglobulin-Mediated Reperfusion Injury	Filed	Yes
00-007	United States	06/08/2001	PCT/US01/18510	Methods and Compositions for Inhibiting Immunoglobulin-Mediated Reperfusion Injury	Filed	Yes
00-007	PCT	06/08/2001	PCT/US01/18510	Methods and Compositions for Inhibiting Immunoglobulin-Mediated Reperfusion Injury	National Phase	Yes
00-007	Japan	06/08/2001	2002-501463	Methods and Compositions for Inhibiting Immunoglobulin-Mediated Reperfusion Injury	Pending	Yes
00-007	Australia	03/01/2005	2005219839	Natural IGM Antibodies and Inhibitors Thereof	Pending	Yes

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
00-007	Canada	06/08/2001	2410458	Methods and Compositions for Inhibiting Immunoglobulin-Mediated Reperfusion Injury	Pending	Yes
00-007	United States	03/01/2005	11/069,834	Natural IgM Antibodies and Inhibitors Thereof	Published	Yes
00-007	European	06/08/2001	01942082.7	Methods and Compositions for Inhibiting Immunoglobulin-Mediated Reperfusion Injury	Published	Yes
00-007	United States	03/01/2005	PCT/US05/006276	Natural IgM Antibodies and Inhibitors Thereof	Published	Yes
00-007	European	03/01/2005	05723931.1	Natural Igm Antibodies and Inhibitors Thereof	Published	Yes
00-007	Japan	03/01/2005	2007-501869	Natural IGM Antibodies and Inhibitors Thereof	Published	Yes
00-008	United States	07/09/2001	09/902,481	Novel Proteins With Integrin-Like Activity	Issued	
00-009	Canada	05/17/2001	2,408,883	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Filed	
00-009	Japan	11/19/2002	2001-585806	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Filed	
00-009	United States	12/01/2004	10/999,477	(Diagnostic Claims) Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Filed	
00-009	United States	02/13/2008	12/030,576	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Filed	
00-009	European	05/17/2001	06075760.6	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Filed	
00-009	Italy	05/17/2001	01935660.9	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Issued	
00-009	France	05/17/2001	01935660.9	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Issued	

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
00-009	Australia	05/17/2001	2001261735	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Issued	
00-009	United Kingdom	05/17/2001	01935660.9	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Issued	
00-009	European	05/17/2001	01935660.9	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Issued	
00-009	Germany	05/17/2001	01935660.9	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Issued	
00-009	United States	02/19/2004	10/782,456	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity (Hemophilia and Bleeding Disorder claims)	Published	
00-009	United States	05/17/2001	09/860,618	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Published	
00-009	PCT	05/17/2001	PCT/US01/16021	Methods for Diagnosing and Treating Hemostatic Disorders by Modulating P-Selectin Activity	Published	
01-001	PCT	01/29/2002	PCT/US02/02412	Energy Regulated Molecules	Published	
01-002	United States	02/17/2003	2004-0048803	Compounds and Methods for the Modulation of CD154	Filed	
01-002	United States	02/28/2003	2004-0072750	Compounds and Methods for the Modulation of CD154	Filed	
01-002	PCT	05/03/2002	PCT/US02/13900	Compounds and Methods for the Modulation of CD154	Filed	
01-002	United States	11/30/2001	10/002,585	Compounds and Methods for the Modulation of CD154	Issued	
01-002	United States	10/29/2003	10/476,237	Compounds and Methods for the Modulation of CD154	Notice of Allowance	
01-003	United States	03/11/2002	10/094,757	A Multi-Plate Electrophoresis System Having Non-Mechanical Buffer Circulation	Issued	

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
02-001	European	10/29/2003	03781487.8	Inhibition of Gene Expression Using RNA Interfering Agents	Filed	
02-001	Japan	10/29/2003	2004-548585	Inhibition of Gene Expression Using RNA Interfering Agents	Filed	
02-001	United States	02/15/2006	10/533,621	Inhibition of Gene Expression Using RNA Interfering Agents	Pending	
02-001	PCT	10/29/2003	PCT/US2003/034424	Inhibition of Gene Expression Using RNA Interfering Agents	Published	
02-004	PCT	06/25/2003	PCT/US03/20270	Vacuolins	Filed	
02-004	United States	12/23/2004	11/021,840	Vacuolins	Filed	
02-005	European	10/30/2003	03816740.9	Methods for Treating and Preventing Apoptosis Related Diseases Using RNA Interfering Agents	Filed	
02-005	Japan	10/30/2003	2005-507650	Methods for Treating and Preventing Apoptosis Related Diseases Using RNAi	Filed	
02-005	United States	10/30/2003	10/533,622	Methods for Treating and Preventing Apoptosis Related Disease Using RNA	Pending	
02-005	PCT	10/30/2003	WO2005/013886	Methods for Treating and Preventing Apoptosis Related Diseases Using RNA Interfering Agents	Published	
02-007	PCT	10/08/2003	PCT/US03/31918	Compounds for Modulation of Cholesterol Transport	Filed	Yes
02-007	Australia	04/06/2005	2003288925	Compounds for Modulation of Cholesterol Transport	Filed	Yes
02-007	European	10/08/2003	03781314.4	Compounds for Modulation of Cholesterol Transport	Filed	Yes
02-007	Canada	10/08/2003	2,502,685	Compounds for Modulation of Cholesterol Transport	Filed	Yes
02-008	PCT	03/20/2003	PCT/US03/08653	HIV Therapeutic	Filed	Yes
02-008	United States	03/20/2003	10/393,411	HIV Therapeutic	Filed	Yes
02-008	Canada	03/20/2003	2,479,530	HIV Therapeutic	Filed	Yes
02-008	Japan	03/20/2003	2003-577602	HIV Therapeutic	Filed	Yes
03-001	United States	10/05/2006	12/089,015	RNAi-Based Treatment Approach for West Nile and Japanese Encephalitis Viruses	National Phase	

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
03-002	PCT	05/21/2004	US2004016210	Compounds and Methods for Improving Platelet Recovery and Function	Filed	
03-002	United States	05/21/2004	10/851,255	Compounds and Methods for Improving Platelet Recovery and Function	Filed	
03-003	United States	05/22/2003	09/863,141	Novel Alkaloids	Issued	Yes
03-005	United States	04/13/2006	10/575,932	MODULATION OF ANERGY AND METHODS FOR ISOLATING ANERGY-MODULATING COMPOUNDS	Filed	
03-007	United States	02/15/2007	10/560,563	SKN-1 Gene and Protein	Filed	
03-008	United States	02/08/2005	11/053,285	CD70 INHIBITION FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY BOWEL DISEASE	Filed	
03-009	United States	04/28/2006	10/577,814	Methods for Treating and Preventing Ischemia-Reperfusion Injury Using RNA Interfering Agents	Filed	
03-009	PCT	11/01/2004	US2004/036200	Methods for Treating and Preventing Ischemia-Reperfusion Injury Using RNA Interfering Agents	Filed	
04-001	PCT	01/21/2005	US/2005/003104	SYSTEMS AND METHODS FOR INDUCING SHORT RNA EXPRESSION	Filed	
04-001	United States	06/25/2007	10/585,886	SYSTEMS AND METHODS FOR INDUCING SHORT RNA EXPRESSION	Pending	
04-002	United States	02/05/2007	11/659,386	Methods for Delivering RNA interference and Uses Thereof	Filed	
04-002	European	08/15/2005	5807329.7	Methods for Delivering RNA interference and Uses Thereof	Filed	
04-002	Australia	08/15/2005	2005277547	Methods for Delivering RNA interference and Uses Thereof	Filed	
04-002	Canada	08/15/2005	2,576,925	Methods for Delivering RNA interference and Uses Thereof	Filed	
04-002	Japan	08/15/2005	2007-527944	Methods for Delivering RNA interference and Uses Thereof	Filed	
04-002	PCT	08/16/2005	PCT/US2005/029111	Methods for Delivering RNA interference and Uses Thereof	Published	
04-003	United States	12/29/2006	PCT/US2005/022926	Gelling Electroporeses Loading Buffer	Published	

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
04-005	United States	04/24/2006	11/409,927	Methods for the Treatment of Multiple Myeloma	Filed	
04-006	United States	03/28/2008	12/057,523	Allele-Specific Silencing of Sickle Cell Anemia and Beta E Thalassemia by Sirnas and Shrnas	Pending	
04-007	PCT	04/28/2006	PCT/US2006/016384	TREATING GASTROINTESTINAL DISORDERS WITH MODULATORS OF RETINOIC ACID	Filed	
04-007	United States	04/28/2006	11/413,874	TREATING GASTROINTESTINAL DISORDERS WITH MODULATORS OF RETINOIC ACID	Filed	
05-001	PCT	06/16/2006	PCT/EP2006/005800	ADAMTS13-Containing Compositions Having Thrombolytic Activity	Filed	Yes
05-001	United States	06/16/2006	11/454,615	ADAMTS13-Containing Compositions Having Thrombolytic Activity	Filed	Yes
05-003	European	06/05/2006	06772167.0	RNAi as a Microbicide	Filed	
05-003	PCT	06/05/2006	PCT/US06/21758	siRNA Microbicides for Preventing and Treating Diseases	Filed	
05-003	United States	06/05/2006	11/916,334	RNAi as a Microbicide	Filed	
05-004	PCT	12/12/2006	PCT/US2006/047281	Novel Integrin α I Domain Mutants with Unprecedented Affinity and Their Therapeutic Use	Published	
05-007	PCT	04/24/2007	PCT/US2007/10075	LAYER BY LAYER COATING OF IMMUNOLIPOSOMES	Filed	
05-009	PCT	01/05/2007	PCT/US2007/000280	Novel Regulators of NFAT	Filed	
06-001	PCT	05/22/2007	PCT/US07/12152	Delivery Across Blood Brain Barrier	Filed	
06-002	PCT	04/25/2007	PCT/US2007/009980	TARGETED DELIVERY TO LEUKOCYTES USING NON-PROTEIN CARRIERS	Filed	
06-002	PCT	04/25/2007	PCT/US2007/009975	TARGETED DELIVERY TO LEUKOCYTES USING PROTEIN CARRIERS	Published	
06-004	Japan	02/22/2005	2006-554260	Conformation Specific Antibodies (LFA1)	Filed	Yes
06-004	PCT	02/22/2005	PCT/US2005/005361	CONFORMATION SPECIFIC ANTIBODIES	Filed	Yes
06-004	Australia	02/22/2005	2005215024	Conformation Specific Antibodies (LFA1)	Filed	Yes
06-004	United States	02/19/2004	60/546,354	LFA-1 Conformation Specific Antibodies	Filed	Yes

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
06-004	United States	02/22/2005	10/589,956	Conformation Specific Antibodies (LFA1)	Filed	Yes
06-004	Canada	02/22/2005	2,554,965	Conformation Specific Antibodies (LFA1)	Filed	Yes
06-004	European	02/22/2005	05723364.5	Conformation Specific Antibodies (LFA1)	Issued	Yes
07-001	PCT	01/29/2008	PCT/US08/52086	Compositions and Methods for Treating Hematopoietic Malignancies	Filed	Yes
07-002	PCT	01/31/2008	PCT/US08/52654	Let-7 Micro-RNA and Mimetics Therof as Therapeutics for Cancer	Filed	
07-003	United States	08/21/2007	60/957,023	Delivery of Hydrophilic and Lipophilic Drugs via Stabilized Nanoparticles Targeting Integrins and Their Ligands	Filed	
07-004	PCT	01/25/2008	PCT/US08/52054	Targeted Delivery of siRNA	Filed	Yes
07-005	PCT	04/30/2007	PCT/US08/62029	Diagnosis and Treatment of Type 1 Diabetes	Filed	
07-006	United States	10/12/2007	60/979,596	Vaccine Nanotechnology	Filed	Yes
07-008	United States	08/15/2007	60/964,936	Methods for Modulating Development and Expansion of IL-17 Expressing Cells	Filed	Yes
07-010	United States	12/14/2007	61/007,766	Treatment and Prevention of HIV Infection	Filed	Yes
07-010	United States	01/15/2008	61/011,157	Treatment and Prevention of HIV Infection	Filed	Yes
07-011	United States	01/04/2008	61/018,919	Treatment or Prevention of Inflammation by Targeting Cyclin D1	Filed	
08-002	United States	05/12/2008	61/127,426	VWF Inhibitors for Treatment of Infarction	Filed	Yes
08-004	United States	05/16/2008	61/053,769	Compositions and Methods for Inhibition of Retroviruses	Filed	
08-005	United States	07/14/2008	61/080,367	Regulation of CD45 Alternative Splicing and Uses Thereof	Filed	
08-006	United States	10/08/2008	61/103,628	Regulators of NFAT and/or Store-Operated Calcium Entry	Filed	
08-007	United States	09/26/2008	61/100,503	Selective Oxidation of 5-Methylcytosine by Tet-Family Proteins	Filed	
08-007	United States	09/29/2008	61/100,995	Selective Oxidation of 5-Methylcytosine by Tet-Family Proteins	Filed	
08-008	United States	09/19/2008	61/098,696	miRNA Targets	Filed	
08-009	United States	09/19/2008	61/098,707	Therapeutic and Diagnostic Strategies	Filed	
80-001	United States	01/09/1980	06/110,592	Amidinophenylmethylsulfonylfluoride	Issued	

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
81-001	United States	07/27/1981	06/287,139	Means and methods for purifying Clq, C1r and C1s	Issued	
86-001	United States	04/11/1986	06/850,759	Platelet Concentrates	Issued	
86-002	United States	09/15/1986	06/907,405	Non-Mechanical Buffer Circulation Apparatus for Electrophoresis	Issued	
89-001	European	02/22/1990	90904139.4	Human Elastase Inhibitor	Filed	
89-001	United States	05/13/1996	29/054344	Flexible Multiple Compartment Medical Container	Issued	
89-001	Italy	02/04/1998	90904139.4	Human Elastase Inhibitor	Issued	
89-001	Germany	02/04/1998	690302025.6	Human Elastase Inhibitor	Issued	
89-001	France	02/04/1998	90904139.4	Human Elastase Inhibitor	Issued	
89-001	Japan	08/23/1991	504382/90	Human Elastase Inhibitor	Issued	
89-001	United Kingdom	02/04/1998	90904139.4	Human Elastase Inhibitor	Issued	
89-001	United States	09/06/1991	07/755,461	Cloned gene encoding human monocyte elastase inhibitor	Issued	
89-001	United States	09/30/1994	08/315,831	Human Monocyte Elastase Inhibitor	Issued	
89-001	United States	06/13/1996	08/662,318	Human Monocyte Elastase Inhibitor Antibodies	Issued	
89-001	PCT	02/02/1990	PCT/US90/00920	Human Elastase Inhibitor	Published	
90-001	United States	11/28/1990	07/618,286	Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1	Issued	
91-001	United States	05/20/1992	07/887,444	Device and Method for Analysis of Blood Components and Identifying Inhibitors and Promoters of the Inflammatory Response	Issued	
91-001	PCT	05/29/1992	PCT/US92/04524	Device and Method for Analysis of Blood Components and Identifying Inhibitors and Promoters of the Inflammatory Response	Published	
91-002	Mexico	06/11/1992	92 2804	Intercellular Adhesion Molecule-3 and its Binding Ligands	Filed	
91-002	Norway	06/11/1992	934491	Intercellular Adhesion Molecule-3 and its Binding Ligands	Filed	
91-002	Bulgaria	06/11/1992	98287	Intercellular Adhesion Molecule-3 and its Binding Ligands	Filed	

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
91-002	Czech Republic	06/11/1992	PV 2702-93	Intercellular Adhesion Molecule-3 and its Binding Ligands	Filed	
91-002	Hungary	06/11/1992	P9303529	Intercellular Adhesion Molecule-3 and its Binding Ligands	Filed	
91-002	Romania	06/11/1992	93-01672	Intercellular Adhesion Molecule-3 and its Binding Ligands	Filed	
91-002	Russian Federation	06/11/1992	93058655	Intercellular Adhesion Molecule-3 and its Binding Ligands	Filed	
91-002	United States	06/11/1997	08/873,288	Intercellular Adhesion Molecule-3 and its Binding Ligands	Filed	
91-002	Brazil	06/11/1992	9206142-7	Intercellular Adhesion Molecule-3 and its Binding Ligands	Filed	
91-002	Slovakia	06/11/1992	PV 1395-93	Intercellular Adhesion Molecule-3 and its Binding Ligands	Filed	
91-002	Republic of Korea	06/11/1992	93-703828	Intercellular Adhesion Molecule-3 and its Binding Ligands	Filed	
91-002	United States	12/23/1992	08/038,990	Method of identifying agents which modulate ICAM-3 binding to LFA-1	Filed	
91-002	United States	06/11/1991	07/712,879	Intercellular adhesion Molecule-3 and its Binding Ligands	Filed	
91-002	United States	06/07/1995	08/474,087	Methods of Using Intercellular Adhesion Molecule-3 (ICAM-3), Antibodies Thereto, and Soluble Fragments Thereof	Issued	
91-002	United States	06/07/1995	08/473,981	Method of identifying agents which modulate ICAM-3 binding to LFA-1	Issued	
91-002	PCT	06/11/1992	PCT/US92/04896	Intercellular Adhesion Molecule-3 and its Binding Ligands	National Phase	
91-003	United States	06/12/1992	07/899,063	Plasmodium Infected Erythrocytes Binding to ICAM-1 & CD36	Filed	
92-001	PCT	05/21/1993	PCT/US93/04956	A Novel Receptor for Alpha4 Integrins & Methods Based Thereon	Published	
92-002	United States	08/22/1995	08/517,589	Antibodies which Bind a Subpopulation of Mac-1 (CD11b/CD18) Molecules which Mediate Neutrophil Adhesion to ICAM-1 and Fibrinogen	Issued	

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
93-001	PCT	03/11/1994	PCT/US94/02632	Assays/Therapeutic Methods Lymphocyte Chemoattractants	Published	
93-002	European	03/23/1994	4014206.9	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Examination Requested	
93-002	Japan	03/24/1994	521367/94	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Filed	
93-002	Canada	03/23/1994	2,159,005	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Filed	
93-002	United Kingdom	03/23/1994	94911692.5	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Issued	
93-002	France	03/23/1994	94911692.5	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Issued	
93-002	Belgium	03/23/1994	94911692.5	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Issued	
93-002	European	03/23/1994	94911692.5	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Issued	
93-002	Germany	03/23/1994	94911692.5	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Issued	
93-002	United States	12/18/1995	08/525,719	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Issued	
93-002	Australia	03/23/1994	64150/94	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Issued	
93-002	Switzerland	03/23/1994	94911692.5	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Issued	
93-002	PCT	03/24/1994	PCT/US94/03189	Method and Apparatus for Encapsulation of Biologically Active Substances in Cells	Published	
94-001	Canada	06/01/1995	2,191,577	Method for Treating and Preventing Atherosclerosis	Filed	
94-001	Germany	06/01/1995	95921563.3	Method for Treating and Preventing Atherosclerosis	Granted	
94-001	France	06/01/1995	95921563.3	Method for Treating and Preventing Atherosclerosis	Issued	
94-001	United Kingdom	06/01/1995	95921563.3	Method for Treating and Preventing Atherosclerosis	Issued	

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
94-001	Italy	06/01/1995	95921563.3	Method for Treating and Preventing Atherosclerosis	Issued	
94-001	Germany	06/01/1995	95921563.3	Method for Treating and Preventing Atherosclerosis	Issued	
95-001	United States	02/10/1995	08/386,728	LIL-Stat DNA Binding Sites and Methods for Identifying Inhibitory Binding Agents	Issued	
95-002	United States	12/05/1997	08/985,499	Methods for Enhancing Thrombolysis in a Mammal	Issued	
95-004	United States	06/07/1995	08/474,387	Use of Functional Derivatives of the Intercellular Adhesion Molecule ICAM-1 in Diagnosis of Viral Infection	Issued	
95-004	United States	04/11/1995	08/420,720	Functional Derivatives of the Intercellular Adhesion Molecule ICAM-1 in Anti-viral Therapy	Issued	
95-004	United States	06/07/1995	08/479,557	Pharmaceutical Composition of the Intercellular Adhesion Molecule ICAM-1 for Use in Anti-viral Prophylactic Therapy	Issued	
96-001	United States	01/29/2003	10/353,494	Purification and Uses of Dendritic Cells and Monocytes	Issued	
96-001	United States	07/29/1997	08/902,246	Enrichment of Dendritic Cells from Blood	Issued	
96-001	United States	01/31/2001	09/774,948	Enrichment of Dendritic Cells from Blood	Issued	
96-001	PCT	07/29/1997	PCT/US97/13448	Enrichment of Dendritic Cells from Blood	Published	
97-003	Japan	07/23/1999	10-532102	Methods for Diagnosing and Treating Body Weight Related Disorders in Animals	Filed	
97-003	United States	01/22/1998	09/012,145	Methods for Diagnosing and Treating Body Weight Related Disorders	Filed	
97-003	Canada	01/22/1998	2,276,691	Methods for Diagnosing and Treating Body Weight Related Disorders in Animals	Filed	
97-003	PCT	01/22/1998	PCT/US98/01110	Methods for Diagnosing and Treating Body Weight Related Disorders in Animals	Published	
97-004	European	08/17/1998	98942081.5	Methods for Using Granzymes and Binding Molecules Thereof for Treating Disease Characterized by Abnormal Apoptosis	Filed	

Tech ID	Country	File Date	Serial No.	Patent Title	Status	Joint Ownership
97-004	PCT	08/17/1998	PCT/US98/17022	Methods for Using Granzymes and Binding Molecules Thereof for Treating Diseases Characterized by Abnormal Apoptosis	Published	
97-005	PCT	08/20/1998	PCT/US98/17280	Methods for Diagnosing and Treating Diseases Associated with Abnormal Levels of Myeloid Cells Utilizing Eotaxin and Antagonists and Agonists Thereof	Published	
98-001	United States	10/25/2005	11/258,620	Specific Inhibitors of NFAT Activation by Calcineurin and their use in Treating Immune-Related Diseases	Filed	
98-001	United States	06/23/2006	11/474,218	Specific Inhibitors of NFAT Activation by Calcineurin and their use in Treating Immune-Related Diseases	Filed	
98-001	United States	01/31/2002	10/066,151	Specific Inhibitors of NFAT Activation by Calcineurin and their use in Treating Immune-Related Diseases	Issued	
98-001	United States	02/04/2003	10/358,052	Specific Inhibitors of NFAT Activation by Calcineurin and the Use in Treating Immune-Related Diseases	Published	Yes
98-002	United States	02/29/2008	12/040,253	Monocyte Locomotion Inhibitory Factor	Filed	
98-002	Canada	06/29/1999	2,331,925	Monocyte Locomotion Inhibitory Factor	Filed	
98-002	United States	06/04/2004	10/861,123	Monocyte Locomotion Inhibitory Factor	Filed	
98-002	Mexico	06/29/1998	985265-21296	Monocyte Locomotion Inhibitory Factor	Filed	
98-002	United States	06/29/1999	09/342,956	Monocyte Locomotion Inhibitory Factor	Issued	
98-002	United States	10/03/2002	10/263,947	Anti-Amoebic Vaccine	Issued	
98-002	PCT	06/29/1999	PCT/US99/14877	Monocyte Locomotion Inhibitory Factor	Published	
99-001	PCT	03/31/2000	PCT/US00/08654	Modified Dendritic Cells and Uses Therefor	Filed	
99-001	United States	03/31/2000	09/540,963	Modified Dendritic Cells and Uses Therefor	Issued	

IDI INTELLECTUAL PROPERTY RIGHTS

II. Copyrights and Applications Therefor

None.

IDI INTELLECTUAL PROPERTY RIGHTS

III. Trademarks and Service Marks and Applications Therefor

Country	File Date	Serial No.	Mark	Status	Joint Ownership
U.S.A.	4/26/2007	77/166,482	CORVUS	Filed	No

IDI INTELLECTUAL PROPERTY RIGHTS

IV. Options and Liens

Party Name	Type	Effective Date	Reference ID	Scope	Term Date	Tech	Summary
CalciMedica	Right of First Negotiation	10/01/2007	CAL-OPT-061307	New disclosures from Rao lab in the areas of initiation and regulation of store operated calcium entry and the function of STIM and ORAI proteins.	10/01/2009	05-009 08-006 07-007	ROFN covers new disclosures in the Field from the lab of Dr. Anjana Rao. First disclosure was made by email to CalciMedica CEO on 10/24/08. Three techs came from the lab and only one fit under the Field. (08-006 ORAI/STIM RNAi Screen). Also disclosed on the same day 07-007 which was known at the time of drafting this application and is explicitly covered.
CalciMedica	Exclusive License, Nonexclusive License and Option Agreement	04/01/2007	CAL-EX-012607	Human Therapeutics - EX License to 05-009 and 03-005; NE License and EX Option to 98-001.	Patent Expiration	05-009 03-005 98-001	IDI grants to CalciMedica a non-exclusive license, without the right to grant sublicenses, under the Patent Rights of Patent Portfolio A to develop, make, have made, use, import, offer for sale, sell and have sold Licensed Products and render Licensed Services in the Field and in the Territory during the Term; and an exclusive license, together with the right to grant sublicenses through multiple tiers of sublicensees, under the Patent Rights of Patent Portfolios B and C to develop, make, have made, use, import, offer for sale, sell and have sold Licensed Products and render Licensed Services in the Field and in the Territory during the Term.
DecImmune Therapeutics, Inc.	Exclusive License and Option Agreement	10/01/2003	NAI-EX-070103	Human and Animal Therapeutics; Option for Diagnostics	Patent Expiration	00-007	Exclusive license for development of therapeutics and option for diagnostic rights should they arise (have not to date). Technology is co-owned based upon joint inventorship by Brigham and Women's Hospital and Harvard.
GlaxoSmithKline	Right of First Negation under Alliance Agreement	05/14/2008	GSK Alliance	Alliance for funding research and fellowships of interest to GSK. Agreement also includes a Right of First Negotiation to obtain an exclusive license to all new disclosures not falling under multiple exceptions listed in the agreement.	05/14/2013	N/A	Funding under the agreement is allocated into 3 categories: ROFN fee; Research Grant funding; and Fellowship funding. Alliance is governed by Joint Steering Committee made up of equal number of both parties.

SCHEDULE 2.9.11

OUTBOUND LICENSES

Agrmnt ID	Type	Effective Date	Party Name	Reference ID	Term Date	Info
ADVANCE	Non-Exclusive License	10/15/1999	Advanced Targeting Systems	(N/A)	10/14/2009	Materials Transferred: M1/70 (Hybridoma); Product is AB-N06 Mac-1 antibody.
ALNYLAM NE DELIVERY	Non-Exclusive License	04/27/2006	Alnylam Pharmaceuticals	ALN-NE-122905	Life of Patent	Tech 04-002 Methods of Delivering RNA Interference and Uses Thereof (Fusion Protein).
APOTECH 01	Non-Exclusive License	02/20/2004	Apotech Corporation	APO-NE-060903	02/20/2014	Materials Transferred: Pab to SET; Mab to pp32 (RJ1).
ASURAGEN MTA 2	Non-Exclusive License	01/04/2008	Asuragen	ASU110107	01/04/2009	Materials Transferred: K562 cell line expressing LFA-1.
AVENTIS	Non-Exclusive License	07/22/2002	Aventis Behring GmbH	vWf mice	07/22/2012	Materials Transferred: vWf knockout mice.
BAXTER SRA 1	Sponsored Research	10/01/2005	Baxter AG	BAX-SRA-071505	12/31/2008	Tech 05-001 ADAMTS13 as an Anti-thrombotic Therapeutic. Tech 08-002 ADAMTS13 as Treatment for Stroke.
BAXTER SRA 2	Sponsored Research	05/04/2007	Baxter AG	BAX-SRA-120706	05/04/2010	Tech 05-003 siRNA Microbicides for Preventing and Treating Diseases.
BAXTER vWf MICE	Non-Exclusive License	01/05/2006	Baxter AG	BAX112905	01/05/2016	Materials Transferred: vWf knockout mice.
BAYER HEALTHCARE MTA	Non-Exclusive License	09/20/2006	Bayer HealthCare	BAY090706	09/20/2011	Materials Transferred: vWf knockout mice.
BENDER NE LICENSE	Non-Exclusive License	09/17/2008	Bender MedSystems	BEN-NE-082208	09/17/2023	Materials Transferred: M3/38.
BIOLEGEND NON-EX. 1	Non-Exclusive License	12/05/2002	BioLegend, Inc.	15 Springer Reagents	12/05/2012	Various Springer reagent sales.
BIOLEGEND NON-EX. 2	Non-Exclusive License	03/10/2003	BioLegend, Inc.	BIL-NE-031003	03/10/2013	Materials Transferred: CB9 cells Human Granzyme A.
BIOLEGEND NON-EX. 3	Non-Exclusive License	03/01/2008	BioLegend, Inc.	BIL-NE-092106	03/01/2018	Various Springer reagent sales.

Agrmnt ID	Type	Effective Date	Party Name	Reference ID	Term Date	Info
BIOMED LICENSE	Non-Exclusive License	07/21/2008	BioMed Central Ltd	BioMed Non-Ex Lic	07/21/2013	To reproduce images from Dr. Thorsten Mempel, produced in the lab of Prof. Ulrich von Andrian.
BOEHRINGER	Exclusive License	07/01/1988	Boehringer Ingelheim Pharmaceuticals, Inc.	BI/SPRINGER	01/01/2015	Tech 91-002 Method of Identifying Agents which Modulate ICAM-3 Binding to LFA-1.
CALCIMEDICA EX & OPT	Field of Use Exclusive	04/01/2007	CalciMedica, Inc.	CAL-EX-012607	Life of Patent	Human Therapeutics - EX License to 05-009 and 03-005; NE License and EX Option to 98-001.
CALTAG 02	Non-Exclusive License	03/30/2004	Invitrogen	CAL-NE-160304 (2278)	03/30/2014	Materials Transferred: M1/70.
CEDARLANE	Non-Exclusive License	01/22/1999	Cedarlane Laboratories Limited	CEDAR NE Lic. 1999	01/22/2009	Materials Transferred: M3/38 M3/84 Rat cell lines.
CYTODYN EX AGREEMENT	Field of Use Exclusive	01/01/2007	CytoDyn, Inc.	CYT-EX-112806	01/01/2027	License to use Materials MAT0026 and MAT0027 in the limited field of HIV Disease applications explicitly excluding targeted delivery of other drugs.
DECIMMUNE- EXCLUSIVE	Field of Use Exclusive	10/01/2003	Declmmune Therapeutics, Inc.	NAI-EX-070103	Life of Patent	Tech 00-007 Methods and Compositions for Inhibiting Immunoglobulin-Mediated Reperfusion Injury.
EBIOSCIENCE01	Non-Exclusive License	10/15/1999	eBioscience	0044.1	10/14/2009	Materials transferred: M17/4, M1/70, M5/114,15.2, M18/2, M3/84.
EBIOSCIENCE02	Non-Exclusive License	12/16/1999	eBioscience	0044.3	12/15/2009	Materials transferred: cell lines 429 and 9F10.
EBIOSCIENCE03	Non-Exclusive License	01/25/2002	eBioscience	0044.4	12/31/2012	Materials transferred: CBR M1/5 and M1/69 Cell lines.
EBIOSCIENCE04	Non-Exclusive License	07/26/2006	eBioscience	EBI-NE-060903 (44.5)	07/26/2021	Materials transferred: M3/38.
EBIOSCIENCE05	Non-Exclusive License	10/01/2007	eBioscience	EBI-NE-100107 (44.6)	10/01/2022	3C4 (m1C2/4) hybridoma producing monoclonal antibodies against mouse CD102; CBRIC2/2 hybridoma producing monoclonal antibodies against human

Agrmnt ID	Type	Effective Date	Party Name	Reference ID	Term Date	Info
						CD102.
EBIOSCIENCE06	Non-Exclusive License	11/12/2007	eBioscience	EBI-NE-110707	11/12/2022	Materials: TS2/16 hybridoma producing monoclonal antibodies against human CD29.
INVITRO/ZYMED 01	Non-Exclusive License	01/22/2005	Invitrogen Corporation	ZYM-NE-II1904 (1759)	01/22/2015	Materials: M3/38 cell line producing Galectin-3.
INVITROGEN CD43	Non-Exclusive License	05/15/1999	Invitrogen	CD43, L-10 (#2279)	05/31/2019	Materials: CD43 (Hybridoma), L-10 clone.
INVITROGEN MTA 1	Non-Exclusive License	02/07/2006	Invitrogen Corporation	INV011206	02/07/2009	Tech 04-002 Methods of Delivering RNA Interference and Uses Thereof (Fusion Protein).
JOSLIN EX LICENSE	Exclusive License	06/13/2005	Joslin Diabetes Center	JDC-EX-052005	Life of Patent	Tech 03-007 SKN-1 Gene and Protein.
LFB BMTA	Non-Exclusive License	06/19/2007	LFB	LFB020205	06/19/2009	Materials: C3 Mice from the Jackson Lab.
LIGOCYTE EXCLUSIVE	Exclusive License	06/01/2003	Ligocyte Pharmaceuticals	LIG-EX-031703	Life of Patent	Tech 91-001 Device and Method for Analysis of Blood Components and Identifying Inhibitors and Promoters of the Inflammatory Response. Tech 91-002 Method of Identifying Agents which Modulate ICAM-3 Binding to LFA-1.
MAXCYTE/ENTREMED	Exclusive License	11/05/1992	MaxCyte, Inc.	Entremed EX-License	03/18/2014	Tech 93-002 Method and Apparatus for Encapsulation of Biologically Active Substances in Cells.
MILLENNIUM GFP-MICE	Non-Exclusive License	07/09/2002	Millennium Pharmaceuticals Inc.	(N/A)	07/09/2012	Materials: C57B1/6 GFP-Pan T Mice; Research & Development.
MILLENNIUM MTA 3	Non-Exclusive License	11/15/2006	Millennium Pharmaceuticals Inc.	MIL092206	11/15/2009	Expression system for recombinant $\alpha 4 \beta 7$ integrin proteins.

Agmmt ID	Type	Effective Date	Party Name	Reference ID	Term Date	Info
NOVARTIS MTA 2	Non-Exclusive License	11/30/2006	Novartis Pharma AG	NOV083106	11/30/2008	Materials: C3 Mice from the Jackson Lab.
NOVO NON-EX LICENSE	Non-Exclusive License	10/11/2007	Novo Nordisk A/S	NOV092007	10/11/2009	vWf mice on C57BL6 background.
PHARMINGEN	Non-Exclusive License	03/06/1998	BD Biosciences PharMingen	1230000063	03/06/2018	Materials transferred: M5/114.15.2.
PHARMINGEN01	Non-Exclusive License	09/27/1991	BD Biosciences PharMingen	1230000061/730	12/31/2016	Materials transferred: M1/69.16.11.HL.
PHARMINGEN02	Non-Exclusive License	08/13/1992	BD Biosciences PharMingen	1230000060	12/31/2016	Various Materials licensed: 16 separate hybridomas.
PHARMINGEN03	Non-Exclusive License	03/06/1998	BD Biosciences PharMingen	1230000062	03/31/2018	Materials transferred: CB9 cells Human Granzyme A.
PHARMINGEN04	Non-Exclusive License	09/18/2001	BD Biosciences PharMingen	(N/A)	09/01/2051	Materials transferred: Granzyme B Baculovirus Plasmid.
PHARMINGEN05	Non-Exclusive License	08/12/2003	BD Biosciences PharMingen	1230000704	08/12/2013	Materials transferred: CBR-IC2/2.
PURDUE PHARMA BMTA	Non-Exclusive License	02/20/2004	Purdue Pharma L.P.	PUR102903	02/20/2009	Materials: C3 knockout mice.
SANTACRUZ 01	Non-Exclusive License	12/10/2001	Santa Cruz Biotech	(N/A)	12/10/2011	Various Springer reagent sales.
SANTACRUZ 02	Non-Exclusive License	05/01/2004	Santa Cruz Biotech	SCZ-NE-050104	05/01/2014	Various Springer reagent sales.
SANTACRUZ 03	Non-Exclusive License	02/01/2007	Santa Cruz Biotech	SCZ-NE-012307	02/01/2017	Reagent sales. Granzyme A and Mab directed against Tenascin, CD34 (CBR-E8).
SANTACRUZ 04	Non-Exclusive License	01/01/2008	Santa Cruz Biotech	SCZ-NE-121707	01/01/2023	Materials: Clones of monoclonal antibody LM2/1 with specificity to Integrin alpha M.
SBH REAGENT NE 01	Non-Exclusive License	10/19/2005	SBH Sciences	SBH-NE-111205	10/19/2015	Materials transferred: Granzyme B Baculovirus Plasmid.
SBH REAGENT NE 02	Non-Exclusive License	02/20/2006	SBH Sciences	SBH-NE-020906	02/20/2016	Materials transferred: Plasmid to make mouse Perforin.
SEROTEC/MORPHOSYS 01	Non-Exclusive License	02/10/2004	MorphoSys AG	SER-NE-060903	02/10/2014	Various Springer reagent sales.
SOUTHBIO	Non-Exclusive License	06/17/1996	Southern Biotechnology Associates, Inc.	SOUTHBIO-NE-061796	06/17/2016	Materials: mouse cell surface antigen CD34.

Agrmnt ID	Type	Effective Date	Party Name	Reference ID	Term Date	Info
SOUTHBIO 1	Non-Exclusive License	07/08/1998	Southern Biotechnology Associates, Inc.	(N/A)	07/28/2018	3 Mouse Cell lines: M1/70, 5H10-27, 3C4.
SOUTHBIO 2	Non-Exclusive License	03/01/2000	Southern Biotechnology Associates, Inc.	(N/A)	03/01/2010	Materials: Clone TS2/4 anti human CD11-alpha ("Hybridoma").
STEM CELL 01	Non-Exclusive License	01/01/2005	Stem Cell Technologies	STM-NE-110904	01/01/2015	Reagent sales: M1/70 cell line.
THROMBOTARGETS MTA	Non-Exclusive License	04/01/2007	ThromboTargets Corporation	THR031507	04/01/2009	Materials Transferred: vWf knockout mice.

SCHEDULE 2.9.12

DOMAIN NAMES OWNED BY IDI

Domain Names	Date
cbrinstitute.org	2/6/2014
immunediseaseinstitute.org	5/30/2017
chct.org	8/30/2009
centerforhumancelltherapy.org	8/30/2009

In addition:

Harvard University has granted IDI permission to use the idi.harvard.edu subdomain.

Harvard Medical School has granted IDI permission to use the cbr.med.harvard.edu domain name.

SCHEDULE 2.11.1

EMPLOYEE BENEFIT PLANS

1. Group Health Insurance Plan
 - a. Blue Choice
 - b. HMO Blue
 - c. Retiree coverage from HMO Blue up to age 65. An employee who retires from employment with IDI after reaching age 59-1/2 and before age 65 can remain on the health plan, paying the full COBRA rate, until reaching age 65.
2. Group Dental Insurance Plan
 - a. Dental Blue
 - b. Retiree coverage up to age 65. An employee who retires from employment with IDI after reaching age 59-1/2 and before age 65 can remain on the health plan, paying the full COBRA rate, until reaching age 65.
3. Group Life Insurance and Accidental Death and Dismemberment Plan
 - a. The Principal Life Insurance Company
4. Group Long-Term Disability Plan
 - a. The Principal Life Insurance Company
5. Short-Term Disability Plan
 - a. Self-insured by IDI.
6. Center for Blood Research, Inc. and CBR Laboratories, Inc. Flexible Benefits Plan
7. Center for Blood Research, Inc. and CBR Laboratories, Inc. Dependent Care Reimbursement Plan
8. Center for Blood Research, Inc. and CBR Laboratories, Inc. Medical Reimbursement Plan
9. Tuition Reimbursement Plan (up to \$5,250 reimbursement for college courses; \$3,250 reimbursement for employees with less than 2 years of service)
10. Center for Blood Research, Inc. Retirement Plan for Investigators
11. Center for Blood Research, Inc. Tax Deferred Annuity Plan
12. The CBR and CBRL Retirement Plan

13. Employee Assistance Program
14. Change in Control Severance Program for Key Employees (dated March 6, 2008)
15. The Company has generally provided standard severance to employees terminated by the Company without cause, equal to 1 week of salary per year of service.

SCHEDULE 2.11.3

CHANGE IN CONTROL AGREEMENTS

Under the Change in Control Severance Program for Key Employees (dated March 6, 2008), an eligible employee is entitled to severance pay, in accordance with the Plan, if he is terminated by the employer (or its successor) or terminates his employment for "good reason" (as defined in the Plan) within 12 months after a "change in control", as defined by the Plan. The following employees are considered "eligible employees" for this Plan:

1. Margaret Bradley
2. Stephen Carriuolo
3. Theodore Cronin
4. Ryan Dietz
5. Doreen Donovan
6. David Frank
7. Helen Hourihan
8. Jurvis LaSalle
9. Rachelle Rosenbaum
10. Steven Simmons

SCHEDULE 2.11.5

AUDIT OF PLANS

1. In a letter dated May 14, 2008, the US Department of Labor, after auditing The CBR and CBRL Retirement Plan, outlined its findings. As a result of the audit, IDI made a contribution to the Plan of \$48.76, representing lost earnings for not transferring participant loan repayments to the Plan as soon as such amounts could reasonably be segregated from IDI's general assets. In addition, IDI changed the Plan's loan policy and ceased charging participants for loan maintenance charges. In a letter dated October 23, 2008, the US Department of Labor determined to take no further action with respect to its findings set forth in the May 14, 2008 letter.

IDI filed a Form 5330, Return of Excise Taxes related to Employee Benefit Plans, to report the excise tax relating to the prohibited transaction of not transferring participant loan payments on a timely basis.

2. In a letter dated May 27, 2005 the Internal Revenue Service, after auditing the CBR and CBRL Retirement Plan for the plan year ending December 31, 2001, outlined its findings. All returns audited were accepted as filed. As a result of the audit, IDI now hires a private locator service to locate terminated participants who do not leave a valid forwarding address. This procedure insures that required distributions are now made within 60 days after the end of the plan year where separation of service occurred.

SCHEDULE 2.12

MATERIAL AGREEMENTS

Contracts with Vendors

1. Operational Consulting Proposal from Awen and related insurance documents
2. Construction Proposal from Admiral
3. Several services agreements with Verizon
4. Project Management Proposals from Diversified Project Management, Inc. regarding relocation to space at 350 Longwood Ave. (2006-2008)
5. Pricing Arrangements with Staples, Waste Management and Steady Vision
6. Letter of Intent and draft Agreement with Tsoi/Kobus and Associates
7. Drafts of Diversified Project Management Owner-Architect Agreement/TSA
8. Cleaning Services pricing agreement with Janitronics, dated 6/4/2008
9. IKON Financial Services addendum, dated 6/13/2008 updating agreement for equipment
10. IKON Office Solutions cost sheet
11. Placement agency Agreement with Kennison & Associates
12. Monster, Inc. job posting resource proposal
13. NEC Unified Solutions, Inc. CallManager Implementation Statement of Work, dated 4/1/2008, and Master Purchase Agreement (not fully executed or dated)
14. Merck & Co., Inc. Purchase Order email
15. Infowires Purchase Order-related emails
16. Service Agreement with Professional Staffing Group (refers candidates for possible employment or consulting work), dated 2/19/2008 (not executed by PSG)
17. Sigma-Aldrich pricing list, dated 1/14/2008
18. Invitrogen Pricing Quote for 2008

Equipment Leases

19. Loan from the Massachusetts Health and Educational Facilities Authority to The CBR Institute for Biomedical Research, Inc. to be funded from proceeds of the Authority's Revenue Bonds, Capital Asset Program Issue, Series M-1A, Closing Date of 10/17/2003
20. Loan from the Massachusetts Health and Educational Facilities Authority to The CBR Institute for Biomedical Research, Inc. to be funded from proceeds of the Authority's Revenue Bonds, Capital Asset Program Issue, Series M-3A (2004) Pool 3, Closing Date of 11/2/2004
21. Master Lease and Sublease Agreement among Banc of America Public Capital Corp as Lessor and Servicer, HEFA as Lessee and Escrow Agent, and The CBR Institute for Biomedical Research, Inc. as Sub-Lessee, dated as of 1/11/2007 and Schedule No. 1 dated 2/6/2007 and Schedule No. 2 dated 4/29/2008
22. Master Lease and Sublease Agreement among Hewlett-Packard Financial Services Company, HEFA and The CBR Institute for Biomedical Research, Inc. dated 12/13/2005 and Schedule No. 1 dated 1/18/2006
23. Master Lease and Sublease Agreement among Banc of America Public Capital Corp as Lessor and Servicer, and HEFA as Lessee and Escrow Agent, and the Immune Disease Institute, Inc. as Sub-Lessee, dated as of April 29, 2008

Real Estate Leases

The leases listed on Schedule 2.19.1 are incorporated herein

Proprietary Rights Agreements

24. Assignment of Licensing Agreement by and between CBR Laboratories, Inc. and The CBR Institute for Biomedical Research, Inc., dated 12/20/2006
- 24.1. Assignment of Licensing Agreement: Exclusive, worldwide license to certain patent rights w/ Entremed (assigned by Entremed to MacCyte, Inc.)
- 24.2. Assignment of Patent 5,612,207 by CBR Laboratories, Inc. to CBR Institute for BioMedical Research, dated 12/20/2006
25. Non-Exclusive License Agreement with BioMed Central Limited, effective 7/21/2008
26. Sponsored Research Agreement with Merck & Company, effective 5/29/2008
27. Joint Invention Administration Agreement with President and Fellows of Harvard College, effective 5/15/2008
28. Research Collaboration Agreement with GlaxoSmithKline Research & Development Limited, effective 5/14/2008
29. Material Transfer Agreement with Integrated DNA Technologies, effective 11/7/2007
30. Material Transfer and Sponsored Research Agreement with Archemix Corp., effective 10/22/2007
31. Non-Exclusive License Agreement with Novo Nordisk A/S, effective 10/11/2007
32. Exclusive Right of First Negotiation Agreement with CalciMedica, Inc., effective 10/1/2007
33. Non-Exclusive License Agreement with eBioscience, effective 10/1/2007
34. Joint Study Agreement with International Business Machines Corporation, effective 9/18/2007
35. Sponsored Research Agreement with Isis Pharmaceuticals, Inc., effective 9/12/2007
36. Research Collaboration Agreement with Garvan Institute of Medical Research, effective 9/1/2007
37. Material Transfer Agreement with Genentech, Inc., effective 8/21/2007
38. Material Transfer and Research Project Agreement with Alnylam Pharmaceuticals, Inc., effective 8/1/2007
39. Material Transfer and Sponsored Research Agreement with Archemix Corp., effective 7/31/2007
40. Research Agreement with Novartis Pharma AG, effective 7/1/2007
41. Amendment to Biological Material Transfer Agreement with LFB, effective 6/19/2007 (and Biological Material Transfer Agreement with LFB, effective 3/15/2002)
42. Sponsored Research Agreement with Proteologics, Inc., effective 2/1/2007
43. Exclusive License Agreement with Advanced Genetic Technologies, Inc., effective 1/1/2007
44. Biological Material Transfer Agreement with Alnylam Pharmaceuticals, Inc., effective 12/14/2006
45. Research Agreement with MedImmune, Inc., effective 10/19/2006

The agreements listed on Schedule 2.9.1, Section IV and on Schedule 2.9.11 are incorporated herein

NIH Research Grants and Agreements

46. Correspondence from NIH indicating grant awards for research of various investigators (2003, 2006-2008)
47. IDI NIH Subcontracts/Memoranda of Understanding with Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Inc.; Subaward Agreement with Boston University; Memorandum of Agreement Modification with Children's Hospital Boston; Subaward Amendments with Harvard Medical School and Massachusetts Institute of Technology

Non-NIH Research Grants and Agreements

48. Letter of Agreement for Research Studies with Dyax
49. Grant or Fellowship Award Notices from the Cancer Research Institute, The Parker B. Francis Fellowship Program, The Leukemia & Lymphoma Society, Harvard Stem Cell Institute, American Cancer Society, Northeast Affiliate Research Committee of the American Heart Association, Lady Tata Memorial Trust (International Awards for Research in Leukemia), Machiah Foundation, Flight Attendant Medical Research Institute
50. Collaboration/Joint Services Agreement with CompuCyt Corporation, effective 8/15/2008
51. Sponsored Research Agreements: the Harvard Stem Cell Institute (Amendment to Project Agreement), Affiliated Institution Sponsored Program Agreement with the President and Fellows of Harvard College on behalf of Harvard Medical School (and Amendments to Agreements)
52. Grant Agreements with the Leukemia & Lymphoma Society, European Hematology Association
53. Memoranda of Agreement – Training Grants with Children's Hospital Boston
54. Cost-Reimbursement Project Agreement with the President and Fellows of Harvard College on behalf of Harvard Stem Cell Institute
55. Research Agreement with MedImmune, dated 10/19/2006
56. Agreements with the French National Agency for Research on AIDS and Viral Hepatitis
57. Ellison Medical Foundation/AFAR Senior Postdoctoral Research Grant Application by Bjoern Schwer
58. Partners Healthcare Grant Agreement
59. Harvard School of Public Health Trainee Appointment Authorization
60. Sponsored Research Agreement with Isis Pharmaceuticals, Inc., effective 9/12/2007
61. Material Transfer Agreement / Sponsored Research Agreement with Archemix Corp., effective 10/22/2007
62. Material Transfer Agreement / Sponsored Research Agreement with Archemix Corp., effective 7/31/2007
63. Agreement between President and Fellows of Harvard College and the CBR Institute for Biomedical Research, dated 6/15/2006
64. Letter of Agreement between CBR Institute for Biomedical Research and Pharming Technologies B.V., effective 7/26/2004 (expired?)
65. Contract Research Agreement with Lev Pharmaceuticals, Inc., dated 7/11/2004 (expired 12/31/2004?)

Mosaic Technologies

66. Research Cooperation and Royalty Agreement between Mosaic Technologies, Inc. and CBR Laboratories, Inc., effective 3/25/1997
67. Mosaic Technologies, Inc. Deferred Payment Note, dated 3/25/1997
68. Mosaic Technologies, Inc. Convertible Note, dated 3/25/1997 (matured by 1/31/2002 at the latest)

DHHS Agreements

69. Nonprofit Rate Agreement with the (federal) Dept. of Health and Human Services
70. DHHS Newco Agreement, dated 4/30/1990 (approval of costs associated with HEFA lease and Newco when it is recognized by the IRS as a 501(c)(3) organization)

Letters of Intent, Memoranda of Understanding

71. Sub-agreements NIH/IDI Prime
72. Amendments to subcontracts between Judy Lieberman and several institutions
73. Memoranda of Agreement related to NIH grant money, between IDI and Beth Israel Deaconess Medical Center, St. George's University of London, Tulane University Health Sciences Center, Alnylam Pharmaceuticals, Inc., Max-Delbruck Center for Molecular Medicine, Massachusetts General Hospital, the Children's Hospital, the Dana Farber Cancer Institute, and Brigham and Women's Hospital

Loans / Financial Commitments to Employees

74. Recruitment Packages for Winau (11/19/2007), Rossi (9/20/2007), and Hur (3/25/2008 and additions 4/2/2008)
75. 5/24/2001 Letter for Professor Klaus Rajewsky from Fred Rosen, pledging funds to cover all mouse costs incurred by Rajewsky for three years and to cover 60% of mouse costs going forward from the 3-year mark
76. Promissory Note between Derrick J. Rossi and IDI, dated 4/1/2008
77. Housing Allowance to Frederick Alt: letter to Fred Alt dated January 8, 2007; promissory note \$240,000 dated January 12, 2007; letter from Children's Hospital Boston (Stuart Novick) to The CBR Institute for Biomedical Research, Inc. (Theodore Cronin) dated January 4, 2007; mortgage executed on January 12, 2007 on real property located at 18 Shipway Place, Charlestown, Massachusetts
78. Letter from CBRI to Von Andrian committing to pay a housing allowance of \$100,000 and an annual bonus of \$15,000, dated 11/2/2006; Mortgage securing payment, dated 12/5/2006; Promissory Note dated 12/5/2006 for \$100,000; Memorandum of Understanding with Von Andrian, dated 10/16/2006
79. Loan documents with Denisa Wagner (purchase of promissory note agreement between CBR and New England Medical Center, mortgages, promissory notes, financial statements, etc.
80. Letter agreement with Ryan Dietz dated November 18, 2008 relating to compensation
81. Change of Control Severance Program for Key Employees dated 3/6/2008

Harvard Affiliation Agreements

82. Harvard University Janeway Professorship Agreement
83. Harvard Medical School Structural Biology Professorship Agreement

84. Harvard Medical School Rosen Professorship in Pediatrics Agreement
85. Harvard Medical School Latham Family Professorship Terms
86. General Policies and Principles Governing Relationships between Harvard Medical School and Center for Blood Research, Inc. dated May 15, 1986

Salary Guaranties for Tenured Harvard Medical School Professors

87. Chester Alper
88. Michael Carroll
89. Thomas Kirchhauser
90. Judy Lieberman
91. Klaus Rajewsky (Fred S. Rosen Professor of Pediatrics)
92. Anjana Rao
93. Timothy Springer (Latham Family Professor of Pathology)
94. Denisa Wagner

Health and Retirement Benefit Agreements

95. Northeast Retirement Services Plan Services Agreement, effective 11/25/2001
96. Welcome Package from Northeast Retirement Services, including Custodial Account Adoption Agreement
97. MB Trust Company, LLC Custodial Account Agreement for CBR & CBRL Retirement Plan, dated 3/20/2008
98. Business Associate Contract Addendums between CBR and Medical Claims Service, Inc. (effective 4/14/2004) and Mount Auburn Hospital Employee Assistance Program (effective 4/14/2004)

Financing Agreements with Citizens Bank

99. Reimbursement Agreement dated October 1, 2003, as amended relating to letter of credit for MHEFA Series M-1A Pool Loan
100. Reimbursement Agreement dated November 1, 2004, as amended relating to letter of credit for MHEAF Series M-3A Pool Loan
101. Application and Agreement for Standby Letter of Credit dated June 1, 2006 relating to letter of credit for the benefit of BMR-Blackfan Circle LLC required under CLSB lease
102. Revolving Credit Agreement dated October 31, 2001 as amended relating to \$2,000,000 revolving credit facility

Other Agreements


103. Exclusive Representation Agreement by and between CBR and Murphy & McManus, LLC, dated 8/1/2004
104. Settlement Agreement with SSga, dated 7/9/2008
105. Independent Contractor Agreement for Consultant between IDI and Piotr Sliz, dated 12/21/2007
106. Documentation related to restricted funds
107. Randstad Service Terms for Center for Blood Research Institute, dated 12/7/2007 (one employee under contract for 6 months or more).

SCHEDULE 2.17

INSURANCE POLICIES

See Attached.

SCHEDULE 2.17



William Gallagher Associates
470 Atlantic Avenue
Boston, MA 02210
Telephone: (617) 261-6700
Fax: (617) 261-6720

Outline of Insurance

Name: Immune Disease Institute, Inc.
800 Huntington Avenue
Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS	INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
I. DOMESTIC PACKAGE POLICY	National Fire Insurance of Hartford (CNA)	1056927008	7/1/08-09	\$74,775
A. <u>PROPERTY SECTION:</u>				
<u>Scheduled Locations:</u>				
1) 800 Huntington Avenue, Boston, MA 02115				
2) 200 & 350 Longwood Ave, Boston, MA 02115				
3) One Blackfan Circle, Boston, MA				
4) 10 Mission Street, Boston, MA 02115				
5) 210 Longwood Ave, Boston, MA 02115				
6) One Blackfan Circle, Boston MA 02115				
7) Three Blackfan Circle, Boston, MA 02115				
<u>Limits:</u>				
Blanket Business Personal Property	\$ 52,015,000			
Blanket Business Income	\$ 10,809,382			
Blanket Flood – Annual Aggregate	\$ 15,000,000			
Blanket Earthquake – Annual Aggregate	\$ 15,000,000			
Property in Transit	\$ 50,000			
Property at Any Other Location	\$ 50,000			
Valuable Papers	\$ 500,000			
Research & Development Restoration Expense	\$ 1,500,000			
Refrigerant Contamination	\$ 1,000,000			
Bio-Contamination	\$ 100,000			
Ordinance/Law/Demolition and ICC	\$ 1,000,000			
Off-Premises Service Interruption	\$ 300,000			
Pollutant Cleanup & Removal Location #1	\$ 1,000,000			
Pollutant Cleanup & Removal –all other locations	\$ 100,000			

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.



William Gallagher Associates
 470 Atlantic Avenue
 Boston, MA 02210
 Telephone: (617) 261-6700
 Fax: (617) 261-6720

Outline of Insurance

Name: Immune Disease Institute, Inc.
 800 Huntington Avenue
 Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS		INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
I. DOMESTIC PACKAGE POLICY (CONTINUED)		National Fire Insurance of Hartford (CNA)	1056927008	7/1/08-09	\$74,775
A. <u>PROPERTY SECTION (Continued)</u>					
<u>Deductibles:</u>					
"All Risk" Perils - Property	\$ 10,000				
<u>Deductibles:</u>					
Flood Peril	\$ 50,000				
Earthquake Peril	\$ 100,000				
Pollutant Cleanup	\$ 25,000				
Business Income and Extra Expense	24 Hours				
B. <u>LIABILITY SECTION:</u>					
<u>General Liability:</u>					
General Aggregate	\$ 2,000,000				
Each Occurrence	\$ 1,000,000				
Personal & Advertising Injury	\$ 1,000,000				
Fire Damage Legal	\$ 300,000				
Medical Expense	\$ 5,000				
<i>Excludes Products/Completed Operations</i>					
<i>Excludes Professional Liability</i>					
<u>Employee Benefits E&O Liability:</u>					
Each Employee	\$ 1,000,000				
Aggregate	\$ 1,000,000				
Deductible	\$ 1,000				

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.



William Gallagher Associates
 470 Atlantic Avenue
 Boston, MA 02210
 Telephone: (617) 261-6700
 Fax: (617) 261-6720


Outline of Insurance

Name: Immune Disease Institute, Inc.
 800 Huntington Avenue
 Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS		INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
I. DOMESTIC PACKAGE POLICY (CONTINUED)		National Fire Insurance of Hartford (CNA)	1056927008	7/1/08-09	Included
C. <u>CRIME SECTION:</u>					
Employee Theft	\$ 500,000				
Forgery or Alteration	\$ 500,000				
Computer Fraud	\$ 500,000				
Money & Securities Inside/Outside	\$ 25,000				
Deductibles:					
Money and Securities	\$ 1,000				
All Other	\$ 10,000				
D. <u>BOILER & MACHINERY POLICY</u>					
<u>Scheduled Locations:</u>					
1) 800 Huntington Avenue, Boston, MA 02115					
2) 200 Longwood Avenue, Boston, MA 02115					
3) 350 Longwood Avenue, Boston, MA 02115					
4) 210 Longwood Avenue, Boston, MA 02115					
5) 10 Mission Street, Boston, MA 02115					
6) One Blackfan Circle, Boston, MA 02115					
7) Three Blackfan Circle, Boston, MA 02115					
<u>Limits:</u>					
Blanket Limit - Direct Damage	\$ 44,282,588				
Blanket Limit - Business Income	\$ 10,809,382				
Spoilage Damage	\$ 100,000				
Utility Interruption	\$ 500,000				
Expediting Expense	\$ 100,000				
Hazardous Substance	\$ 100,000				
Ammonia Contamination	\$ 100,000				
Water Damage	\$ 100,000				

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.



William Gallagher Associates
 470 Atlantic Avenue
 Boston, MA 02210
 Telephone: (617) 261-6700
 Fax: (617) 261-6720

Outline of Insurance

Name: Immune Disease Institute, Inc.
 800 Huntington Avenue
 Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS	INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
I. DOMESTIC PACKAGE POLICY (CONTINUED) <u>Deductibles:</u> Direct Damage \$ 10,000 Business Income 24 Hours	National Fire Insurance of Hartford (CNA)	1056927008	7/1/08-09	Included
II. AUTOMOBILE POLICY <u>Hired Car Physical Damage:</u> Actual Cash Value or \$35,000, whichever is less, subject to: \$500 Comprehensive Deductible \$500 Collision Deductible	National Fire Ins. Co. (CNA)	2083328381	7/1/08-09	\$666

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.



William Gallagher Associates
 470 Atlantic Avenue
 Boston, MA 02210
 Telephone: (617) 261-6700
 Fax: (617) 261-6720

Outline of Insurance

Name: Immune Disease Institute, Inc.
 800 Huntington Avenue
 Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS		INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
III. WORKERS' COMPENSATION POLICY		Continental Casualty Insurance Company (CNA)	WC251583761	7/1/08-09	\$46,145 Deposit Premium
<u>Workers' Compensation Coverage:</u>					
Statutory Benefits – State of Hire					
Covered State: Massachusetts					
<u>Employer's Liability Coverage:</u>					
Bodily Injury by Accident (each accident)	\$ 1,000,000				
Bodily Injury by Disease (each employee)	\$ 1,000,000				
Bodily Injury by Disease (policy limit)	\$ 1,000,000				
<u>Payrolls</u>					
MA Class Code 8810	\$ 2,860,386				
MA Class Code 4512	\$ 11,031,408				
Experience Mod of 1.32					

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.



William Gallagher Associates
 470 Atlantic Avenue
 Boston, MA 02210
 Telephone: (617) 261-6700
 Fax: (617) 261-6720

Outline of Insurance

Name: Immune Disease Institute, Inc.
 800 Huntington Avenue
 Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS		INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
IV. FOREIGN PACKAGE POLICY		Continental Insurance Co. (CNA)	PST283529617	7/1/08-09	\$3,650
A. GENERAL LIABILITY SECTION:					
Bodily Injury & Property Damage	\$ 1,000,000				
Personal & Advertising Injury	\$ 1,000,000				
Premises Legal Liability	\$ 1,000,000				
Medical Expense (Each person)	\$ 10,000				
Medical Expense (Each accident)	\$ 50,000				
Employee Benefits (Each employee)	\$ 1,000,000				
Employee Benefits (Aggregate)	\$ 1,000,000				
Deductible (Each employee)	\$ 1,000				
<i>Excluding Products Liability</i>					
<i>Excluding Professional Liability</i>					
B. DIC/EXCESS AUTOMOBILE LIABILITY:					
Bodily Injury & Property Damage	\$ 1,000,000				
Non-Owned & Hired Autos Only					
Auto Medical Expense Coverage - Ea. Person	\$ 10,000				
Auto Medical Expense Coverage - Ea. Accident	\$ 50,000				
Hired Auto - Any One Accident	\$ 2,500				
DIC/Excess Physical Damage - Any One					
Policy Period	\$ 25,000				

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.



William Gallagher Associates
 470 Atlantic Avenue
 Boston, MA 02210
 Telephone: (617) 261-6700
 Fax: (617) 261-6720

Outline of Insurance

Name: Immune Disease Institute, Inc.
 800 Huntington Avenue
 Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS		INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
IV. FOREIGN PACKAGE POLICY (CONTINUED)		Continental Insurance Co. (CNA)	PST283529617	7/1/08-09	\$6,250
C. <u>WORKERS' COMPENSATION SECTION:</u>					
Statutory Benefits – State of Hire Benefits (excludes 3 rd country nationals & local national employees)					
Employer's Liability:					
Bodily Injury by Accident (Each Accident)	\$ 1,000,000				
Bodily Injury by Disease (Policy Limit)	\$ 1,000,000				
Excess Repatriation Expense (Any One Employee)	\$ 100,000				
Excess Repatriation Expense (Annual Aggregate)	\$ 250,000				
D. <u>KIDNAP & RANSOM:</u>					
Each occurrence	\$ 25,000				
Aggregate Limit	\$ 25,000				

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.



William Gallagher Associates
 470 Atlantic Avenue
 Boston, MA 02210
 Telephone: (617) 261-6700
 Fax: (617) 261-6720


Outline of Insurance

Name: Immune Disease Institute, Inc.
 800 Huntington Avenue
 Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS		INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
V. UMBRELLA LIABILITY POLICY		Continental Casualty Ins. Co. (CNA)	A1064097008	7/1/08-09	\$16,160
<u>Limits of Liability:</u>					
Each Incident	\$ 10,000,000				
Aggregate	\$ 10,000,000				
Deductible/Retention:	\$ 0				
Coverage is Excess Over:					
General Liability					
Employee Benefits					
Non-Owned & Hired Automobile Liability					
Employers Liability					
Foreign Liability					
<u>Excludes:</u>					
Products/Completed Operations					
Professional Liability					
Sexual Misconduct					
Human Clinical Trials					

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.



William Gallagher Associates
 470 Atlantic Avenue
 Boston, MA 02210
 Telephone: (617) 261-6700
 Fax: (617) 261-6720

Outline of Insurance

Name: Immune Disease Institute, Inc.
 800 Huntington Avenue
 Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS	INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
VI. PROFESSIONAL LIABILITY POLICY	Columbia Casualty Company (CNA)	ADT1028638447-12	7/1/08-09	\$32,320 Plus 4% MA Surplus Line Tax
<u>Limits of Liability:</u> Each Occurrence \$ 5,000,000 Annual Aggregate \$ 5,000,000 <u>Deductible:</u> Each Claim \$ - 10,000 Claims-Made Coverage Form Retroactive Date is 5/4/1987 Worldwide Coverage Territory Defense Included within the Limits of Liability				

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.



William Gallagher Associates
 470 Atlantic Avenue
 Boston, MA 02210
 Telephone: (617) 261-6700
 Fax: (617) 261-6720

Outline of Insurance

Name: Immune Disease Institute, Inc.
 800 Huntington Avenue
 Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS	INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
VII. ASSOCIATION LIABILITY POLICY	National Union Fire Insurance (AIG)	6462994	7/1/08-09	\$17,307
<u>Coverage Afforded:</u> Directors & Officers Liability Employment Practices Liability <u>Limits of Liability:</u> D&O and EPLI Combined – Policy Aggregate \$ 5,000,000 Crisis Management Funds for D&O \$ 25,000 <u>D&O</u> Crisis Management Events \$ 2,500 All other Claims \$ 25,000 <u>Employment Practices</u> All Claims \$ 25,000 <u>Deductible/Retention:</u> Non-Indemnifiable Loss \$ 0 Indemnifiable Loss \$ 25,000 Claims-Made Coverage Form Continuity Dates: 12/01/02 Defense Costs are included within the Limits of Liability				

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.



William Gallagher Associates
 470 Atlantic Avenue
 Boston, MA 02210
 Telephone: (617) 261-6700
 Fax: (617) 261-6720


Outline of Insurance

Name: Immune Disease Institute, Inc.
 800 Huntington Avenue
 Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS	INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
VIII. BUSINESS TRAVEL ACCIDENT POLICY <u>Covered Individuals:</u> (Class 1) All employees of Immune Disease Institute, Inc. (Class 2) Spouse of a Primary Insured Person (Class 3) Dependent Children of a Primary Insured Person. <u>Covered Benefits:</u> Accidental Loss of Life, Limb, Sight, Speech, Hearing and Thumb or Index Finger. <u>Covered Hazards:</u> Worldwide Business Travel; must be on assignment by or at the direction of Immune Disease Institute, Inc. Includes personal excursions when in conjunction with business travel. Does not include daily travel to and from work. <u>Benefit Amounts:</u> (Class 1) 24 Hour Business Travel / Extraordinary Commutation Bomb: 5 x Annual Salary to a Maximum of \$500,000 and a Minimum of \$250,000 (Class 2) Business Travel Family \$ 25,000 (Class 3) Business Travel Family \$ 10,000 Aggregate amount of insurance (per accident) \$ 500,000 Medical Evaluation and Repatriation \$ 50,000 <u>Additional Benefits:</u> Family Coverage - \$25,000 for Spouse and \$10,000 for each Dependent Child and Medex Travel Assistance worldwide services	Federal Insurance Co. (Chubb)	64777014	7/1/08-09	\$1,750

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.



William Gallagher Associates
 470 Atlantic Avenue
 Boston, MA 02210
 Telephone: (617) 261-6700
 Fax: (617) 261-6720

Outline of Insurance

Name: Immune Disease Institute, Inc.
 800 Huntington Avenue
 Boston, MA 02115

Date: November 2008

COVERAGE AND LIMITS		INSURANCE COMPANY	POLICY NUMBER	TERM	PREMIUM
IX. FIDUCIARY LIABILITY POLICY		Travelers Property Casualty Ins. Co.	104968798	7/1/07-10	\$2,669 (08-09 Installment)
Limit of Liability: Aggregate	\$ 2,000,000				
Prior & Pending Date: 04/11/2001					
Claims-Made Coverage Form					

This outline is intended for informational purposes only and is not intended as nor should be construed as a grant of coverage for any policy of insurance. Please refer to the actual policies for information relating to limits, terms, conditions, exclusions and endorsements. Please contact your WGA Account Executive or Account Manager with any questions that you may have.

SCHEDULE 2.19.1

OWNED REAL PROPERTY AND REAL PROPERTY LEASES

OWNED REAL PROPERTY

1. 800 Huntington Avenue, Boston, MA
2. 10 Mission Street, Boston, MA

REAL PROPERTY LEASES

3. Lease dated May 10, 2006, between CBRI, as landlord, and 800 Huntington Avenue LLC, as tenant ("800 LLC")
4. Sublease dated May 10, 2006, between 800 LLC, as sublandlord, and CBRI, as subtenant
5. Subordination, Non-Disturbance and Attornment Agreement dated June 29, 2006, among Citizens, 800 LLC and CBRI
6. Lease dated May 23, 2006, between CLSB I LLC, as landlord, and CBRI, as tenant, as amended through a 3rd Amendment.
7. Sublease dated as of September 3, 1992, between Blood Research Institute, Inc., as sublandlord, and CBRI, as subtenant
8. Children's Hospital Corporation (Lessor) to The CBR Institute for Biomedical Research, Inc (Lessee) dated April 29, 2005. Space: 1,583 rsf on the 9th floor of the Karp Family Laboratory Building. Term: February 1, 2005 through December 31, 2009.
9. President & Fellows of Harvard College (Landlord) to The CBR Institute for Biomedical Research, Inc. (Tenant); Space: 2,902 nsf on the 2nd floor of the Armenise Building. Dated June 21, 2006. Term: June 21, 2006 through December 31, 2010.
10. Longwood Galleria Lease: Newton Place Associates I, LLC (c/o Druker Company, LTD) as landlord; the Center for Blood Research, Inc. (tenant). Space: 5,315 rsf on the ground level of the Longwood Galleria Building at 350 Longwood Avenue Boston. Effective February 1, 2001 for a 72 month term. Amended on July 20, 2006, extending the termination date to January 31, 2010.

SCHEDULE 2.19.2

ENCUMBRANCES ON REAL PROPERTY

1. Mortgage dated May 8, 2006, from CBR Institute for Biomedical Research, Inc. to 800 Huntington Avenue LLC
2. Mortgage dated on or about June 29, 2006, from 800 Huntington Avenue LLC, as tenant, to Citizens Bank of Massachusetts, encumbering 800's leasehold estate
3. The landlord's interests in IDI's leased premises at 350 Longwood Avenue and 3 Blackfin Circle are encumbered by mortgages

C

SCHEDULE 3

CMCC DISCLOSURE SCHEDULE

SCHEDULE 3.4

REQUIRED CONSENTS

1. Notice to the National Institutes of Health would be required for a merger of IDI into a CMCC affiliate pursuant to Section 6.1.2 of the Agreement.
2. Filing of a certificate of merger with the Secretary of State of Massachusetts

2

FEDERAL IDENTIFICATION
NO. 04-2158520

 Examiner

The Commonwealth of Massachusetts

William Francis Galvin
Secretary of the Commonwealth
One Ashburton Place, Boston, Massachusetts 02108-1512

RESTATED ARTICLES OF ORGANIZATION (General Laws, Chapter 180, Section 7)


 Name
Approved

We, Theodore M. Cronin, *President / ~~Vice President~~,
and David R. Pokross, Jr., *Clerk / ~~Assistant Secretary~~,
of Immune Disease Institute, Inc.,
(Exact name of corporation)
located at 800 Huntington Avenue, Boston, MA 02115,
(Street address of corporation in Massachusetts)

do hereby certify that the following Restatement of the Articles of Organization was duly adopted at a meeting

held on December 18, 20 08, by a vote of: thirteen,
Thirteen (13) directors, or stockholders.

- ☐ Being at least two-thirds of the members or directors legally qualified to vote in meetings of the corporation where there is no amendment to the Articles of Organization; OR
- ☐ Being at least two-thirds of its members legally qualified to vote in meetings of the corporation where there is an amendment to the Articles of Organization; OR
- ☒ Being at least two-thirds of its directors where there are no members pursuant to General Laws, Chapter 180, Section 3 and there is an amendment to the Articles of Organization; OR
- ☐ In the case of a corporation having capital stock, by the holders of at least two-thirds of the capital stock having the right to vote therein where there is an amendment to the Articles of Organization.

C ☐
P ☐
M ☐
R.A. ☐

9
P.C.

* Delete the inapplicable words.

* * Check only one box that applies.

Note: If the space provided under any article or item on this form is insufficient, additions shall be set forth on one side only of separate 8 1/2 x 11 sheets of paper with a left margin of at least 1 inch. Additions to more than one article may be made on a single sheet as long as each article requiring each addition is clearly indicated.

1-19-53

IMMUNE DISEASE INSTITUTE, INC.

ATTACHMENT II

Purposes

The corporation is organized exclusively for charitable, educational, and scientific purposes, including:

- (a) to support and operate for the benefit of The Children's Medical Center Corporation and its affiliates, including the Children's Hospital Corporation;
- (b) to further scientific knowledge and public health through research in immunology and inflammation and other areas of biomedical science;
- (c) to advance biomedical education; and
- (d) to engage in any activity which may lawfully be conducted by a corporation organized under Massachusetts General Laws chapter 180 and exempt from tax under Section 501(c)(3) of the Internal Revenue Code of 1986, as amended.

ARTICLE I

The name of the corporation is:

Immune Disease Institute, Inc.

ARTICLE II

The purpose of the corporation is to engage in the following activities:

See page 2A attached hereto and made a part hereof.

ARTICLE III

A corporation may have one or more classes of members. If it does, the designation of such classes, the manner of election or appointments, the duration of membership and the qualification and rights, including voting rights, of the members of each class, may be set forth in the by-laws of the corporation or may be set forth below:

The designation, qualification and rights of members, if any, ^{may}~~shall~~ be set forth in the bylaws.

ARTICLE IV

**Other lawful provisions, if any, for the conduct and regulation of the business and affairs of the corporation, for its voluntary dissolution, or for limiting, defining, or regulating the powers of the corporation, or of its directors or members, or of any class of members, are as follows:

See pages 4A-4C attached hereto and made a part hereof.

***If there are no provisions, state "None".*

Note: The preceding four (4) articles are considered to be permanent and may ONLY be changed by filing appropriate Articles of Amendment.

IMMUNE DISEASE INSTITUTE, INC.

ATTACHMENT IV

Other lawful provisions for the conduct and regulation of the business and affairs of the corporation or for limiting, defining, or regulating the powers of the corporation, or of its trustees, are as follows:

(a) Tax Exemption. No part of the assets or net earnings of the corporation shall inure to the benefit of any member, trustee, or officer of the corporation or any individual; no substantial part of the activities of the corporation shall be the carrying on of propaganda, or otherwise attempting to influence legislation, except to the extent permitted by Section 501(h) of the Internal Revenue Code of 1986, as amended (the "Internal Revenue Code"); and the corporation shall not participate in, or intervene in (whether or not by the publication or distribution of statements), any political campaign on behalf of (or in opposition to) any candidate for public office. It is intended that the corporation shall be entitled to exemption from federal income tax under Section 501(a) of the Internal Revenue Code as an organization described in Section 501(c)(3) of the Internal Revenue Code and shall not be a private foundation under Section 509(a) of the Internal Revenue Code.

(b) Amendment of the By-laws by the Member. The member of the corporation may make, amend or repeal the by-laws of the corporation in whole or in part in accordance with the by-laws.

(c) Exculpation; No Personal Liability. No officer or trustee shall be personally liable to the corporation or its member for monetary damages for breach of fiduciary duty as an officer or trustee, except to the extent that the elimination of limitation of liability is not permitted under applicable law as in effect when such liability is determined. No amendment or repeal of this provision shall deprive an officer or trustee of the benefits hereof with respect to any act or omission occurring prior to such amendment or repeal.

(d) Powers. The corporation shall have in furtherance of its corporate purposes all of the powers specified in Section 6 of Chapter 180 and in Sections 9 and 9A of Chapter 156B of the Massachusetts General Laws (except those provided in paragraph (m) of said Section 9) as now in force or as hereafter amended, and may carry on any operation or activity referred to in Article II to the same extent as might an individual, either alone or in a joint venture or other arrangement with others, or through a wholly or partly owned or controlled corporation; provided, however, that no such power shall be exercised in a manner inconsistent with said Chapter 180 or any other chapter of the Massachusetts General Laws or inconsistent with the exemption from federal income tax to which the corporation shall be entitled under Section 501(c)(3) of the Internal Revenue Code.

(e) Interested Trustees, Officers, and Member. In the absence of fraud, no contract or transaction between the corporation and one or more of its trustees or officers, or member, or between the corporation and any other corporation, partnership, association, or other organization in which one or more of its trustees or officers, or member, are trustees, directors, officers, or a member, or have a financial or other interest, shall be void or voidable solely for

this reason, or solely because such trustee, officer, or member is present at or participates in the meeting of the Board of Trustees or a committee thereof which authorizes the contract or transaction, or solely because his or their votes are counted for such purpose, nor shall any trustee or officer, or member, be under any liability to the corporation on account of any such contract or transaction if:

- (1) the material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Trustees or the committee, and the Board of Trustees or the committee authorized the contract or transaction by the affirmative votes of a majority of the disinterested trustees, even though the disinterested trustees are less than a quorum; or
- (2) the contract or transaction is fair as to the corporation as of the time it is authorized, approved or ratified by the Board of Trustees, the committee of the Board, or otherwise by the corporation; or
- (3) the contract or transaction is fair as to the corporation as of the time it is authorized, approved or ratified by the member, at any meeting of the member the notice of which, or an accompanying statement, summarizes the nature of such transaction and such interest.

No interested trustee or member of this corporation may vote at any meeting at which such transaction shall be authorized, but may participate in discussion thereof, to the extent permitted by the non-conflicted trustees.

(f) If and so long as the corporation is a private foundation (as that term is defined in Section 509 of the Internal Revenue Code), then notwithstanding any other provisions of the articles of organization or the by-laws of the corporation, the following provisions shall apply:

- (1) the income of the corporation for each taxable year shall be distributed at such time and in such manner as not to subject the corporation to the tax on undistributed income imposed by Section 4942 of the Internal Revenue Code, and
- (2) the corporation shall not engage in any act of self dealing (as defined in Section 4941(d) of the Internal Revenue Code), nor retain any excess business holdings (as defined in Section 4943(c) of the Internal Revenue Code), nor make any investments in such manner as to subject the corporation to tax under Section 4944 of the Internal Revenue Code, nor make any taxable expenditures (as defined in Section 4945(d) of the Internal Revenue Code).

(g) Upon the liquidation or dissolution of the corporation, after payment of all of the liabilities of the corporation or due provision therefor, all of the assets of the corporation shall, subject to Section 11A of Chapter 180 of the Massachusetts General Laws, be disposed of to The Children's Hospital Corporation, a Massachusetts non-profit corporation, so long as it is then

exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code, or if it is not then so exempt, to one or more organizations exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code.

(h) Successor Provisions. All references herein to provisions of the Internal Revenue Code and the Massachusetts General Laws refer to such provisions as in effect from time to time, including any successor provisions thereto.

ARTICLE V

The effective date of the Restated Articles of Organization of the corporation shall be the date approved and filed by the Secretary of the Commonwealth. If a *later* effective date is desired, specify such date which shall not be more than thirty days after the date of filing.

ARTICLE VI

The information contained in Article VI is not a permanent part of the Articles of Organization.

a. The street address (post office boxes are not acceptable) of the principal office of the corporation in *Massachusetts* is:

800 Huntington Avenue, Boston, MA 02115

b. The name, residential address and post office address of each director and officer of the corporation is as follows:

	NAME	RESIDENTIAL ADDRESS	POST OFFICE ADDRESS
President:	See page 6(b) attached hereto and made a part hereof.		

Treasurer:

Clerk:

Directors:
(or officers
having the
powers of
directors)

c. The fiscal year of the corporation shall end on the last day of the month of: June

d. The name and business address of the resident agent, if any, of the corporation is:

N/A

****We further certify that the foregoing Restated Articles of Organization affect no amendments to the Articles of Organization of the corporation as heretofore amended, except amendments to the following articles. Briefly describe amendments below:**

Articles II, III, IV and VI are amended and restated in their entirety.

SIGNED UNDER THE PENALTIES OF PERJURY, this 20th day of February, 2009.

Therese M. Grant, *President / ~~**Vice President~~,
ARBY, *Clerk / ~~**Assistant Clerk~~.

*Delete the inapplicable words.

**If there are no such amendments, state "None".

IMMUNE DISEASE INSTITUTE, INC.

ATTACHMENT VI6(b). Officers

<u>Name</u>	<u>Title</u>	<u>Address</u>
Theodore Cronin	President	800 Huntington Avenue, Boston, MA 02115
David Kirshner	Treasurer	800 Huntington Avenue, Boston, MA 02115
Stuart Novick	Clerk	800 Huntington Avenue, Boston, MA 02115
Rachelle Rosenbaum	Assistant Clerk	800 Huntington Avenue, Boston, MA 02115

6(b). Trustees

<u>Name</u>	<u>Address</u>
Frederick Alt	800 Huntington Avenue, Boston, MA 02115
Carleena Brunelli	800 Huntington Avenue, Boston, MA 02115
Robert Carpenter	800 Huntington Avenue, Boston, MA 02115
Gary Fleisher, M.D.	800 Huntington Avenue, Boston, MA 02115
David Kirshner	800 Huntington Avenue, Boston, MA 02115
Harvey Lodish, Ph.D.	800 Huntington Avenue, Boston, MA 02115
James Mandell, M.D.	800 Huntington Avenue, Boston, MA 02115
Walt Pressey	800 Huntington Avenue, Boston, MA 02115
Enid Starr	800 Huntington Avenue, Boston, MA 02115

THE COMMONWEALTH OF MASSACHUSETTS

RESTATED ARTICLES OF ORGANIZATION
(General Laws, Chapter 180, Section 7)

8510205181

I hereby approve the within Restated Articles of Organization and,
the filing fee in the amount of \$ 35 having been paid, said
articles are deemed to have been filed with me this 20 day of
Feb, 2009.

Effective Date: February 20 2009

William Francis Galvin

1077511

WILLIAM FRANCIS GALVIN

Secretary of the Commonwealth

20 FEB 20 PM 3:23
CORPORATION DIVISION

TO BE FILLED IN BY CORPORATION

Contact information:

Stuart J. Novick, Esq.

Children's Hospital Boston, 300 Longwood Avenue

Boston, MA 02115

Telephone: 617-355-6000

Email: stuart.novick@childrens.harvard.edu

A copy this filing will be available on-line at www.state.ma.us/sec/cor once
the document is filed.

3

AMENDED AND RESTATED BY-LAWS

OF

IMMUNE DISEASE INSTITUTE, INC.

Adopted November 16, 1989

Amended December 6, 1995

Amended June 14, 2001

Name Changed June 5, 2007

Amended February 20, 2009

Adopted:	November 16, 1989
Amended:	December 6, 1995
Amended:	June 14, 2001
Name Changed:	June 5, 2007
Amended:	February 20, 2009

AMENDED AND RESTATED BY-LAWS

OF

IMMUNE DISEASE INSTITUTE, INC.

In accordance with Section 10 of the By-laws of Immune Disease Institute, Inc. (the "Corporation") in effect as of June 5, 2007, the By-laws are hereby amended and restated in their entirety as follows:

Section 1. MEMBERS

1.1. Member. The Children's Medical Center Corporation, acting through its board of trustees, shall serve as the sole member of the Corporation.

1.2. Powers and Rights. In addition to the rights provided to the member in Section 2.1 and Section 9, and such other powers and rights as are vested in the member by law, the Articles of Organization of the Corporation (the "Articles") or these By-laws, the member shall have such other powers and rights as the trustees may designate.

1.3. Annual Meeting. The annual meeting of the member shall be held within six (6) months after the end of the fiscal year of the Corporation on such date and at such hour and place as the trustees or an officer designated by the trustees shall determine. In the event that no date for the annual meeting is established or such meeting has not been held on the date so determined, a special meeting in lieu of the annual meeting may be held with all of the force and effect of an annual meeting.

1.4. Regular Meetings. Regular meetings of the member may be held at such times as the member may determine.

1.5. Special Meetings. Special meetings of the member may be held at any time when called by the president or by the trustees.

1.6. Place of Meetings. All meetings of the member shall be held at the principal office of the Corporation in Massachusetts or at such other place within the United States as shall be fixed by the trustees or the president.

1.7. Notice of Meetings. A written notice of each meeting of the member, stating the place, date, and time and the purposes of the meeting, shall be given at least seven (7) days before the meeting to the clerk of the member. Whenever notice of a meeting is required, such notice need not be given to the clerk of the member if a written waiver of notice, executed by the member (or the member's attorney thereunto authorized) before or after the meeting, is filed with the records of the meeting.

1.8. Quorum. At any meeting of the member, the existence of a quorum shall be as determined in the by-laws of the member, except when a larger quorum is required by law, the Articles or by these By-laws. Any meeting may be adjourned to such date or dates not more than ninety (90) days after the first session of the meeting by a majority of the votes cast upon the question, whether or not a quorum is present, and the meeting may be held as adjourned without further notice.

1.9. Action by Vote. The member shall act as provided in its by-laws.

1.10. Action by Writing. Any action required or permitted to be taken at any meeting of the member may be taken without a meeting if the member consents to the action in writing and the written consent is filed with the records of the meetings of the member. Such consents shall be treated for all purposes as a vote at a meeting.

1.11. Proxies. The member may vote through its president or other duly authorized officer either in person or by written proxy dated not more than six (6) months before the meeting named therein, which proxies shall be filed before being voted with the clerk or other person responsible for recording the proceedings of the meeting. Unless otherwise specifically limited by their terms, such proxies shall entitle the holders thereof to vote at any adjournment of the meeting but the proxy shall terminate after the final adjournment of such meeting.

Section 2. OFFICERS AND TRUSTEES

2.1. Number and Election. The trustees shall be divided into two classes: (i) Class A trustees, of whom there shall be a maximum of three (3) trustees if GlaxoSmithKline Research & Development Limited ("GSK") elects not to appoint a trustee pursuant to a certain Research Collaboration Agreement by and between the Corporation and GSK, or a maximum of four (4) trustees if GSK elects to appoint a trustee; and (ii) Class B trustees, of whom there shall be not fewer than four (4) trustees if GSK elects not to appoint a trustee, or not fewer than five (5) trustees if GSK elects to appoint a trustee. As of the effective date of these Amended and Restated By-laws, the individuals set forth on Schedule A attached hereto shall become the trustees of the Corporation and shall serve for the terms designated on said Schedule A. Successor trustees shall be elected as follows:

Class A Trustees. At each annual meeting of the trustees, a majority of the Historical Trustees (as defined in Schedule A) then in office shall elect the appropriate number of successors to the Historical Trustees whose terms are then expiring and GSK shall select the GSK Trustee, if any, provided, however, that the member shall have the authority to object to any trustee elected by the Historical Trustees, in the member's reasonable discretion. Without limiting the foregoing, no individual shall serve as a Class A trustee unless and until the member shall have determined, in its sole discretion, that each such individual is independent. An individual shall be deemed to be independent for purposes of this Section 2.1 provided that such

individual is not a director, trustee, officer, agent, or employee of the member or of Children's Hospital Corporation, and is not an officer, employee or agent of this Corporation. Each Class A trustee so elected shall hold office for a term of one (1) year and until his or her successor is elected and qualified, or until he sooner dies, resigns, is removed, or becomes disqualified.

Class B Trustees. At each annual meeting of the member of the Corporation, the member shall elect the appropriate number of successors to the Class B trustees whose terms are then expiring. Each Class B trustee so elected shall hold office for a term of one (1) year and until his or her successor is elected and qualified, or until he sooner dies, resigns, is removed, or becomes disqualified.

At any special or regular meeting, the member may increase or decrease the total number of trustees, provided, however, that at all times the number of Historical Trustees shall not be fewer than three (3) trustees and a majority of the trustees shall be Class B trustees, and provided that at least twenty percent (20%) of the trustees shall be Class A trustees.

The trustees at their annual meeting in each year shall elect a president, a scientific director, a treasurer, and a clerk, and may at any time appoint such other officers as they shall determine. Except as otherwise provided in these By-laws, the president, the treasurer, and the clerk shall hold office until the next annual meeting of the trustees and until their respective successors are elected and qualified. Other officers shall serve at the pleasure of the trustees.

2.2. Resignations and Removal. Any trustee or officer may resign at any time by delivering his resignation in writing to the chairman of the board, if any, the president or the clerk, or to the Corporation at its principal office. Such resignation shall be effective upon receipt unless specified to be effective at some other time. A Class A trustee may be removed (i) for cause by the vote of two-thirds (2/3) of the total number of Class A and Class B trustees and (ii) without assignment of cause by the vote of two-thirds (2/3) of the total number of Class A and Class B trustees (provided that in the case of (ii), with respect to the removal of a Historical Trustee, such number shall include a majority of the Historical Trustees eligible to vote). A Class B trustee may be removed with or without assignment of cause by the vote of the member. An officer may be removed with or without assignment of cause by the vote of a majority of the trustees then in office. A trustee or officer may be removed for cause only after reasonable notice and opportunity to be heard before the body proposing to remove him or her.

2.3. Vacancies. Any vacancy in the (i) Historical Trustees shall be filled by a vote of a majority of the Historical Trustees then in office and (ii) GSK Trustee shall be filled by GSK, provided, however, that the member shall have the authority to object to any trustee elected by the Historical Trustees, in the member's reasonable discretion. Any vacancy in Class B trustees shall be filled by a vote of the member. Any vacancy in Class A trustees resulting from the enlargement of the board may be filled by vote of a majority of the Class A trustees then in office, provided, however, that the member shall have the authority to object to any trustee elected by the Class A trustees, in the member's reasonable discretion. Any vacancy in Class B trustees resulting from the enlargement of the board may be filled by the member. The trustees shall elect a successor if the office of the president, treasurer, or clerk becomes vacant and may elect a successor if any other office becomes vacant. Each such successor shall hold office for the unexpired term and in the case of the president, treasurer, and clerk until his successor is chosen and qualified, or in each case until he or she sooner dies, resigns, is removed, or becomes

disqualified. The member and the trustees shall have and may exercise all their powers notwithstanding the existence of one or more vacancies in their number.

2.4. Honorary Trustees. The trustees may elect as honorary trustees former trustees who have served the Corporation with distinction. Honorary trustees shall be entitled to notice of and to participate in discussions at meetings of the trustees but shall not have the right to vote. Honorary trustees may be elected to serve at the pleasure of the trustees or for specified terms.

Section 3. POWERS AND DUTIES OF TRUSTEES AND OFFICERS

3.1. Trustees. The affairs of the Corporation shall be managed by the trustees who shall have and may exercise all the powers of the Corporation, except those powers reserved to the member by law, the Articles, or these By-laws.

The following powers are reserved to the member:

- (1) the amendment of the Articles or these By-laws in accordance with Section 9;
- (2) the selection of the independent auditor and legal counsel of the Corporation;
- (3) hiring and firing of senior management of the Corporation excluding the officers;
- (4) any engagement in, or entry into, any transaction providing for the sale, mortgage or other disposition of all or substantially all of the Corporation's assets, or the approval and adoption of a plan of merger or consolidation of the Corporation with another corporation;
- (5) the creation or acquisition of any subsidiary or affiliate corporation of the Corporation;
- (6) the adoption of a plan of dissolution and/or distribution of the assets of Corporation;
- (7) the borrowing of any sum whose stated term is greater than one (1) year or which is secured by a mortgage of all or any portion of the Corporation's real property or by a security interest in the Corporation's assets or revenues;
- (8) any borrowing in excess of \$50,000 whether long term or short term and whether secured or unsecured; and
- (9) the sale, lease, or disposition, not including a lease having less than a five (5) year term, of any real property owned by the Corporation.

3.2. Chairman and President. The trustees may appoint a chairman of the board who, unless otherwise determined by the trustees, shall when present preside at all meetings of the trustees and shall have such other powers and duties as customarily belong to the office of chairman of the board or as may be designated from time to time by the trustees. Unless otherwise determined by the trustees, the president shall be the chief executive officer of the Corporation and shall, subject to the direction of the trustees, have general supervision and control of the business of the corporation. The president shall perform such other duties and shall have such other powers as the trustees may designate from time to time.

3.3. Scientific Director. The scientific director shall be the chief scientific officer of the Corporation and shall have charge of the development and management of the scientific and educational program of the corporation.

3.4. Vice Presidents. The vice presidents, if any, shall have such powers and duties as may be designated from time to time by the trustees or by the president.

3.5. Treasurer. Except as the trustees shall otherwise determine, the treasurer shall be the chief financial and accounting officer of the Corporation and shall have such other powers and duties as customarily belong to the office of treasurer or as may be designated from time to time by the trustees or the president.

3.6. Clerk. The clerk shall record all proceedings of the trustees in a book or books to be kept therefor and shall have custody of the seal of the Corporation.

3.7. Other Officers. Other officers shall have such powers as may be designated from time to time by the trustees.

Section 4. MEETINGS OF THE TRUSTEES

4.1. Annual Meeting. The annual meeting of trustees shall be held immediately following the annual meeting of the member, pursuant to Section 1.3.

4.2. Regular and Special Meetings. Regular meetings of the trustees may be held at such places and at such times as the trustees may determine. Special meetings of the trustees may be held at any time and at any place when called by the chairman of the board of trustees, if any, the president, or a majority of the trustees.

4.3. Notice. No notice need be given for a regular meeting. Forty-eight (48) hours' notice by mail or telephone shall be given for a special meeting unless shorter notice is adequate under the circumstances. A notice or waiver of notice need not specify the purpose of any special meeting. Notice of a meeting need not be given to any trustee if a written waiver of notice, executed before or after the meeting, is filed with the records of the meeting, or to any trustee who attends the meeting without protesting prior thereto or at its commencement the lack of notice to such trustee.

4.4. Quorum. A majority of the trustees then in office shall constitute a quorum, but a smaller number may adjourn finally or from time to time without further notice until a quorum is secured. If a quorum is present, a majority of the trustees present may take any action on behalf of the board except to the extent that a larger number is required by law, the Articles, or these By-laws.

4.5. Action by Vote. When a quorum is present at any meeting, a majority of the trustees present and voting shall decide any question, including election of officers, unless otherwise provided by law, the Articles, or these By-laws.

4.6. Action by Consent. Any action required or permitted to be taken at any meeting of the trustees may be taken without a meeting if all the trustees consent to the action in writing and the written consents are filed with the records of the meetings of trustees. Such consents shall be treated for all purposes as a vote at a meeting.

4.7. Presence Through Communications Equipment. Unless otherwise provided by law or the Articles, trustees may participate in a meeting of the board of trustees by means of a conference telephone or similar communications equipment by means of which all persons

participating in the meeting can hear each other at the same time, and participation by such means shall constitute presence in person at a meeting.

Section 5. COMMITTEES

5.1. Executive Committee. The trustees may elect from their number an executive committee of no less than three (3) persons. The executive committee shall have all of the powers of the board of trustees except those which by law, the Articles, or these By-laws may not be delegated.

5.2. Other Committees. The trustees may from time to time establish such other committees, the members of which need not be trustees, as they deem appropriate with such powers and duties as the trustees may determine.

5.3. General. The members of any committee shall hold office at the pleasure of the trustees. All committees appointed by the trustees shall be subject to removal at the pleasure of the trustees. All decisions of committees appointed by the trustees shall be subject to review and alteration by the trustees, provided that any such alteration by the trustees shall not affect any action taken prior thereto in reliance upon authorized committee action. Except as the trustees may otherwise determine, any committee may make rules for the conduct of its business, but unless otherwise provided by the trustees or such rule, its business shall be conducted as nearly as may be in the same manner as is provided by these By-laws for the conduct of business by the trustees.

Section 6. SPONSORS, BENEFACTORS, CONTRIBUTORS, ADVISORS, FRIENDS OF THE CORPORATION

The trustees may designate persons or groups of persons as sponsors, benefactors, contributors, advisors, or friends of the Corporation or such other title as they deem appropriate. Such persons shall serve in an honorary capacity and, except as the trustees shall otherwise designate, shall in such capacity have no right to notice of or to vote at any meeting, shall not be considered for purposes of establishing a quorum, and shall have no other rights or responsibilities.

Section 7. INDEMNIFICATION

The Corporation shall, to the extent legally permissible, indemnify each person who may serve or who has served at any time as a member, trustee, director, officer, or committee member of the Corporation or of any of its subsidiaries, or who at the request of the Corporation may serve or at any time has served as a trustee, director, officer, or committee member of, or in a similar capacity with, another organization or an employee benefit plan (each such person being called in this Section 7 a "Person"), against all expenses and liabilities (including counsel fees, judgments, fines, excise taxes, penalties, and amounts payable in settlements) reasonably incurred by or imposed upon such Person in connection with any threatened, pending, or completed action, suit, or other proceeding, whether civil, criminal, administrative, or investigative, in which such Person may become involved by reason of serving or having served in such capacity (other than a proceeding voluntarily initiated by such Person unless he or she is successful on the merits, the proceeding was authorized by the Corporation, or the proceeding seeks a declaratory judgment regarding his or her own conduct); provided that no

indemnification shall be provided for any such Person with respect to any matter as to which he or she shall have been finally adjudicated in any proceeding not to have acted in good faith in the reasonable belief that his or her action was in, or not opposed to, the best interests of the Corporation and in the case of any criminal proceeding, such Person had no reasonable cause to believe that the conduct was unlawful, or to the extent such matter relates to service with respect to any employee benefit plan, in the best interests of the participants or beneficiaries of such employee benefit plan. A Person whose duties include service or responsibilities as a fiduciary with respect to a subsidiary or other organization shall be deemed to have acted in good faith in the reasonable belief that his or her action was in the best interests of the Corporation if he or she acted in good faith in the reasonable belief that his or her action was in the best interests of such subsidiary or organization or of the participants or beneficiaries of, or other persons with interests in such subsidiary or organization to whom he or she had a fiduciary duty.

Such indemnification shall include payment by the Corporation of expenses incurred in defending a civil or criminal action or proceeding in advance of the final disposition of such action or proceeding, upon receipt of an undertaking by the Person to repay such payment if he or she shall be adjudicated to be not entitled to indemnification under this article, which undertaking may be accepted without regard to the financial ability of such Person to make repayment.

Notwithstanding the foregoing, as to any matter disposed of by compromise payment by any Person pursuant to a consent decree or otherwise, no indemnification either for said payment or for any other expenses shall be provided unless such compromise shall be approved as in the best interests of the Corporation, after notice that it involves such indemnification:

- (i) by a disinterested majority of the trustees then in office; or
- (ii) by a majority of the disinterested trustees then in office, provided that there has been obtained an opinion in writing of legal counsel to the effect that such Person appears to have acted in good faith in the reasonable belief that his or her action was in the best interests of the Corporation; or
- (iii) by the member.

Any indemnification or advance of expenses under this article shall be paid promptly, and in any event within thirty (30) days, after the receipt by the Corporation of a written request therefor from the Person, unless with respect to a claim for indemnification the Corporation shall have determined that the Person is not entitled to indemnification. If the Corporation denies the request or if payment is not made within such thirty-day period, the Person may at any time thereafter seek to enforce his or her rights hereunder in a court of competent jurisdiction and, if successful in whole or in part, he or she shall be entitled also to indemnification for the expenses of prosecuting such action. Unless otherwise provided by law, the burden of proving that the Person is not entitled to indemnification shall be on the Corporation.

The right of indemnification under this article shall be a contract right inuring to the benefit of the member, trustees, directors, officers and other persons entitled to be indemnified hereunder and no amendment or repeal of this article shall adversely affect any right of such Person existing at the time of such amendment or repeal.

The indemnification provided hereunder shall inure to the benefit of the heirs, executors, and administrators of the Persons entitled to indemnification hereunder. The indemnification provided hereunder may, to the extent authorized by the Corporation, apply to the member, trustees, directors, officers and other persons associated with constituent corporations that have been merged into or consolidated with the Corporation who would have been entitled to indemnification hereunder had they served in such capacity with or at the request of the Corporation.

The right of indemnification under this article shall be in addition to and not exclusive of all other rights to which such Persons may be entitled. Nothing contained in this article shall affect any rights to indemnification to which Corporation employees or agents other than the Persons entitled to indemnification hereunder may be entitled by contract or otherwise under law.

Section 8. SEAL AND FISCAL YEAR

The seal shall be circular in form with the name of the Corporation around the periphery and the year and state of incorporation within or in such other form as the trustees may determine. The fiscal year shall commence on July 1 of each year or such other date as the trustees may determine.

Section 9. AMENDMENT OF BY-LAWS

These By-laws may be altered, amended or repealed at any annual or special meeting of the member, notice of which shall specify the subject matter of the proposed alteration, amendment, or repeal or the sections to be affected thereby, by vote of the member; provided, however, that any amendment that adversely affects or diminishes the rights of the Historical Trustees under Sections 2.1, 2.2, 2.3 and 9 of these By-laws shall require consent of a majority of the Historical Trustees.

Schedule A

Class A trustees

(i) The "Historical Trustees":

Robert Carpenter
Walt Pressey
Enid Starr

(ii) The "GSK Trustee" (if applicable):

[Not applicable]

Class B trustees

Frederick Alt
Gary Fleisher, M.D.
David Kirshner
Harvey Lodish, Ph.D.
James Mandell, M.D.
Vice President Research Administration of Children's Hospital Boston*

*Position currently filled by Carleen Brunelli

4


OFFICER'S CERTIFICATE

The undersigned, on behalf of Immune Disease Institute, Inc. ("IDI"), hereby certifies the following in connection with the Affiliation Agreement (the "Affiliation Agreement") dated as of December 24, 2008, by and between IDI and The Children's Medical Center Corporation. All capitalized terms not otherwise defined in this Certificate shall have the meanings assigned to them in the Affiliation Agreement.

1. The representations and warranties of IDI contained in Section 2 of the Affiliation Agreement are true, complete and accurate in all material respects on and as of the Closing Date as though made on and as of the Closing Date.
2. All covenants, obligations and agreements contained in the Affiliation Agreement required to be performed by IDI prior to or at the Closing have been performed in all material respects.
3. The conditions contained in Section 5.1.3 of the Affiliation Agreement have been fulfilled as of the Closing Date.

February 20, 2009

[The remainder of this page is intentionally left blank]


Theodore M. Cronin
Acting President and Chief Financial Officer

5

Execution Version


OFFICER'S CERTIFICATE

The undersigned, on behalf of The Children's Medical Center Corporation ("CMCC"), hereby certifies the following in connection with the Affiliation Agreement (the "Affiliation Agreement") dated as of December 24, 2008, by and between CMCC and Immune Disease Institute, Inc. All capitalized terms not otherwise defined in this Certificate shall have the meanings assigned to them in the Affiliation Agreement.

1. The representations and warranties of CMCC contained in Section 3 of the Affiliation Agreement are true, complete and accurate in all material respects on and as of the Closing Date as though made on and as of the Closing Date.
2. All covenants, obligations and agreements contained in the Affiliation Agreement required to be performed by CMCC prior to or at the Closing have been performed in all material respects.
3. The conditions contained in Section 5.2.3 of the Affiliation Agreement have been fulfilled as of the Closing Date.

February 20, 2009

[The remainder of this page is intentionally left blank]

A handwritten signature in black ink, appearing to read "James Mandell", written over a horizontal line.

James Mandell, M.D.
Chief Executive Officer

6

EDWARDS ANGELL PALMER & DODGE LLP

111 Huntington Avenue Boston, MA 02199 617.239.0100 fax 617.227.4420 eaprlaw.com

February 20, 2009

The Children's Medical Center Corporation
300 Longwood Avenue
Boston, MA 02115

Ladies and Gentlemen:

We are furnishing this opinion to you pursuant to Section 5.1.5 of the Affiliation Agreement dated as of December 24, 2008 (the "Affiliation Agreement") between The Children's Medical Center Corporation ("CMCC") and Immune Disease Institute, Inc. ("IDI"), each a Massachusetts nonprofit corporation. Capitalized terms that are defined in the Affiliation Agreement and not otherwise defined in this opinion are used in this opinion as so defined.

We have acted as counsel to IDI in connection with the Affiliation Agreement. We have reviewed such documents and made such examination of law as we have deemed appropriate to give this opinion. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to this opinion, on representations made in the Affiliation Agreement and certificates and other inquiries of officers of IDI.

When used in this opinion, the phrase "to our knowledge" or an equivalent phrase limits the statements it qualifies to the actual knowledge of the lawyers in this firm responsible for preparing this opinion after such inquiry as they deemed appropriate.

This opinion is limited to Massachusetts law and the federal law of the United States.

Based upon the foregoing and subject to the additional qualifications set forth below, we are of the opinion that:

1. IDI is validly existing as a nonprofit corporation under Massachusetts law and has the corporate power to execute and deliver the Affiliation Agreement and to perform its obligations thereunder.
2. IDI has duly authorized, executed and delivered the Affiliation Agreement, and the Affiliation Agreement constitutes its valid and binding obligation enforceable against it in accordance with its terms.
3. The execution and delivery by IDI of the Affiliation Agreement do not and the performance by it of its obligations thereunder will not (i) violate Massachusetts or federal law, (ii) result in a breach of, or constitute a default under, any agreement listed on Exhibit A hereto or (iii) violate its articles of organization or bylaws.

EDWARDS ANGELL PALMER & DODGE LLP

The Children's Medical Center Corporation

February 20, 2009

Page 2

4. To our knowledge, no consent or permit by any governmental authority is required to be obtained by IDI in connection with its execution and delivery of the Affiliation Agreement or the performance by it of its obligations thereunder, other than those that have been obtained, except for such consents and permits that, if not obtained, could not reasonably be expected to have a material adverse effect on IDI, taken as a whole.

Our opinions above are subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors and to general principles of equity.

This opinion does not address any future merger of IDI into an affiliate of CMCC pursuant to Section 6.1.2 of the Affiliation Agreement.

This opinion shall be interpreted in accordance with the Legal Opinion Principles issued by the Committee on Legal Opinions of the American Bar Association's Section of Business Law as published in 53 Business Lawyer 831 (May 1998).

This opinion is being furnished only to you for your use solely in connection with the closing under the Affiliation Agreement and may not be relied on without our prior written consent for any other purpose or by anyone else.

Very truly yours,

A handwritten signature in cursive script, appearing to read "Edwards Angell Palmer + Dodge LLP", written in dark ink.

EDWARDS ANGELL PALMER & DODGE LLP

Exhibit A

1. Loan from the Massachusetts Health and Educational Facilities Authority to The CBR Institute for Biomedical Research, Inc. to be funded from proceeds of the Authority's Revenue Bonds, Capital Asset Program Issue, Series M-1A, Closing Date of 10/17/2003
2. Loan from the Massachusetts Health and Educational Facilities Authority to The CBR Institute for Biomedical Research, Inc. to be funded from proceeds of the Authority's Revenue Bonds, Capital Asset Program Issue, Series M-3A (2004) Pool 3, Closing Date of 11/2/2004
3. Master Lease and Sublease Agreement among Banc of America Public Capital Corp as Lessor and Servicer, HEFA as Lessee and Escrow Agent, and The CBR Institute for Biomedical Research, Inc. as Sub-Lessee, dated as of 1/11/2007 and Schedule No. 1 dated 2/6/2007 and Schedule No. 2 dated 4/29/2008
4. Master Lease and Sublease Agreement among Hewlett-Packard Financial Services Company, HEFA and The CBR Institute for Biomedical Research, Inc. dated 12/13/2005 and Schedule No. 1 dated 1/18/2006
5. Master Lease and Sublease Agreement among Banc of America Public Capital Corp as Lessor and Servicer, and HEFA as Lessee and Escrow Agent, and the Immune Disease Institute, Inc. as Sub-Lessee, dated as of April 29, 2008
6. Research Collaboration Agreement with GlaxoSmithKline Research & Development Limited, effective 5/14/2008
7. Reimbursement Agreement dated October 1, 2003, as amended relating to letter of credit for MHEFA Series M-1A Pool Loan
8. Reimbursement Agreement dated November 1, 2004, as amended relating to letter of credit for MHEFA Series M-3A Pool Loan
9. Application and Agreement for Standby Letter of Credit dated June 1, 2006 relating to letter of credit for the benefit of BMR-Blackfan Circle LLC required under CLSB lease
10. Revolving Credit Agreement dated October 31, 2001 as amended relating to \$2,000,000 revolving credit facility
11. Lease dated May 10, 2006, between CBRI, as landlord, and 800 Huntington Avenue LLC, as tenant ("800 LLC")
12. Sublease dated May 10, 2006, between 800 LLC, as sublandlord, and CBRI, as subtenant
13. Lease dated May 23, 2006, between CLSB I LLC, as landlord, and CBRI, as tenant, as amended through a 3rd Amendment.
14. Sublease dated as of September 3, 1992, between Blood Research Institute, Inc., as sublandlord, and CBRI, as subtenant
15. President & Fellows of Harvard College (Landlord) to The CBR Institute for Biomedical Research, Inc. (Tenant); Space: 2,902 nsf on the 2nd floor of the Armenise Building. Dated June 21, 2006. Term: June 21, 2006 through December 31, 2010.

7



ROPES & GRAY LLP
ONE INTERNATIONAL PLACE
BOSTON, MA 02110-2624
WWW.ROPESGRAY.COM

February 20, 2009

Immune Disease Institute, Inc.
800 Huntington Avenue
Boston, MA 02115

Ladies and Gentlemen:

We have acted as counsel to The Children's Medical Center Corporation, a Massachusetts corporation ("CMCC"), in connection with the Affiliation Agreement, dated as of December 24, 2008 (the "Affiliation Agreement"), by and between CMCC and Immune Disease Institute, Inc. ("IDI"), each a Massachusetts nonprofit corporation.

This opinion is being rendered to you pursuant to Section 5.2.5 of the Affiliation Agreement. Unless otherwise specifically defined herein, each of the capitalized terms used herein shall have the meaning ascribed to it in the Affiliation Agreement.

In connection with this opinion, we have examined, among other documents, an executed copy of the Affiliation Agreement. We also have examined such records, certificates and other documents of CMCC and such other matters of law as we have considered necessary or appropriate for purposes of the opinions expressed below.

We have relied as to factual matters upon certificates of, and information received from, CMCC and/or representatives thereof. We have made no independent investigation of the facts stated in such certificates or as to any information received from CMCC or representatives thereof and do not opine as to the accuracy of any such factual matters. We also have relied upon certain certificates and other documents from public officials.

In rendering the following opinions, we have assumed, without investigation, that the representations and warranties of CMCC true and correct. In addition, we have assumed, without investigation, the authenticity of any document or other instrument submitted to us as an original, the conformity to the originals of any document or other instrument submitted to us as a copy or as the form of a document or other instrument, the legal capacity of natural persons, and the genuineness of all signatures on such original or copies (other than that of CMCC on the Affiliation Agreement). We also have assumed, but not independently verified, that all documents executed by a party other than CMCC were duly and validly executed and delivered by such party and are legal, valid and binding obligations of such party enforceable against such party in accordance with their respective terms, and that IDI has the requisite power and authority to enter into the Affiliation Agreement and to consummate the transaction contemplated thereby.

ROPES & GRAY LLP

With respect to the opinions set forth in the paragraph 1 below, we have relied solely on a certificate of good standing from the Secretary of State of The Commonwealth of Massachusetts, and our opinion with respect to such matters is rendered as of the date of such certificate and is limited accordingly.

This opinion does not address any future merger of IDI into CMCC or a controlled affiliate of CMCC pursuant to Section 6.1.2 of the Affiliation Agreement.

The opinions expressed herein are limited to matters governed by the laws of The Commonwealth of Massachusetts and the federal laws of the United States of America.

Based upon and subject to the foregoing, we are of the opinion that:


1. CMCC is a corporation validly existing and in good standing under the laws of The Commonwealth of Massachusetts, with all requisite corporate power and authority to execute, deliver and perform its obligations under the Affiliation Agreement.
2. The Affiliation Agreement has been duly authorized, executed and delivered by CMCC and, subject to the qualifications stated in the penultimate paragraph of this letter, constitutes the valid and binding obligation of CMCC enforceable against CMCC in accordance with its terms.
3. To our knowledge, no consent or permit by any federal or state governmental agency or body is required to be obtained by CMCC in connection with its execution and delivery of the Affiliation Agreement, or for the consummation by CMCC of the transaction contemplated thereby, except for such other consents or permits that, if not obtained, could not reasonably be expected to have a material adverse effect on CMCC, taken as a whole.
4. The execution and delivery by CMCC of the Affiliation Agreement and the consummation by CMCC of the transaction contemplated thereby does not and will not violate, or constitute a breach or default under, any provision of (i) applicable Massachusetts or federal law, or (ii) its articles of organization or by-laws.

Our opinion that the Affiliation Agreement is the legal, valid and binding obligation of CMCC, enforceable against CMCC in accordance with its terms, is subject to, and we express no opinion with respect to, (a) bankruptcy, insolvency, reorganization, receivership, liquidation, fraudulent conveyance, moratorium and other similar laws affecting the rights and remedies of creditors and secured parties, and (b) general principles of equity, regardless of whether applied in proceedings in equity or at law. We express no opinion herein as to any provisions of the Affiliation Agreement that provide for indemnification, contribution, waiver or release to the extent such provisions may be limited or rendered unenforceable, in whole or in part, as a matter of public policy.

ROPES & GRAY LLP

The foregoing opinion is furnished by us to you in connection with the transaction described above and is solely for your benefit. Except as otherwise expressly consented to by us in writing, this opinion may not be relied upon for any other purpose or by any other person.

Very truly yours,


Ropes & Gray LLP

8



800 Huntington Avenue
Boston, Massachusetts 02115
t: 617.278.3000
f: 617.278.3493
www.idi.harvard.edu

December 8, 2008

GlaxoSmithKline Research & Development Ltd.
Medicines Research Centre
Gunnels Wood Road
Stevenage SG1 2NY
UK

Attn: Russell Brooks, Attorney

Re: Request for Consent

Dear Mr. Brooks:

With respect to the Research Collaboration Agreement by and between GlaxoSmithKline Research & Development Limited ("GSK") and Immune Disease Institute, Inc. ("IDI"), dated May 14, 2008 (the "GSK Agreement"), IDI hereby (i) provides notice and requests the consent of GSK to the proposed change of control of IDI, (ii) requests that GSK forego its right to appoint trustees to the IDI board of trustees (the "IDI Board"), and (iii) seeks to clarify certain intellectual property rights established under the GSK Agreement. By way of signature below, GSK agrees to and acknowledges the requests contained in this consent and waiver letter. Capitalized terms not otherwise defined herein shall have the meanings set forth in the GSK Agreement.

1. GSK consents to the change of control of IDI and the affiliation between IDI and The Children's Medical Center Corporation ("CMCC"), whereby CMCC will become the sole corporate member of IDI with the right to control a majority of the IDI Board (the "Affiliation").
2. In recognition of the Affiliation, GSK agrees to waive and forego its right under Section 16.3 of the GSK Agreement to terminate the GSK Agreement in whole or in part on the basis of the Affiliation or the potential subsequent merger of IDI into CMCC or an affiliate of CMCC.
3. GSK agrees that its right to appoint up to two trustees to the IDI Board pursuant to Section 11 of the GSK Agreement shall (i) be reduced to the appointment of one trustee upon the effective date of the Affiliation and (ii) terminate in the event at any time after the consummation of the Affiliation IDI is merged into CMCC or an affiliate of CMCC and ceases to be a separate entity.
4. GSK agrees and acknowledges that upon the effective date of the Affiliation and for as long as the GSK Agreement remains in effect, all rights and licenses to the



intellectual property or technology of IDI granted to GSK under the GSK Agreement, including without limitation the right of first negotiation under Section 4, shall continue to be limited solely to IDI's intellectual property and technology, and in no way shall apply to or include any intellectual property or technology of CMCC or its Affiliates other than IDI. Nothing in the GSK Agreement shall be construed or interpreted in a manner that would provide GSK or its successors or permitted assigns with an interest in, or a right, option or license with respect to, any intellectual property or technology licensed to or owned by CMCC or any of its Affiliates other than IDI.


5. In the event at any time after the consummation of the Affiliation IDI is merged into CMCC, or an affiliate of CMCC, and ceases to be a separate entity, CMCC agrees to continue to operate IDI as a separate department, division or program of CMCC or its Affiliate ("CMCC Program"). GSK agrees and acknowledges that upon such merger all rights and licenses to the intellectual property or technology of IDI granted to GSK under the GSK Agreement, including without limitation the right of first negotiation under Section 4 of the GSK Agreement, shall continue to be limited solely to the intellectual property and technology of such CMCC Program as successor to IDI, and in no way shall apply to or include any other intellectual property or technology of CMCC or its Affiliates. Nothing in the GSK Agreement shall be construed or interpreted in a manner that would provide GSK or its successors or permitted assigns with an interest in, or a right, option or license with respect to, any intellectual property or technology licensed to or owned by CMCC or any of its Affiliates other than such CMCC Program as successor to IDI.
6. Nothing herein shall be construed to have any effect on rights or licenses to the intellectual property or technology granted by GSK to IDI under the GSK Agreement which rights and licenses shall continue in full force and effect.
7. GSK and IDI hereby agree this consent and waiver letter shall be for the benefit of IDI and CMCC.
8. Except for the changes and clarifications expressly stated above, the terms of the GSK Agreement remain in full force and effect and all of GSK's rights as stated under the original GSK Agreement shall remain in full force and effect, without any change, and shall not be restricted or otherwise limited in any way as a result of this change of control.

[The remainder of this page is intentionally left blank.]

If you have any questions, please feel free to contact me at (617) 278-3420. Thank you.


Very truly yours,

IMMUNE DISEASE INSTITUTE, INC.

By: 
Theodore M. Cronin
Acting President and Chief Financial Officer

Acknowledged and Agreed:

GLAXOSMITHKLINE RESEARCH
AND DEVELOPMENT LIMITED

By: 
Name: Paul Williamson
Title: For and on behalf of
Edinburgh Pharmaceutical Industries Limited
Date: Corporate Director

9

CONSENT TO SUBLEASE ASSIGNMENT

THIS CONSENT TO SUBLEASE ASSIGNMENT ("Consent") dated as of February 12, 2009 is made with reference to that certain sublease (the "Sublease") dated September 3, 1992 by and between Blood Research Institute, Inc. with an address at 800 Huntington Avenue, Boston, MA ("Tenant") and Center for Blood Research, Inc., with an address at 800 Huntington Avenue, Boston, MA ("Subtenant"), and is entered into by and among President and Fellows of Harvard College, with an address at 180A Longwood Avenue, Boston, Massachusetts ("Landlord"), Tenant, Subtenant, and The Children's Medical Center Corporation ("CMCC") with reference to the following facts:

(A) Landlord and Tenant are the parties to that certain lease dated as of September 3, 1992 ("Master Lease");

(B) Tenant and Subtenant (now known as Immune Disease Institute, Inc.) are parties to the Sublease; and

(C) Tenant has requested Landlord's approval of a transaction (the "Transaction") pursuant to which CMCC will become the sole corporate member of Subtenant.

(D) Tenant has also requested that Landlord approve the potential merger, at a future date, of Subtenant into (x) CMCC, (y) The Children's Hospital Corporation or (z) any nonprofit corporation of which either of them is the sole member (the "Merger").

NOW, THEREFORE, for good and valuable consideration, the parties agree as follows:

1. Landlord hereby consents to the Transaction and Merger upon the terms and conditions set forth below. Landlord expressly waives, to the extent arising out of the Transaction and/or the Merger, any rights of first refusal and first offer pursuant to Sections 21.3 and 21.4, respectively, of each of the Master Lease and the Sublease.

2. This Consent shall not release Tenant from any existing or future duty, obligation or liability to Landlord pursuant to the Master Lease, nor shall this Consent change, modify or amend the Master Lease in any manner, except insofar as it constitutes Landlord's consent to the Transaction and the Merger. This Consent shall not relieve Tenant from any requirement set forth in the Master Lease that Tenant obtain Landlord's prior written approval of any additional subleases, assignments or other dispositions of its interest in the Master Lease, the Sublease or the Premises (as defined in the Master Lease).

3. Landlord shall not (i) be liable to CMCC for any act, omission or breach of the Assignment by Subtenant or Tenant, or (ii) be subject to any offsets of defenses which CMCC might have against Subtenant or Tenant.

4. CMCC hereby acknowledges that it has read and has knowledge of all of the terms and provisions of the Sublease and the Master Lease

5. This Agreement shall be binding upon and shall inure to the benefit of the parties' respective successors in interest and assigns, subject at all times, nevertheless, to all agreements and restrictions contained in the Lease, the Sublease, and this Consent, with respect to subleasing, assignment, or other transfer. The agreements contained herein constitute the entire understanding between the parties with respect to the subject matter hereof, and supersede all prior agreements, written or oral, inconsistent herewith.

6. Tenant and Subtenant agree to indemnify and hold Landlord harmless from and against any loss, cost, expense, damage or liability, including reasonable attorneys' fees, incurred as a result of a claim by any person or entity (i) that it is entitled to a commission, finder's fee or like payment in connection with the Transaction or (ii) arising out of the Transaction or the Merger.

7. Landlord shall not be considered to have consented to the Transaction or the Merger until this Consent is executed and delivered by Landlord, Tenant, Subtenant and CMCC. Any liability of Landlord to Tenant, Subtenant and/or CMCC under or in connection with this Consent, shall be limited to the same extent as Landlord's liability to Tenant is limited under the Master Lease.


EXECUTED under seal.


LANDLORD:

TENANT:

President and Fellows of Harvard College

Blood Research Institute, Inc.


By: 
Name: Daniel G. Ennis
Duly Authorized


By: 
Name: THEODORE M. CRONIN
Duly Authorized

SUBTENANT:

Immune Disease Institute, Inc.

The Children's Medical Center Corporation

By: 
Name: THEODORE M. CRONIN
Duly Authorized

By: 
Name: STUART J. NOVICK
Duly Authorized

10



800 Huntington Avenue
Boston, Massachusetts 02115
t: 617.278.3000
f: 617.278.3493
www.idi.harvard.edu

November 21, 2008

Blood Research Institute, Inc.
c/o David R. Pokross, Jr., Clerk
Edwards Angell Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02109

RE: Consent to Proposed Affiliation

Dear Mr. Pokross:

Pursuant to Section 21.1 of the Sublease dated September 3, 1992 (the "Sublease"), by Blood Research Institute, Inc. ("BRI"), as Sublandlord, to Center for Blood Research, Inc. (now known as Immune Disease Institute, Inc. ("IDI")), as Subtenant, IDI hereby requests BRI's consent to the transfer of a majority of the controlling interest in IDI as described below.

IDI contemplates entering a transaction (the "Affiliation") with The Children's Medical Center Corporation ("CMCC") whereby CMCC will become the sole corporate member of IDI with the right to control a majority of the board of trustees of IDI (the "IDI Board"). In connection with the Affiliation, CMCC shall acquire the right to merge IDI into CMCC or a controlled affiliate of CMCC on or after October 1, 2012 (or earlier with the agreement of the minority trustees on the IDI Board).

By signature below, BRI acknowledges and consents to IDI's change of control under the Affiliation and any future merger of IDI into CMCC or a controlled affiliate of CMCC that may occur in connection with the Affiliation. BRI also hereby expressly waives and forgoes, with respect to such change of control and any such future merger, the requirement under Section 21.4 of the Sublease that the surviving entity in any such future merger must enter into a separate written agreement with BRI agreeing to be bound by all of the obligations of Subtenant. Furthermore, BRI hereby acknowledges, confirms and agrees that the Affiliation and any future merger of IDI into CMCC or a controlled affiliate of CMCC shall not constitute defaults under the Sublease.

BRI and IDI hereby agree this consent and waiver letter shall be for the benefit of IDI and CMCC and shall survive any merger of IDI into CMCC or a controlled affiliate of CMCC. Except as provided in this consent and waiver letter, the terms of the Sublease remain in full force and effect.

If you have any questions, please feel free to contact me at (617) 278-3000. Thank you.



Very truly yours,

IMMUNE DISEASE INSTITUTE, INC.

By: Theodore M. Cronin
Theodore M. Cronin
Acting President and Chief Financial Officer

Acknowledged, agreed and consented to:

BLOOD RESEARCH INSTITUTE, Inc.

By: Edward J. Benz, Jr.
Name: EDWARD J. BENZ, JR., M.D.
Title: PRESIDENT
Date: 11/24/08

11



800 Huntington Avenue
Boston, Massachusetts 02115
t: 617.278.3000
f: 617.278.3493
www.idi.harvard.edu

January 5, 2009

Mr. Joseph Ellis, Director
NIH Office of Policy for Extramural Research Administration (OPERA)
Suite 350, MSC 7974
6705 Rockledge Drive
Bethesda, MD 20817

Re: Affiliation between the Immune Disease Institute and Children's Hospital Boston

Dear Mr. Ellis:

As we discussed over the phone, Immune Disease Institute, Inc. (IDI) and The Children's Medical Center Corporation (CMCC), the parent of Children's Hospital Boston (collectively, Children's) signed an affiliation agreement on December 24, 2008. The summary below outlines the key terms of the affiliation agreement that are relevant to IDI's conduct of research under NIH grants or funding for such research. We want to confirm with your office that this affiliation will have no impact on the current grant awards or the eligibility of IDI for future grant awards and that no further action by IDI is required at this time.

Under the terms of the affiliation agreement, there will be no change in IDI's legal status as a separate corporation. IDI will continue to operate as a separate legal entity under the IDI name and tax ID number. IDI will become an affiliate of CMCC when CMCC becomes the sole corporate member of IDI, with the authority to appoint the majority of the IDI board of trustees, while the present IDI board will have a minority representation on the IDI board of trustees (the IDI minority trustees). The affiliation does not involve a corporate merger. At a later time, Children's may elect to merge IDI into one of its corporate affiliates, but not before October 1, 2012, unless a majority of the IDI minority trustees agree to a merger prior to that date.


As a result of the affiliation, IDI will do business as a multi-disciplinary research program associated with Children's as the "Program in Cellular and Molecular Medicine." Children's will provide financial support to IDI. IDI faculty members will receive faculty appointments at Children's, but there is no present intention that Children's provide them with direct salary support or that the responsibility for IDI research grants be shared with Children's. IDI will stay in its present space. Ted Cronin will remain CEO for at least one year and his successor will be approved by the IDI minority trustees. Children's and IDI will explore opportunities for efficiency in IDI operations, but any consolidations are not expected to be undertaken for a year and IDI would continue to be responsible for the cost of any services provided through Children's.



We plan to speak with the EHS Division of Cost Allocation about the F&A rate.

We request that you contact us at your earliest convenience if our summary of our conversation is not completely accurate or if our understanding concerning the impact of the affiliations on IDI grant awards is incorrect. A confirmation of the summary would be appreciated.

Sincerely,

A handwritten signature in dark ink, appearing to read "Theodore M. Cronin", with a long horizontal flourish extending to the right.

Theodore M. Cronin, CPA
Acting President & CFO
Immune Disease Institute, Inc.
800 Huntington Avenue
Boston, MA 01225
617-278-3420 (v)
cronin@idi.harvard.edu

- Page break -
- Next document -



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
Bethesda, Maryland 20892

January 29, 2009

Mr. Theodore M. Cronin, CPA
Acting President & CEO
Immune Disease Institute, Inc.
800 Huntington Avenue
Boston, MA 01225

Dear Mr. Cronin:

This is in response to your letter of January 5, 2009, in which you summarized our phone conversation regarding Immune Disease Institute, Inc. (IDI) affiliation with Children's Medical Center Corporation (CMCC). We have noted that the affiliation agreement was signed on December 24, 2008, and under the terms of the affiliation agreement there will be no change in the legal status of IDI as a separate corporation. With respect to IDI NIH grant applications and awards, it is also noted that IDI will continue to operate as a separate legal entity under the IDI name and tax ID number.

With this letter, NIH confirms that the affiliation between IDI and CMCC will have no impact on the current grant awards or the eligibility of IDI for future grant awards. Accordingly, no further action is required by the NIH or IDI at this time.

Copies of this confirmation will be distributed to Grants Management Officers of NIH Institutes and Centers with active awards with Immune Disease Institute, Inc. Please call myself or George Gardner at (301) 435-0949 if you have a question.

Sincerely,

Joseph J. Ellis
Director
Office of Policy for Extramural Research Administration
Office of Extramural Research, OD
National Institutes of Health, DHHS

cc:
Grants Management Advisory Committee (GMAC)

Rockledge I, 6705 Rockledge Drive, Suite 350, MSC 7974, Bethesda, MD 20892-7974
Phone: 301-435-0938, FAX: 301-435-3059, Email: ellisjl@mail.nih.gov

- Page break -
- Next document -



800 Huntington Avenue
Boston, Massachusetts 02115
t: 617.278.3000
f: 617.278.3493
www.idi.harvard.edu

January 12, 2009

Mr. Robert Aaronson, Director
Department of Health and Human Services
Regional Administrative Support Center
Division of Cost Allocation
26 Federal Plaza
Room 41-122
New York, NY 10278

Re: Affiliation between the Immune Disease Institute and Children's Hospital Boston

Dear Mr. Aaronson:

This letter confirms our telephone conversation concerning the affiliation agreement recently signed between Immune Disease Institute, Inc. (IDI) and The Children's Medical Center Corporation (CMCC), the parent of Children's Hospital Boston (collectively, Children's) and summarizes key terms of the affiliation agreement relevant to IDI's conduct of federally-funded research and the costs associated with that research. Based on our discussion, we understand that the affiliation will involve no change in IDI's F&A and fringe benefit rates at this time.

IDI and CMCC signed an affiliation agreement on December 24, 2008. Under the terms of the affiliation agreement, there will be no change in IDI's legal status as a separate corporation. IDI will continue to operate as a separate legal entity under the IDI name and tax ID number. IDI will become an affiliate of CMCC when CMCC becomes the sole corporate member of IDI, with the authority to appoint the majority of the IDI board of trustees, while the present IDI board will have a minority representation on the IDI board of trustees (the IDI minority trustees). The affiliation does not involve a corporate merger. At a later time, Children's may elect to merge IDI into one of its corporate affiliates, but not before October 1, 2012, unless a majority of the IDI minority trustees agree to a merger prior to that date.

As a result of the affiliation, IDI will do business as a multi-disciplinary research program associated with Children's as the "Program in Cellular and Molecular Medicine." Children's will provide financial support to IDI. IDI faculty members will receive faculty appointments at Children's, but there is no present intention that Children's provide them with direct salary support or that the responsibility for IDI research grants be shared with Children's. IDI will stay in its present space and will continue to conduct its research activities in the same facilities. (Children's may, but is




not required to, lease some space from IDI and provide other services, at cost). Ted Cronin will remain CEO for at least one year and his successor will be approved by the IDI minority trustees. Children's and IDI will explore opportunities for efficiency in IDI operations, but any consolidations are not expected to be undertaken for a year and IDI will continue to be responsible for the cost of any services provided through Children's. If there is a further change in our legal status or research operations that may be relevant to our costs or F&A and fringe benefit rates, we will discuss its implications with you.

As you know, IDI is operating under a provisional F&A rate for the years ended June 30, 2009 and 2010. We expect to submit an accounting of incurred costs for fiscal 2009 by December 31, 2009, and at that time we plan to negotiate with the Division of Cost Allocation to finalize the 2009 rate, fix the 2010 rate, and establish a rate for 2011. We will also submit a fringe benefit proposal at that time.

We have spoken with NIH OPERA about the continued award of grants to IDI, and are waiting for their confirmation of our discussion that the affiliation will have no impact on the current IDI grant awards or the eligibility of IDI for future grant awards and that no further action by IDI is required at this time.

We request that you contact us at your earliest convenience if this summary of our conversation is not completely accurate or if our understanding of the impact of the Children's affiliation on our F&A and fringe rates is incorrect. A confirmation of receipt of the summary would be appreciated.

Sincerely,



Theodore M. Cronin, CPA
Acting President & CFO
Immune Disease Institute, Inc.
800 Huntington Avenue
Boston, MA 02115
617-278-3420 (v)
cronin@idi.harvard.edu

cc: Mr. Louis Martillotti

12

EDWARDS ANGELL PALMER & DODGE LLP

111 Huntington Avenue Boston, MA 02199 617.239.0100 fax 617.227.4420 eapdlaw.com

David R. Pokross, Jr.
617.239.0287
dpokross@eapdlaw.com

January 8, 2009

VIA FIRST CLASS MAIL

David Spackman, Esq.
Division of Public Charities
Office of the Attorney General
One Ashburton Place
Boston, MA 02108

*Re: Affiliation of Immune Disease Institute, Inc. and The Children's Medical
Center Corporation*

Dear Mr. Spackman:

While we do not believe that notice to your office of the transaction described below is required, nonetheless we would like to provide the following information as a courtesy.

Our client, the Immune Disease Institute, Inc. ("IDI"), a tax-exempt Massachusetts nonprofit corporation, is affiliating with The Children's Medical Center Corporation ("CMCC"), a tax-exempt Massachusetts charitable corporation (the "Affiliation"). Pursuant to the Affiliation, CMCC will become the sole member of IDI and elect a majority of its trustees. IDI will continue its operations as a separate Massachusetts nonprofit corporation with its own board of trustees.

Over the last year, the IDI Board of Trustees (the "IDI Board") and management have engaged in examination and evaluation of various options to determine how best to meet IDI's needs. After discussions with several organizations, the IDI Board concluded that the goals of improved efficiency, cost effectiveness and program quality and scope were best served by seeking affiliation with a similarly aligned but larger and more financially stable organization. CMCC's mission, purpose and programs are compatible with those of IDI. IDI's charitable mission and purpose will remain unchanged and its operations will continue without interruption.


We believe that no notice to, or action on the part of, your office is required to effectuate the Affiliation, and that the provisions of Section 8A(c) of Chapter 180 of the Massachusetts General Laws do not apply because (i) there is no sale, lease, exchange or other disposition of all

EDWARDS ANGELL PALMER & DODGE LLP

David Spackman, Esq.
January 8, 2009
Page 2

or substantially all of IDI's property and assets and (ii) there will not be a material change in the nature of the activities of IDI as a result of the Affiliation. In the interest of ensuring that your office is aware of the Affiliation, however, we are providing you with this letter as a courtesy.

Very truly yours,

A handwritten signature in black ink, appearing to read "D. Pokross, Jr.", with a stylized flourish at the end.

David R. Pokross, Jr.

Enclosures

cc: Theodore M. Cronin
Immune Disease Institute, Inc.
Stuart J. Novick
The Children's Medical Center Corporation
Michele M. Garvin
Ropes & Gray, LLP

13

Execution Version

ENDOWMENT INVESTMENT AGREEMENT

This Endowment Investment Agreement (the "Agreement") is made as of February 20, 2009 (the "Effective Date") by and among The Children's Medical Center Corporation ("CMCC") and Immune Disease Institute, Inc. ("IDI") (each a "Party" and collectively the "Parties"). All terms used herein, unless otherwise defined herein, have the meanings ascribed to them in the Affiliation Agreement, dated December 24, 2008 (the "Affiliation Agreement").

WHEREAS, pursuant to Section 6.4.1 of the Affiliation Agreement, the Parties have agreed to enter an agreement to transfer management of IDI's endowment fund balances (the "IDI Endowment") in order to allow CMCC to invest and manage the IDI Endowment consistent with the terms of this Agreement;

WHEREAS, CMCC desires to allocate \$20 million in additional funds (the "CMCC Support") to be invested along side the IDI Endowment (together the "Combined IDI Account"), with all net investment earnings to be used for the benefit of IDI.

WHEREAS, CMCC desires to manage, and IDI consents to the management of, the Combined IDI Account consistent with the terms of this Agreement.

NOW, THEREFORE, for and in consideration of the mutual covenants and agreements set forth in this Agreement, the Parties agree as follows:

1. Creation of the Combined IDI Account. As soon as practicable after the Effective Date, IDI shall transfer the IDI Endowment (consisting of approximately \$19.2 million at September 30, 2008) to an account controlled by CMCC. Upon completion of such transfer, CMCC shall allocate the CMCC Support to be invested along side the IDI Endowment. CMCC's obligation to provide the CMCC Support shall continue for at least five (5) years from the Effective Time, after which, CMCC will continue to provide the CMCC Support at CMCC's discretion.

2. Investment and Management of the Combined IDI Account. CMCC agrees to invest and manage the Combined IDI Account consistent with CMCC's investment of other CMCC endowed funds. CMCC agrees to track the investment return/loss on the Combined IDI Account separately from the balance of CMCC's other endowment funds. CMCC agrees to provide to IDI quarterly reports indicating the financial performance of the Combined IDI Account to the extent such information is available.

3. Use of Combined IDI Account. Subject to Section 6 of this Agreement, all net investment earnings on the Combined IDI Account shall be used exclusively for the benefit of IDI until at least the fifth (5th) anniversary of the Effective Time.

4. Use of IDI Endowment. Subject to Section 6 of this Agreement, the IDI Endowment, together with all net investment earnings on the IDI Endowment, shall be used exclusively for the benefit of IDI until the earlier of (i) the merger of IDI into CMCC or a controlled affiliate of CMCC; or (ii) termination of the Affiliation under Section 6 of this Agreement (the "Management Period"). Upon request by IDI to satisfy any outstanding liability or obligation of IDI during the Management Period, CMCC shall make any amounts in the IDI Endowment, together with all net investment earnings on the IDI Endowment, available as soon as commercially practicable to IDI to satisfy any such liability or obligation to the extent, in the aggregate, of the IDI Endowment together with all net investment earnings on the IDI Endowment.

5. Line of Credit. CMCC shall extend to IDI a \$3 million line of credit, such line of credit to be used by IDI to satisfy its ongoing operational expenses consistent with IDI's agreed upon budget. The amount of the line of credit may be increased or decreased from time to time by written agreement of the Parties.

6. Event of Termination of Affiliation. In the event CMCC and IDI terminate their affiliation prior to any merger of IDI into CMCC or a controlled affiliate of CMCC as contemplated by the Affiliation Agreement, (i) the IDI Endowment, including all gains and subtracting any losses, shall be returned to IDI, (ii) CMCC shall have exclusive right and title to the CMCC Support, including all gains on said funds, and (iii) IDI shall repay to CMCC all outstanding amounts under its line of credit with CMCC as soon as commercially reasonable, but no later than 30 days after the termination of the affiliation.

7. Limitation on Liability. Notwithstanding anything in this Agreement to the contrary, CMCC shall not be liable to IDI or any other party for any action taken or omitted or for any loss or injury resulting from its actions or its performance or lack of performance of its duties hereunder in the absence of gross negligence or willful misconduct on its part. Without limiting the generality of the foregoing, CMCC shall not be held responsible, financially or otherwise, for any losses the Combined IDI Account may sustain by virtue of the investments selected CMCC or its investment custodian(s).

8. Expenses. Each Party shall be responsible for its own costs and expenses incurred in connection with this Agreement.


9. Affiliation Agreement. This Agreement is subject to the terms and conditions set forth in the Affiliation Agreement, including without limitation, Sections 6.4.1, 6.4.2 and 6.4.3.

10. Benefit of the Parties. The Parties hereby agree this Agreement is for the exclusive benefit of the Parties hereto (including any affiliates of CMCC) and their respective successors hereunder, and shall not be deemed to give, either express or implied, any legal or equitable right, remedy, or claim to any other entity or person whatsoever.

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed on their behalf, in the day and year first hereinabove set forth, as an instrument under seal.

THE CHILDREN'S MEDICAL CENTER
CORPORATION

By:


James Mandell, M.D.
Chief Executive Officer

IMMUNE DISEASE INSTITUTE, INC.

By:

Theodore M. Cronin
Acting President and Chief Financial Officer

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed on their behalf, in the day and year first hereinabove set forth, as an instrument under seal.


THE CHILDREN'S MEDICAL CENTER
CORPORATION

By: _____

James Mandell, M.D.
Chief Executive Officer

IMMUNE DISEASE INSTITUTE, INC.

By: _____


Theodore M. Cronin
Acting President and Chief Financial Officer

14

Execution Version

THE CHILDREN'S MEDICAL CENTER CORPORATION


Appointment of Class B Trustees to the Immune Disease Institute, Inc. Board of Trustees

The Children's Medical Center Corporation ("CMCC"), as sole member of the Immune Disease Institute, Inc. ("IDI"), hereby appoints the following individuals as Class B Trustees pursuant to Section 2.1 of the Amended and Restated By-Laws of IDI, as amended February 20, 2009:

Frederick Alt
Carleen Brunelli
Gary Fleisher, M.D.
David Kirshner
Harvey Lodish, Ph.D.
James Mandell, M.D.

Such appointments shall become effective as of the closing date of the affiliation between CMCC and IDI, as effected by the Affiliation Agreement by and between CMCC and IDI, dated December 24, 2008.

IN WITNESS WHEREOF, I have hereunto set my hand as of this 20th day of February, 2009.



James Mandell, M.D.
Chief Executive Officer

15



William Francis Galvin
Secretary of the
Commonwealth

The Commonwealth of Massachusetts
Secretary of the Commonwealth
State House, Boston, Massachusetts 02133

February 17, 2009

TO WHOM IT MAY CONCERN:

I hereby certify that according to the records of this office

IMMUNE DISEASE INSTITUTE, INC.

is a domestic corporation organized on **January 19, 1953 (Chapter 180)**.

I further certify that there are no proceedings presently pending under the Massachusetts General Laws Chapter 180 section 26 A, for revocation of the charter of said corporation; that the State Secretary has not received notice of dissolution of the corporation pursuant to Massachusetts General Laws, Chapter 180, Section 11, 11A, or 11B; that said corporation has filed all annual reports, and paid all fees with respect to such reports, and so far as appears of record said corporation has legal existence and is in good standing with this office.



Processed By crm

In testimony of which,
I have hereunto affixed the
Great Seal of the Commonwealth
on the date first above written.

William Francis Galvin
Secretary of the Commonwealth

* This is not a tax clearance. Certificates certifying that all taxes due and payable by the corporation have been paid or provided for are issued by the Department of Revenue.

- Page break -
- Next document -



William Francis Galvin
Secretary of the
Commonwealth

The Commonwealth of Massachusetts
Secretary of the Commonwealth
State House, Boston, Massachusetts 02133

February 17, 2009.

TO WHOM IT MAY CONCERN:

I hereby certify that according to the records in this office, **PROTEIN FOUNDATION, INCORPORATED** was incorporated under the General Laws of this Commonwealth on **January 19, 1953 (Chapter 180)**.

I further certify that in Articles of Amendment filed here **May 19, 1967**, the name of said corporation was changed to **BLOOD RESEARCH INSTITUTE, INC.**

I also certify that in Articles of Amendment filed here **August 2, 1972**, the name of said corporation was changed to **CENTER FOR BLOOD RESEARCH, INC.**

I further certify that in Articles of Amendment filed here **August 12, 2003**, the name of said corporation was changed to **THE CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC.**

I also certify that in Articles of Amendment filed here **June 5, 2007**, the name of said corporation was changed to **IMMUNE DISEASE INSTITUTE, INC.**

I further certify that so far as appears of record here, said corporation still has legal existence.



In testimony of which,
I have hereunto affixed the
Great Seal of the Commonwealth
on the date first above written.

William Francis Galvin
Secretary of the Commonwealth

16



William Francis Galvin
Secretary of the
Commonwealth

The Commonwealth of Massachusetts
Secretary of the Commonwealth
State House, Boston, Massachusetts 02133

February 17, 2009

TO WHOM IT MAY CONCERN:

I hereby certify that according to the records of this office

THE CHILDREN'S MEDICAL CENTER CORPORATION

is a domestic corporation organized on **December 31, 1959 (Chapter 180)**.

I further certify that there are no proceedings presently pending under the Massachusetts General Laws Chapter 180 section 26 A, for revocation of the charter of said corporation; that the State Secretary has not received notice of dissolution of the corporation pursuant to Massachusetts General Laws, Chapter 180, Section 11, 11A, or 11B; that said corporation has filed all annual reports, and paid all fees with respect to such reports, and so far as appears of record said corporation has legal existence and is in good standing with this office.



In testimony of which,
I have hereunto affixed the
Great Seal of the Commonwealth
on the date first above written.

William Francis Galvin

Secretary of the Commonwealth

Processed By sam

* This is not a tax clearance. Certificates certifying that all taxes due and payable by the corporation have been paid or provided for are issued by the Department of Revenue.